"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,EP,A4,EP 3060198 A4,008-451-494-557-718,2017-06-28,2017,EP 14855080 A,2014-10-03,US 201361894165 P;;US 201461949032 P;;US 2014/0059092 W,2013-10-22,INHALED SURFACTANT-MODIFIED LIPOSOMAL FORMULATIONS PROVIDING BOTH AN IMMEDIATE AND SUSTAINED RELEASE PROFILE,,ARADIGM CORP,CIPOLLA DAVID;;GONDA IGOR,,https://lens.org/008-451-494-557-718,Search Report,no,4,0,10,10,0,A61K9/127;;A61K9/127;;A61K9/0078;;A61K9/0078;;A61K31/496;;A61K31/496;;A61K47/10;;A61K47/10;;A61K47/26;;A61K47/26;;A61P11/00;;A61P31/04,A61K9/127;;A61K47/26,,1,0,,,See also references of WO 2015061025A1,DISCONTINUED
2,WO,A1,WO 2015/156904 A1,001-027-006-341-321,2015-10-15,2015,US 2015/0015433 W,2015-02-11,US 201461976729 P,2014-04-08,LIPOSOMES THAT FORM DRUG NANOCRYSTALS AFTER FREEZE-THAW,"Methods for formulating a liposome comprised of a surfactant and a cryopreservative that can be frozen for long term stability, and upon thawing provides an immediate and sustained release delivery profile. Specific liposome formulations include anti-infectives and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.",ARADIGM CORP,CIPOLLA DAVID;;GONDA IGOR,,https://lens.org/001-027-006-341-321,Patent Application,yes,12,3,13,16,0,A61K9/0078;;A61K45/06;;A61K9/127;;A61K47/26;;A61K31/496;;A61P31/00;;A61K9/0078;;A61K9/127;;A61K31/496;;A61K45/06;;A61K47/26;;A61K9/127;;A61K47/26;;A61K31/496;;A61K9/0078;;A61K45/06;;Y02A50/30,A61K9/19;;A61K9/127;;A61K9/133,,68,59,038-604-184-677-717;;040-912-152-710-03X;;102-231-993-063-766;;012-252-886-612-459;;032-540-097-522-655;;032-540-097-522-655;;154-415-293-408-578;;031-426-424-414-729;;128-345-886-759-353;;128-345-886-759-353;;035-121-678-040-243;;067-024-524-311-940;;050-665-220-730-241;;101-904-038-391-443;;096-430-335-321-467;;065-011-806-820-297;;012-210-322-057-335;;012-650-141-047-778;;041-923-661-960-985;;135-866-219-244-046;;022-758-786-690-485;;019-988-630-331-801;;036-582-222-376-548;;083-698-431-720-922;;029-704-263-480-383;;076-312-210-864-326;;003-924-759-694-183;;012-062-928-890-733;;110-934-436-932-405;;043-248-504-408-501;;007-122-013-064-944;;034-910-153-767-189;;096-970-773-696-231;;117-414-976-171-550;;032-708-511-260-192;;086-931-563-365-931;;085-282-321-416-333;;050-768-728-208-368;;008-565-993-389-128;;083-903-071-523-844;;045-559-172-047-180;;032-933-505-288-325;;011-205-311-656-508;;045-929-999-901-942;;116-973-337-420-471;;106-368-456-709-368;;037-892-728-929-664;;023-708-751-561-393;;015-132-669-034-026;;069-271-598-076-315;;048-157-998-339-224;;066-267-219-024-523;;005-355-449-252-481;;086-952-662-851-508;;037-256-374-574-44X;;004-758-352-546-31X;;012-361-294-266-137;;116-079-433-915-689;;009-893-982-767-479,10.1007/s11095-013-1135-z;;23881305;;10.1016/0169-409x(93)90004-n;;10.1016/j.jconrel.2004.02.017;;15120901;;10.1086/587906;;18422455;;10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a3214;;10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a3214;;10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a3191;;10.1016/s1569-1993(09)60196-x;;10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a3192;;10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a3192;;12909649;;10.1099/jmm.0.05224-0;;10.7326/0003-4819-113-5-358;;2382918;;10.4155/tde.13.71;;23919478;;10.1128/aac.41.6.1288;;pmc163901;;9174185;;10.1146/annurev.micro.49.1.711;;10.1146/annurev.mi.49.100195.003431;;8561477;;3285894;;10.1016/0304-4157(88)90015-9;;10.1128/aac.36.7.1567;;1387303;;pmc191622;;8354928;;10.1093/infdis/168.3.793;;10.1002/jps.21358;;18351638;;10.1586/17476348.2.4.479;;20477211;;8419592;;10.1016/s0022-3476(05)83478-x;;16807259;;10.1183/09031936.06.00149805;;9524452;;10.1177/08959374970110010701;;pmc4068435;;24637682;;10.1128/aac.02555-13;;7792438;;10.1159/000196491;;pmc171452;;10.1128/aac.33.2.176;;2719461;;10.1128/cmr.6.3.266;;pmc358286;;8358707;;10.1586/eri.12.88;;pmc3562728;;23106280;;10.1111/j.1462-5822.2007.01067.x;;21328583;;10.1002/jps.22518;;10.1016/0014-5793(92)80947-f;;1426260;;10.1016/0005-2736(95)00159-z;;7488619;;10.1016/s0005-2736(98)00175-8;;9858673;;10.1093/jac/37.suppl_c.1;;8818841;;pmc245550;;1482150;;10.1128/aac.36.12.2808;;10.1111/j.1469-0691.2010.03307.x;;20636426;;pmc2978799;;18305202;;10.1093/jac/dkn059;;10.1378/chest.120.3_suppl.107s;;11555564;;10.1128/aac.39.9.2104;;pmc162889;;8540724;;2293210;;10.1023/a:1015924124180;;10.1128/aac.45.11.3262-3266.2001;;pmc90822;;11600396;;10.1164/rccm.201002-0310oc;;20538958;;pmc2970866;;pmc4770250;;10.1136/thoraxjnl-2013-203207;;23681906;;7585155;;10.1038/nm0795-703;;10.1056/nejm199608083350602;;8676931;;17905224;;10.1016/j.cryobiol.2007.08.002;;10.1016/j.cryobiol.2008.09.011;;18854181;;2515523;;10.1002/ppul.1950070413;;10.1016/j.ejps.2010.08.010;;20800680;;pmc323309;;10.1073/pnas.83.8.2422;;16593683;;10.1002/ppul.1950170511;;8058428;;10.1016/s0168-3659(03)00358-4;;14568408;;10.3109/10731190009118586;;11009114;;10.1136/thorax.57.3.212;;pmc1746273;;11867823;;10.1016/j.bbamem.2003.12.006;;15003875;;16611229;;10.1111/j.1462-5822.2005.00667.x;;10.1164/arrd.1973.108.3.547;;4745250;;8825494;;10.1146/annurev.ge.29.120195.004021;;10.1146/annurev.genet.29.1.777;;10.1016/j.jconrel.2005.10.011;;16318894,"ANTONIO P. COSTA ET AL.: ""Freeze-Anneal-Thaw Cycling of Unilamellar Liposomes: Effect on Encapsulation Efficiency"", PHARMACEUTICAL RESEARCH, vol. 31, no. 1, 24 July 2013 (2013-07-24), pages 97 - 103, XP055390114, ISSN: 0724-8741, DOI: 10.1007/s11095-013-1135-z;;""Peptide and Protein Drug Delivery"", 1991, MARCEL DEKKER, INC., pages: 247 - 301;;JONES, A., ADV. DRUG DELIVERY REV., vol. 10, 1993, pages 29 - 90;;ABRAHAM SAEDWARDS KKARLSSON GHUDON NMAYER LDBALLY MB: ""An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes"", J CONTROL REL., vol. 96, 2004, pages 449 - 461, XP004505678, DOI: 10.1016/j.jconrel.2004.02.017;;BERMUDEZ LEMOTAMEDI NKOLONOSKI PCHEE CBAIMUKANOVA GBILDFELL RWANG GPHAN LTYOUNG LS: ""The efficacy of clarithromycin and the bicyclolide EDP-420 against Mycobacterium avium in a mouse model of pulmonary infection"", J INFECT DIS, vol. 197, 2008, pages 1506 - 10;;BILTON DP BRUINENBERG POTULANA B: ""Inhaled liposomal ciprofloxacin hydrochloride significantly reduces sputum Pseudomonas aeruginosa density in CF and non-CF bronchiectasis. Presented at American Thoracic Society (ATS) International Conference, San Diego, CA"", AM J RESPIR CRIT CARE MED, vol. 179, 2009, pages A3214;;BILTON DBRUINENBERG POTULANA BMORISHIGE RBLANCHARD JDESOYZA ASERISIER D.: ""Inhaled liposomal ciprofloxacin hydrochloride significantly reduces sputum Pseudomonas aeruginosa density in CF and non-CF bronchiectasis"", EUROPEAN RESPIRATORY SOCIETY (ERS) CONFERENCE, 2009;;BILTON DDE SOYZA AHAYWARD CBRUINENBERG P: ""Effect of a 28-day course of two different doses of once a day liposomal ciprofloxacin for inhalation on sputum Pseudomonas aeruginosa density in non-CF bronchiectasis, Presented at American Thoracic Society (ATS) International Conference"", AM J RESPIR CRIT CARE MED, vol. 181, 2010, pages A3191;;BILTON DSERISIER DJDESOYZA AWOLF RBRUINENBERG P: ""Multicenter, randomized, double-blind, placebo-controlled study (ORBIT 1) to evaluate the efficacy, safety, and tolerability of once daily ciprofloxacin for inhalation in the management of Pseudomonas aeruginosa infections in patients with non-cystic fibrosis bronchiectasis"", EUROPEAN RESPIRATORY SOCIETY ANNUAL CONGRESS, 2011;;BLANCHARD JD: ""Respiratory Drug Delivery X"", 2006, DAVIS HEALTHCARE INTERNATIONAL, article ""Pulmonary drug delivery as a first response to bioterrorism"", pages: 73 - 82;;BRUINENBERG POTULANA BBLANCHARD JCIPOLLA DWILSON JSERISIER D: ""Pharmacokinetics and antibacterial activity of inhaled liposomal ciprofloxacin hydrochloride in healthy volunteers and in cystic fibrosis (CF) patients. Presented at 32nd European Cystic Fibrosis Conference"", J CYSTIC FIBROSIS, vol. 8, no. 2, 2009, pages 49;;BRUINENBERG PBLANCHARD JCIPOLLA DSERISIER D: ""Safety, tolerability and pharmacokinetics of novel liposomal ciprofloxacin formulations for inhalation in healthy volunteers and in non-cystic bronchiectasis patients. Presented at American Thoracic Society (ATS) International Conference"", AM J RESPIR CRIT CARE MED, vol. 181, 2010, pages A3192;;BRUINENBERG, PBLANCHARD JDCIPOLLA DCDAYTON FMUDUMBA SGONDA I: ""Respiratory Drug Delivery 2010"", 2010, DAVIS HEALTHCARE INTERNATIONAL, article ""Inhaled liposomal ciprofloxacin: once a day management of respiratory infections"", pages: 73 - 81;;BRUINENBERG PSERISIER DBLANCHARD JCIPOLLA DGONDA I: ""Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis"", EUROPEAN RESPIRATORY SOCIETY ANNUAL CONGRESS, 2010;;BRUINENBERG PSERISIER DCIPOLLA DBLANCHARD J: ""Safety, tolerability pharmacokinetics and antimicrobial activity of inhaled liposomal ciprofloxacin formulations in humans"", NORTH AMERICAN CYSTIC FIBROSIS CONFERENCE, vol. 45, no. 33, 2010;;BRUINENBERG PSERISIER DCIPOLLA DBLANCHARD J.: ""Safety, tolerability, and pharmacokinetics of novel liposomal ciprofloxacin formulations in healthy volunteers (HV) and non-cystic fibrosis bronchiectasis (BE) patients"", J CYSTIC FIBROSIS, vol. 10, no. 1, 2011, pages 29;;CARTER GDRUMMOND DBERMUDEZ LE: ""Characterization of biofilm formation by Mycobacterium avium strains"", J MED MICROBIOL, vol. 52, 2003, pages 747 - 52;;CHIU JNUSSBAUM JBOZZETTE STILLES JGYOUNG LSLEEDOM JHESELTINE PNMCCUTCHAN JA: ""Treatment of disseminated Mycobacterium avium complex infection in AIDS with amikacin, ethambutol and ciprofloxacin"", ANN INTERN MED, vol. 113, 1990, pages 358 - 61;;CIPOLLA DGONDA ICHAN H-K: ""Liposomal Formulations for Inhalation"", THER. DELIV., vol. 4, no. 8, 2013, pages 1047 - 1072, XP009194915, DOI: 10.4155/tde.13.71;;CIPOLLA DWU HEASTMAN SREDELMEIER TGONDA ICHAN HK: ""Development and Characterization of an In Vitro Release Assay for Liposomal Ciprofloxacin for Inhalation"", J. PHARM. SCI., vol. 103, no. 1, 2014, pages 314 - 327, XP055390072, DOI: 10.1002/jps.23795;;CONLEY JYANG HWILSON TBLASETTI KDI NINNO VSCHNELL GWONG JP: ""Aerosol delivery of liposome encapsulated ciprofloxacin: aerosol characterization and efficacy against Francisella tuleransis infection in mice"", ANTIMICROB AGENTS CHEMOTHER, vol. 41, 1997, pages 1288 - 92;;COSTERTON JWLEWANDOWSKI ZCALDWELL DEKORBER DRLAPPIN-SCOTT HM.: ""Microbial biofilms"", ANNU REV MICROBIOL., vol. 49, 1995, pages 711 - 45, XP002919540, DOI: 10.1146/annurev.mi.49.100195.003431;;CROWE JHCROWE LMCARPENTER JFRUDOLPH ASWISTROM CASPARGO BJANCHORDOGUY TJ: ""Biochim Biophys Acta"", INTERACTIONS OF SUGARS WITH MEMBRANES, vol. 947, 1988, pages 367 - 384;;DE LALLA FMASERATI RSCARPELLINI PMARONE PNICOLIN RCACCAMO FRIGOLI R: ""Clarithromycin-ciprofloxacin-amikacin for therapy of Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS"", ANTIMICROB AGENTS CHEMOTHER, vol. 36, 1992, pages 1567 - 9, XP002536416;;DI NINNO VLCHERWONOGRODZKY JWWONG JP: ""Liposome-encapsulated ciprofloxacin is effective in the protection and treatment of Balb/c mice against Francisella tularensis"", J INFECT DIS, vol. 168, 1993, pages 793 - 794;;DRUMMOND DCNOBLE COHAYES MEPARK JWKIRPOTIN DB: ""Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development"", J PHARM SCI., vol. 97, 2008, pages 4696 - 4740;;FIEL SB: ""Aerosolized antibiotics in cystic fibrosis: current and future trends"", EXPERT REV RESPIR MED, vol. 2, 2008, pages 479 - 487;;FITZSIMMONS SC: ""The changing epidemiology of cystic fibrosis"", J PEDIATR., vol. 122, no. 1, January 1993 (1993-01-01), pages 1 - 9;;FOWLER SJFRENCH JSCRANTON NJFOWERAKER JCONDLIFFE AHAWORTH CSEXLEY ARBILTON D: ""Nontuberculous mycobacteria in bronchiectasis: prevalence and patient characteristics"", EUR RESPIR J, vol. 28, 2006, pages 1204 - 10;;GILBERT PDAS JFOLEY I.: ""Biofilm susceptibility to antimicrobials"", ADV DENT RES., vol. ll, no. l, April 1997 (1997-04-01), pages 160 - 7;;HAMBLIN KABLANCHARD JDATKINS HS: ""Efficacy of liposome-encapsulated ciprofloxacin against Francisella tularensis Schu S4 strain"", INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (ICACC, 2011;;HAMBLIN KAARMSTRONG SJKAY BBARNES KBDAVIES CWONG JPBLANCHARD JDHARDING SVSIMPSON AJHATKINS HS: ""Liposome-encapsulation of ciprofloxacin improves protection against highly resistant Francisella tularensis Schu S4 strain"", ANTIMICROB AGENTS CHEMOTHER, 2014;;HODSON MSHAH PL: ""DNase trials in cystic fibrosis"", RESPIRATION, vol. 62, no. 1, 1995, pages 29 - 32;;INDERLIED CKOLONOSKI PWU MYOUNG L: ""Amikacin, ciprofloxacin, and imipenem treatment for disseminated Mycobacterium avium complex infection of beige mice"", ANTIMICROB AGENTS CHEMOTHER, vol. 33, 1989, pages 176 - 80;;INDERLIED CBKEMPER CABERMUDEZ LE: ""The Mycobacterium avium complex"", CLIN MICRO REV, vol. 6, 1993, pages 266 - 310;;ISLAM MSRICHARDS JPOJHA AK: ""Targeting drug tolerance in mycobacteria: a perspective from mycobacterial biofilms"", EXPERT REV ANTI INFECT THER., vol. 10, no. 9, 2012, pages 1055 - 1066;;JORDAO LBLECK CKMAYORGA LGRIFFTHS GANES E: ""On the killing of mycobacteria by macrophages"", CELL MICROBIOL, vol. 10, 2008, pages 529 - 48;;IZUTSU KIYOMOTA CKAWANISHI T: ""Stabilization of liposomes in frozen solutions through control of osmotic flow and internal solution freezing by trehalose"", J PHARM SCI., vol. 100, no. 7, 2011, pages 2935 - 2944;;LASIC DDFREDERICK PMSTUART MCABARENHOLZ YMCINTOSH TJ: ""Gelation of liposome interior: A novel method for drug encapsulation"", FEBS LETT., vol. 312, 1992, pages 255 - 258, XP055038881, DOI: 10.1016/0014-5793(92)80947-F;;LASIC DDCEH BSTUART MCAGUO LFREDERIK PMBARENHOLZ Y: ""Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery"", BIOCHIM BIOPHYS ACTA, vol. 1239, 1995, pages 145 - 156, XP000573479, DOI: 10.1016/0005-2736(95)00159-Z;;LI XHIRSH DJCABRAL-LILLY DZIRKEL AGRUNER SMJANOFF ASPERKINS WR: ""Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient"", BIOCHIM BIOPHYS ACTA, vol. 1415, no. 1, 9 December 1998 (1998-12-09), pages 23 - 40, XP002233914, DOI: 10.1016/S0005-2736(98)00175-8;;LODE HBORNER KKOEPPE PSCHABERG T.: ""Azithromycin--review of key chemical, pharmacokinetic and microbiological features"", J ANTIMICROB CHEMOTHER., vol. 37, no. C, 1996, pages 1 - 8, XP008078035, DOI: 10.1093/jac/37.1.1;;MAJUMDAR SFLASHER DFRIEND DSNASSOS PYAJKO DHADLEY WKDIIZGIINE N: ""Efficacies of liposome-encapsulated streptomycin and ciprofloxacin against Mycobacterium avium-M. intracellulare complex infections in human peripheral blood monocytes/macrophages"", ANTIMICROB AGENTS CHEMOTHER, vol. 36, 1992, pages 2808 - 15;;MCNABE MTENNANT RDANELISHVILI LYOUNG LBERMUDEZ LE: ""Mycobacterium avium ssp. hominissuis biofilm is composed of distinct phenotypes and influenced by the presence of antimicrobials"", CLIN MICROBIOL INFECT, vol. 17, no. 5, 2012, pages 697 - 703;;MEERS PNEVILLE MMALININ VSCOTTO AWSARDARYAN GKURUMUNDA RMACKINSON CJAMES GFISHER SPERKINS WR: ""Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomanas aeruginosa lung infections"", J ANTIMICROB CHEMOTHER, vol. 61, 2008, pages 859 - 68, XP002632705, DOI: 10.1093/jac/dkn059;;MOSS RB.: ""Administration of aerosolized antibiotics in cystic fibrosis patients"", CHEST., vol. 120, no. 3, September 2001 (2001-09-01), pages 107S - 113S;;OH YKNIX DESTRAUBINGER RM: ""Formulation and efficacy of liposome-encapsulated antibiotics for therapy of intracellular Mycobacterium avium infection"", ANTIMICROB AGENTS CHEMOTHER, vol. 39, 1995, pages 2104 - 11, XP002065382;;NIVEN RNSCHREIER H: ""Nebulization of Liposomes: I. Effects of Lipid Composition"", PHARMRES., vol. 7, 1990, pages 1127 - 1133, XP009031185, DOI: 10.1023/A:1015924124180;;POLONIO REMERMEL LAPAQUETTE GESPERRY JF.: ""Eradication of biofilm-forming Staphylococcus epidermidis (RP62A) by a combination of sodium salicylate and vancomycin"", ANTIMICROB AGENTS CHEMOTHER., vol. 45, no. 11, November 2001 (2001-11-01), pages 3262 - 6, XP055460071, DOI: 10.1128/AAC.45.11.3262-3266.2001;;PREVOTS RDSHAW PASTRICKLAND DJACKSON LARAEBEL MABLOSKY MAMONTES DE OCA RSHEA YRSEITZ AEHOLLAND SM: ""Nontuberculosis mycobacterial lung disease prevalence at four integrated health care delivery systems"", AM J RESPIR CRIT CARE MED, vol. 182, 2010, pages 970 - 976;;SERISIER DJBILTON DDE SOYZA ATHOMPSON PJKOLBE JGREVILLE HWCIPOLLA DBRUINENBERG PGONDA I: ""Inhaled, Dual-Release Liposomal Ciprofloxacin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-2) - a Randomised, Double-Blind, Placebo-Controlled Trial"", THORAX, vol. 68, no. 9, 2013, pages 812 - 817, XP055576959, DOI: 10.1136/thoraxjnl-2013-203207;;SCHROEDER SAGAUGHAN DMSWIFT M.: ""Protection against bronchial asthma by CFTR delta F508 mutation: a heterozygote advantage in cystic fibrosis"", NAT MED., vol. 1, no. 7, July 1995 (1995-07-01), pages 703 - 5;;SHAFRAN SDSINGER JZAROWNY DPPHILLIPS PSALIT IWALMSLEY SLFONG IWGILL MJRACHLIS ARLALONDE RG: ""A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS, rifampin, ethambutol, and clarithromycin, versus rifampin, ethambutol, clofazimine and ciprofloxacin"", N ENGL J MED, vol. 335, 1996, pages 377 - 83, XP000987186, DOI: 10.1056/NEJM199608083350602;;SIOW LFRADES TLIM MH: ""Characterizing the freezing behavior of liposomes as a tool to understand the cryopreservation procedures"", CRYOBIOLOGY, vol. 55, 2007, pages 210 - 221, XP022357589, DOI: 10.1016/j.cryobiol.2007.08.002;;SIOW LFRADES TLIM MH: ""Cryo-responses of two types of large unilamellar vesicles in the presence of non-permeable or permeable cryoprotecting agents"", CRYOBIOLOGY, vol. 57, 2008, pages 276 - 285, XP025691889, DOI: 10.1016/j.cryobiol.2008.09.011;;SMITH ALRAMSEY BWHEDGES DLHACK BWILLIAMS-WARREN JWEBER AGORE EJREDDING GJ: ""Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis"", PED PULMONOL., vol. 7, no. 4, 1989, pages 265 - 271, XP001107253;;STARK BPABST GPRASSL R: ""Long-term stability of sterically stabilized liposomes by freezing and freeze-drying: Effects of cryoprotectants on structure"", EUR J PHARM SCI., vol. 41, 2010, pages 546 - 555, XP027369053;;STRAUSS GHAUSER H: ""PNAS. Stabilization of lipid bilayer vesicles by sucrose during freezing"", PNAS, vol. 83, 1986, pages 2422 - 2426;;WEBER ASMITH AWILLIAMS-WARREN JRAMSEY BCOVERT DS: ""Nebulizer delivery of tobramycin to the lower respiratory tract"", PEDIATR PULMONOL., vol. 17, no. 5, May 1994 (1994-05-01), pages 331 - 9;;WONG JPYANG HBLASETTI KLSCHNELL GCONLEY JSCHOFIELD LN: ""Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection"", J CONTROL RELEASE, vol. 92, 2003, pages 265 - 73, XP004467641, DOI: 10.1016/S0168-3659(03)00358-4;;WONG JPSCHNELL GSIMPSON MSARAVOLAC E: ""Effects of liposome-encapsulated ciprofloxacin on phagocytosis, nitric oxide, and intracellular killing of Staphylcoccus aureus by murine macrophages"", ARTIFIC CELLS BLOOD SUBSTIT IMMOBIL BIOTECHNOL, vol. 28, 2000, pages 415 - 28, XP055659636, DOI: 10.3109/10731190009118586;;WOLTER JSEENEY SBELL SBOWLER SMASEL PMCCORMACK J.: ""Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial"", THORAX, vol. 57, 2002, pages 212 - 216;;WOLKERS WFOLDENHOF HTABLIN FCROWE JH: ""Preservation of dried liposomes in the presence of sugar and phosphate"", BIOCHIM. BIOPHYS. ACTA, vol. 1661, 2004, pages 125 - 134, XP004495430, DOI: 10.1016/j.bbamem.2003.12.006;;YAMAZAKI YDANELISHVILI LWU MHIDAKA EKATSUYAMA TSTANG BPETROFSKY MBILDFELL RBERMUDEZ L: ""The ability to form biofilm influences Mycobacterium avium invasion and translocation of bronchial epithelial cells"", CELL MICROBIOL, vol. 8, 2006, pages 806 - 14;;YEAGER HRALEIGH JW: ""Pulmonary disease due to Mycobacterium intracellulare"", AM REV RESP DIS, vol. 108, 1973, pages 547 - 52;;ZIELENSKI JTSUI LC.: ""Cystic fibrosis: genotypic and phenotypic variations"", ANNUAL REV GENET., vol. 29, 1995, pages 777 - 807;;ZHIGALTSEV IVMAURER NEDWARDS KKARLSSON GCULLIS PR: ""Formation of drug-arylsulfonate complexes inside liposomes: A novel approach to improve drug retention"", J CONTROL REL., vol. 110, 2006, pages 378 - 386, XP024957390, DOI: 10.1016/j.jconrel.2005.10.011;;See also references of EP 3129008A4",PENDING
3,MX,A,MX 2016005232 A,001-709-469-670-007,2017-01-19,2017,MX 2016005232 A,2014-10-03,US 201361894165 P;;US 201461949032 P;;US 2014/0059092 W,2013-10-22,INHALED SURFACTANT-MODIFIED LIPOSOMAL FORMULATIONS PROVIDING BOTH AN IMMEDIATE AND SUSTAINED RELEASE PROFILE.,"Methods for formulating and compositions of immediate and sustained release liposomal products which comprise a surfactant that interacts with liposomes to effect drug release therefrom, and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.",ARADIGM CORP,DAVID CIPOLLA;;IGOR GONDA,,https://lens.org/001-709-469-670-007,Patent Application,no,0,0,10,10,0,A61K9/127;;A61K9/127;;A61K9/0078;;A61K9/0078;;A61K31/496;;A61K31/496;;A61K47/10;;A61K47/10;;A61K47/26;;A61K47/26;;A61P11/00;;A61P31/04,A61K9/127,,0,0,,,,PENDING
4,EP,A4,EP 3129008 A4,077-814-271-006-372,2017-09-06,2017,EP 15777307 A,2015-02-11,US 201461976729 P;;US 2015/0015433 W,2014-04-08,LIPOSOMES THAT FORM DRUG NANOCRYSTALS AFTER FREEZE-THAW,,ARADIGM CORP,CIPOLLA DAVID;;GONDA IGOR,,https://lens.org/077-814-271-006-372,Search Report,no,0,0,13,16,0,A61K9/0078;;A61K45/06;;A61K9/127;;A61K47/26;;A61K31/496;;A61P31/00;;A61K9/0078;;A61K9/127;;A61K31/496;;A61K45/06;;A61K47/26;;A61K9/127;;A61K47/26;;A61K31/496;;A61K9/0078;;A61K45/06;;Y02A50/30,A61K9/19;;A61K9/127;;A61K9/133,,5,3,038-604-184-677-717;;057-723-944-383-350;;043-178-087-245-527,10.1007/s11095-013-1135-z;;23881305;;10.1016/0168-3659(94)90257-7;;10.1002/jps.23795,"ANTONIO P. COSTA ET AL: ""Freeze-Anneal-Thaw Cycling of Unilamellar Liposomes: Effect on Encapsulation Efficiency"", PHARMACEUTICAL RESEARCH, vol. 31, no. 1, 24 July 2013 (2013-07-24), US, pages 97 - 103, XP055390114, ISSN: 0724-8741, DOI: 10.1007/s11095-013-1135-z;;AUSBORN M ET AL: ""The protective effect of free and membrane-bound cryoprotectants during freezing and freeze-drying of liposomes"", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 30, no. 2, 1 May 1994 (1994-05-01), pages 105 - 116, XP023856284, ISSN: 0168-3659, [retrieved on 19940501], DOI: 10.1016/0168-3659(94)90257-7;;ANONYMOUS: ""Nanotechnology for Cancer Therapy"", 19 December 2006, CRC PRESS, XP002772115;;DAVID CIPOLLA ET AL: ""Development and Characterization of an In Vitro Release Assay for Liposomal Ciprofloxacin for Inhalation"", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 103, no. 1, 1 January 2014 (2014-01-01), WASHINGTON, US, pages 314 - 327, XP055390072, ISSN: 0022-3549, DOI: 10.1002/jps.23795;;See also references of WO 2015156904A1",DISCONTINUED
5,AU,B2,AU 2014/340568 B2,155-940-355-170-916,2017-02-02,2017,AU 2014/340568 A,2014-10-03,US 201461949032 P;;US 201361894165 P;;US 2014/0059092 W,2013-10-22,Inhaled surfactant-modified liposomal formulations providing both an immediate and sustained release profile,"Methods for formulating and compositions of immediate and sustained release liposomal products which comprise a surfactant that interacts with liposomes to effect drug release therefrom, and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.",ARADIGM CORP,CIPOLLA DAVID;;GONDA IGOR,,https://lens.org/155-940-355-170-916,Granted Patent,no,2,0,10,10,0,A61K9/0078;;A61K9/127;;A61K31/496;;A61K47/10;;A61K47/26;;A61P11/00;;A61P31/04;;A61K9/127;;A61K31/496;;A61K47/10;;A61K47/26;;A61K9/0078,A61K9/127,,0,0,,,,INACTIVE
6,EP,A1,EP 3129008 A1,162-151-949-691-26X,2017-02-15,2017,EP 15777307 A,2015-02-11,US 201461976729 P;;US 2015/0015433 W,2014-04-08,LIPOSOMES THAT FORM DRUG NANOCRYSTALS AFTER FREEZE-THAW,,ARADIGM CORP,CIPOLLA DAVID;;GONDA IGOR,,https://lens.org/162-151-949-691-26X,Patent Application,yes,0,3,13,16,0,A61K9/0078;;A61K45/06;;A61K9/127;;A61K47/26;;A61K31/496;;A61P31/00;;A61K9/0078;;A61K9/127;;A61K31/496;;A61K45/06;;A61K47/26;;A61K9/127;;A61K47/26;;A61K31/496;;A61K9/0078;;A61K45/06;;Y02A50/30,A61K9/19;;A61K9/127;;A61K9/133,,0,0,,,,DISCONTINUED
7,DE,D1,DE 69009476 D1,091-677-232-949-123,1994-07-07,1994,DE 69009476 T,1990-06-27,US 37382589 A;;US 9003669 W,1989-06-30,HEMMUNG DES REAKTIONSWEGS FÜR DIE N-ENDE-REGEL IN LEBENDEN ZELLEN.,"The half-life of a Type I, II and III non-compartmentalized intracellular proteins is increased in living eukaryotic cells by contacting the cells with a regulator having an amino-terminal amino acid residue which is the same or similar to the amino-terminal residue of the intracellular protein. The regulator is a dipeptide, a small polypeptide or a carboxyl-terminal derivative of an amino acid. The dipeptide or small polypeptide has an N-terminal amino acid residue which is Arg, Lys or His for the Type I protein, Phe, Leu, Trp, Tyr or Ile for the Type II protein and Ala, Ser or Thr for the Type III protein. The carboxyl-terminal derivative of an amino acid may be an amino acid modified at its C-terminus by the addition of a group selected from methyl, ethyl, propyl, butyl and isobutyl. The amino acid modified is the N-terminal amino acid residue of the dipeptide or small polypeptide for the respective Type I, II and III proteins. Compositions may be formed containing the regulator for contacting with the cells. Increasing the half-life of intracellular protein with the regulator may be used for treating diseases resulting from an abnormal breakdown of a desired protein, and for enhancing in vivo production of a desired protein.",MASSACHUSETTS INST TECHNOLOGY,BAKER ROHAN;;GONDA DAVID,,https://lens.org/091-677-232-949-123,Granted Patent,no,0,0,14,14,0,C07K2319/00;;C07K2319/61;;C07K2319/95;;C12N15/62;;C12N15/67;;C12N15/81;;C12P21/02;;C12Y302/01023;;C12N9/2471;;A61P43/00;;C12P21/02;;C12N15/67;;C07K2319/95;;C07K2319/00;;C12N15/62;;C07K2319/61;;C12N15/81;;C12Y302/01023;;C12N9/2471,A61P43/00;;C07K2/00;;C07K4/00;;C07K5/06;;C12N9/00;;C12N9/38;;C12N15/09;;A61K38/00;;C12N15/62;;C12N15/67;;C12N15/81;;C12P21/00;;C12P21/02;;C12R1/865,,0,0,,,,EXPIRED
8,EP,A1,EP 3060198 A1,149-495-035-647-084,2016-08-31,2016,EP 14855080 A,2014-10-03,US 201361894165 P;;US 201461949032 P;;US 2014/0059092 W,2013-10-22,INHALED SURFACTANT-MODIFIED LIPOSOMAL FORMULATIONS PROVIDING BOTH AN IMMEDIATE AND SUSTAINED RELEASE PROFILE,,ARADIGM CORP,CIPOLLA DAVID;;GONDA IGOR,,https://lens.org/149-495-035-647-084,Patent Application,yes,0,3,10,10,0,A61K9/127;;A61K9/127;;A61K9/0078;;A61K9/0078;;A61K31/496;;A61K31/496;;A61K47/10;;A61K47/10;;A61K47/26;;A61K47/26;;A61P11/00;;A61P31/04,A61K9/127,,0,0,,,,DISCONTINUED
9,CA,A1,CA 2923647 A1,187-244-059-597-618,2015-04-30,2015,CA 2923647 A,2014-10-03,US 201361894165 P;;US 201461949032 P;;US 2014/0059092 W,2013-10-22,INHALED SURFACTANT-MODIFIED LIPOSOMAL FORMULATIONS PROVIDING BOTH AN IMMEDIATE AND SUSTAINED RELEASE PROFILE,"Methods for formulating and compositions of immediate and sustained release liposomal products which comprise a surfactant that interacts with liposomes to effect drug release therefrom, and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.",ARADIGM CORP,CIPOLLA DAVID;;GONDA IGOR,,https://lens.org/187-244-059-597-618,Patent Application,no,0,0,10,10,0,A61K9/127;;A61K9/127;;A61K9/0078;;A61K9/0078;;A61K31/496;;A61K31/496;;A61K47/10;;A61K47/10;;A61K47/26;;A61K47/26;;A61P11/00;;A61P31/04,A61K9/127;;A61K9/133;;A61K9/72;;A61K31/496;;A61P31/04,,0,0,,,,DISCONTINUED
10,AU,A1,AU 2014/340568 A1,164-940-834-332-261,2016-03-10,2016,AU 2014/340568 A,2014-10-03,US 201461949032 P;;US 201361894165 P;;US 2014/0059092 W,2013-10-22,Inhaled surfactant-modified liposomal formulations providing both an immediate and sustained release profile,"Methods for formulating and compositions of immediate and sustained release liposomal products which comprise a surfactant that interacts with liposomes to effect drug release therefrom, and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.",ARADIGM CORP,CIPOLLA DAVID;;GONDA IGOR,,https://lens.org/164-940-834-332-261,Patent Application,no,0,0,10,10,0,A61K9/127;;A61K9/127;;A61K9/0078;;A61K9/0078;;A61K31/496;;A61K31/496;;A61K47/10;;A61K47/10;;A61K47/26;;A61K47/26;;A61P11/00;;A61P31/04,A61K9/127,,0,0,,,,INACTIVE
11,DE,T2,DE 69009476 T2,054-916-885-591-37X,1994-12-22,1994,DE 69009476 T,1990-06-27,US 37382589 A;;US 9003669 W,1989-06-30,HEMMUNG DES REAKTIONSWEGS FÜR DIE N-ENDE-REGEL IN LEBENDEN ZELLEN.,"The half-life of a Type I, II and III non-compartmentalized intracellular proteins is increased in living eukaryotic cells by contacting the cells with a regulator having an amino-terminal amino acid residue which is the same or similar to the amino-terminal residue of the intracellular protein. The regulator is a dipeptide, a small polypeptide or a carboxyl-terminal derivative of an amino acid. The dipeptide or small polypeptide has an N-terminal amino acid residue which is Arg, Lys or His for the Type I protein, Phe, Leu, Trp, Tyr or Ile for the Type II protein and Ala, Ser or Thr for the Type III protein. The carboxyl-terminal derivative of an amino acid may be an amino acid modified at its C-terminus by the addition of a group selected from methyl, ethyl, propyl, butyl and isobutyl. The amino acid modified is the N-terminal amino acid residue of the dipeptide or small polypeptide for the respective Type I, II and III proteins. Compositions may be formed containing the regulator for contacting with the cells. Increasing the half-life of intracellular protein with the regulator may be used for treating diseases resulting from an abnormal breakdown of a desired protein, and for enhancing in vivo production of a desired protein.",MASSACHUSETTS INST TECHNOLOGY,BAKER ROHAN;;GONDA DAVID,,https://lens.org/054-916-885-591-37X,Granted Patent,no,0,0,14,14,0,C07K2319/00;;C07K2319/61;;C07K2319/95;;C12N15/62;;C12N15/67;;C12N15/81;;C12P21/02;;C12Y302/01023;;C12N9/2471;;A61P43/00;;C12P21/02;;C12N15/67;;C07K2319/95;;C07K2319/00;;C12N15/62;;C07K2319/61;;C12N15/81;;C12Y302/01023;;C12N9/2471,A61P43/00;;C07K2/00;;C07K4/00;;C07K5/06;;C12N9/00;;C12N9/38;;C12N15/09;;A61K38/00;;C12N15/62;;C12N15/67;;C12N15/81;;C12P21/00;;C12P21/02;;C12R1/865,,0,0,,,,EXPIRED
12,WO,A1,WO 2015/061025 A1,161-954-925-197-606,2015-04-30,2015,US 2014/0059092 W,2014-10-03,US 201361894165 P;;US 201461949032 P,2013-10-22,INHALED SURFACTANT-MODIFIED LIPOSOMAL FORMULATIONS PROVIDING BOTH AN IMMEDIATE AND SUSTAINED RELEASE PROFILE,"Methods for formulating and compositions of immediate and sustained release liposomal products which comprise a surfactant that interacts with liposomes to effect drug release therefrom, and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.",ARADIGM CORP,CIPOLLA DAVID;;GONDA IGOR,,https://lens.org/161-954-925-197-606,Patent Application,yes,2,1,10,10,0,A61K9/127;;A61K9/127;;A61K9/0078;;A61K9/0078;;A61K31/496;;A61K31/496;;A61K47/10;;A61K47/10;;A61K47/26;;A61K47/26;;A61P11/00;;A61P31/04,A61K9/127,,1,0,,,See also references of EP 3060198A4,PENDING
13,AU,A1,AU 2015/244399 A1,193-936-320-261-603,2016-10-13,2016,AU 2015/244399 A,2015-02-11,US 201461976729 P;;US 2015/0015433 W,2014-04-08,Liposomes that form drug nanocrystals after freeze-thaw,"Methods for formulating a liposome comprised of a surfactant and a cryopreservative that can be frozen for long term stability, and upon thawing provides an immediate and sustained release delivery profile. Specific liposome formulations include anti-infectives and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.",ARADIGM CORP,CIPOLLA DAVID;;GONDA IGOR,,https://lens.org/193-936-320-261-603,Patent Application,no,0,0,13,16,0,A61K9/0078;;A61K45/06;;A61K9/127;;A61K47/26;;A61K31/496;;A61P31/00;;A61K9/0078;;A61K9/127;;A61K31/496;;A61K45/06;;A61K47/26;;A61K9/127;;A61K47/26;;A61K31/496;;A61K9/0078;;A61K45/06;;Y02A50/30,A61K9/19;;A61K9/127;;A61K9/133,,0,0,,,,INACTIVE
14,KR,A,KR 20160144404 A,116-184-017-980-208,2016-12-16,2016,KR 20167030501 A,2015-02-11,US 201461976729 P;;US 2015/0015433 W,2014-04-08,- LIPOSOMES THAT FORM DRUG NANOCRYSTALS AFTER FREEZE-THAW,"장기간 안정성을 위해 냉동될 수 있고, 해동시 즉각적인 및 지속적인 방출 전달 프로파일을 제공하는, 계면활성제 및 냉동보존제로 구성된 리포솜의 제형 방법. 특정 리포솜 제형은 항감염제를 포함하고, 기도 감염 및 다른 의학적 상태의 치료를 위한 그것의 전달, 그것과 관련하여 사용된 장치 및 제형들이 기술된다.",ARADIGM CORP,CIPOLLA DAVID;;GONDA IGOR,,https://lens.org/116-184-017-980-208,Patent Application,no,0,0,13,16,0,A61K9/0078;;A61K45/06;;A61K9/127;;A61K47/26;;A61K31/496;;A61P31/00;;A61K9/0078;;A61K9/127;;A61K31/496;;A61K45/06;;A61K47/26;;A61K9/127;;A61K47/26;;A61K31/496;;A61K9/0078;;A61K45/06;;Y02A50/30,A61K9/127;;A61K9/00;;A61K31/496;;A61K45/06;;A61K47/26,,0,0,,,,DISCONTINUED
15,CA,A1,CA 2943201 A1,171-910-847-282-650,2015-10-15,2015,CA 2943201 A,2015-02-11,US 201461976729 P;;US 2015/0015433 W,2014-04-08,LIPOSOMES THAT FORM DRUG NANOCRYSTALS AFTER FREEZE-THAW,"Methods for formulating a liposome comprised of a surfactant and a cryopreservative that can be frozen for long term stability, and upon thawing provides an immediate and sustained release delivery profile. Specific liposome formulations include anti-infectives and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.",ARADIGM CORP,CIPOLLA DAVID;;GONDA IGOR,,https://lens.org/171-910-847-282-650,Patent Application,no,0,0,13,16,0,A61K9/0078;;A61K45/06;;A61K9/127;;A61K47/26;;A61K31/496;;A61P31/00;;A61K9/0078;;A61K9/127;;A61K31/496;;A61K45/06;;A61K47/26;;A61K9/127;;A61K47/26;;A61K31/496;;A61K9/0078;;A61K45/06;;Y02A50/30,A61K9/19;;A61K9/127;;A61K9/133,,0,0,,,,DISCONTINUED
16,CN,A,CN 106456551 A,029-756-686-302-428,2017-02-22,2017,CN 201580030744 A,2015-02-11,US 201461976729 P;;US 2015/0015433 W,2014-04-08,Liposomes that form drug nanocrystals after freeze-thaw,"Methods for formulating a liposome comprised of a surfactant and a cryopreservative that can be frozen for long term stability, and upon thawing provides an immediate and sustained release delivery profile. Specific liposome formulations include anti-infectives and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.",ARADIGM CORP,CIPOLLA DAVID;;GONDA IGOR,,https://lens.org/029-756-686-302-428,Patent Application,no,5,5,13,16,0,A61K9/0078;;A61K45/06;;A61K9/127;;A61K47/26;;A61K31/496;;A61P31/00;;A61K9/0078;;A61K9/127;;A61K31/496;;A61K45/06;;A61K47/26;;A61K9/127;;A61K47/26;;A61K31/496;;A61K9/0078;;A61K45/06;;Y02A50/30,A61K9/19;;A61K9/127;;A61K9/133,,0,0,,,,DISCONTINUED
17,AU,B2,AU 2015/244399 B2,094-621-016-419-618,2019-10-03,2019,AU 2015/244399 A,2015-02-11,US 201461976729 P;;US 2015/0015433 W,2014-04-08,Liposomes that form drug nanocrystals after freeze-thaw,"Methods for formulating a liposome comprised of a surfactant and a cryopreservative that can be frozen for long term stability, and upon thawing provides an immediate and sustained release delivery profile. Specific liposome formulations include anti-infectives and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.",ARADIGM CORP,CIPOLLA DAVID;;GONDA IGOR,,https://lens.org/094-621-016-419-618,Granted Patent,no,1,0,13,16,0,A61K9/0078;;A61K45/06;;A61K9/127;;A61K47/26;;A61K31/496;;A61P31/00;;A61K9/0078;;A61K9/127;;A61K31/496;;A61K45/06;;A61K47/26;;A61K9/127;;A61K47/26;;A61K31/496;;A61K9/0078;;A61K45/06;;Y02A50/30,A61K9/19;;A61K9/127;;A61K9/133,,3,2,038-604-184-677-717;;057-723-944-383-350,10.1007/s11095-013-1135-z;;23881305;;10.1016/0168-3659(94)90257-7,"ANTONIO P. COSTA ET AL, ""Freeze-Anneal-Thaw Cycling of Unilamellar Liposomes: Effect on Encapsulation Efficiency"", PHARMACEUTICAL RESEARCH, US, (2013-07-24), vol. 31, no. 1, doi:10.1007/s11095-013-1135-z, ISSN 0724-8741, pages 97 - 103;;AUSBORN M ET AL, ""The protective effect of free and membrane-bound cryoprotectants during freezing and freeze-drying of liposomes"", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 30, no. 2, (1994-05-01), pages 105 - 116;;Anonymous, Nanotechnology for Cancer Therapy, CRC Press, (2006-12-19)",INACTIVE
18,BR,A2,BR PI1008930 A2,044-911-538-484-785,2016-03-15,2016,BR PI1008930 A,2010-01-26,US 2010/0022071 W;;US 15355609 P,2009-02-18,formulação moduladas pelo ph para liberação pulmonar,,ARADIGM CORP,CIPOLLA DAVID C;;GONDA IGOR,,https://lens.org/044-911-538-484-785,Patent Application,no,0,0,20,20,0,A61K9/0078;;A61K31/43;;A61K31/545;;A61K31/65;;A61K33/24;;A61K31/496;;A61P11/00;;A61P3/14;;A61P31/00;;A61P31/04;;A61P7/00;;A61K9/0078;;A61K9/12;;A61K31/496;;A61K2121/00;;A61K33/24;;A61K31/43;;A61K31/545;;A61K31/65;;A61K33/24;;A61K9/0078;;A61K31/496;;A61K9/007;;A61K9/12,A61K9/12;;A61K33/24,,0,0,,,,DISCONTINUED
19,US,B2,US 9987227 B2,011-073-019-753-632,2018-06-05,2018,US 201414506181 A,2014-10-03,US 201414506181 A;;US 201361894165 P;;US 201461949032 P,2013-10-22,Inhaled surfactant-modified liposomal formulations providing both an immediate and sustained release profile,"Methods for formulating and compositions of immediate and sustained release liposomal products which comprise a surfactant that interacts with liposomes to effect drug release therefrom, and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.",ARADIGM CORP,CIPOLLA DAVID C;;GONDA IGOR,ARADIGM CORPORATION (2014-10-09);;GRIFOLS S.A (2020-03-31),https://lens.org/011-073-019-753-632,Granted Patent,yes,53,1,10,10,0,A61K9/127;;A61K9/127;;A61K9/0078;;A61K9/0078;;A61K31/496;;A61K31/496;;A61K47/10;;A61K47/10;;A61K47/26;;A61K47/26;;A61P11/00;;A61P31/04,A61K9/127;;A61K9/00;;A61K31/496;;A61K47/10;;A61K47/26,,29,23,075-949-839-628-664;;101-904-038-391-443;;001-072-770-278-869;;000-420-896-836-274;;066-267-219-024-523;;089-040-092-049-181;;050-768-728-208-368;;023-708-751-561-393;;049-892-690-627-761;;079-972-396-442-57X;;072-344-092-374-780;;048-497-642-568-879;;058-433-709-835-418;;048-157-998-339-224;;020-470-228-204-854;;032-708-511-260-192;;033-150-287-738-644;;011-205-311-656-508;;050-665-220-730-241;;027-637-339-787-964;;054-239-054-807-234;;002-172-916-785-260;;027-466-297-564-565,5859039;;10.1016/s0022-2836(65)80093-6;;10.1128/aac.41.6.1288;;pmc163901;;9174185;;10.1002/jps.10021;;11835207;;12399169;;10.1016/s0168-3659(02)00264-x;;10.1016/s0168-3659(03)00358-4;;14568408;;11555566;;10.1378/chest.120.3_suppl.118s;;10.1378/chest.120.3_suppl.107s;;11555564;;2515523;;10.1002/ppul.1950070413;;15246977;;10.1152/ajplung.00387.2003;;14514520;;10.3410/f.1018171.207650;;10.1152/ajplung.00227.2003;;10.1038/sj.gt.3300593;;9614554;;10.1258/002367702320162405;;12144741;;10.1164/ajrccm.161.1.9903019;;10619831;;10.1002/ppul.1950170511;;8058428;;16805947;;10.1211/jpp.58.7.0002;;pmc245550;;1482150;;10.1128/aac.36.12.2808;;9814848;;10.1016/s0005-2736(98)00125-4;;pmc4770250;;10.1136/thoraxjnl-2013-203207;;23681906;;10.4155/tde.13.71;;23919478;;10.4155/ppa.13.47;;24237172;;10.1021/jp2026187;;21604798;;10387952;;10.1016/s0378-5173(99)00105-2;;10.1016/0005-2736(88)90234-9;;3334842,"Bangham et al., “Diffusion of Univalent Ions across the Lamellae of Swollen Phospholipids” J. Mol. Biol., 13:238-252 (1965).;;Conley et al., “Aerosol Delivery of Liposome-Encapsulated Ciprofloxacin: Aerosol Characterization and Efficacy against Francisella tularensis Infection in Mice” Antimicrobial Angents, 41(6):1288-1292 (Jun. 1997).;;Desai et al., “A Novel Approach to the Pulmonary Delivery of Liposomes in Dry Powder Form to Eliminate the Deleterious Effects of Milling” Journal of Pharmaceutical Sciences, 91(2):482-491 (Feb. 2002).;;Desai et al., “A facile method of delivery of liposomes by nebulization” Journal of Controlled Release, 84:69-78 (2002).;;Wong et al., “Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection” Journal of Controlled Release, 92:265-273 (2003).;;Lipuma JJ., Microbiological and immunologic considerations with aerosolized drug delivery. Chest. Sep. 2001;120(3 Suppl):118S-123S.;;Moss RB., Administration of aerosolized antibiotics in cystic fibrosis patients. Chest. Sep. 2001;120(3 Suppl):107S-113S.;;Smith AL, et al. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Ped Pulmonol. 1989;7(4):265-271.;;Van Heeckeren AM, et al. Role of Cftr genotype in the response to chronic Pseudomonas aeruginosa lung infection in mice. Am J Physiol Lung Cell Mol Physiol. Nov. 2004;287(5):L944-52. Epub Jul. 9, 2004.;;Van Heeckeren AM, et al.. Delivery of CTFR by adenoviral vector to cystic fibrosis mouse lung in a model of chronic Pseudomonas aeruginosa lung infection. Am J Physiol Lung Cell Mol Physiol. Apr. 2004;286(4):L717-26. Epub Sep. 26, 2003.;;Van Heeckeren A, et al.., Effects of bronchopulmonary inflammation induced by pseudomonas aeruginosa on adenovirus-mediated gene transfer to airway epithelial cells in mice. Gene Ther. Mar. 1998;5(3):345-51.;;Van Heeckeren AM, et al., Murine models of chronic Pseudomonas aeruginosa lung infection. Lab Anim. Jul. 2002;36(3):291-312.;;Van Heeckeren AM, et al., Effect of Pseudomonas infection on weight loss, lung mechanics, and cytokines in mice. Am J Respir Crit Care Med. Jan. 2000;161(1):271.;;Weber A, et al., Nebulizer delivery of tobramycin to the lower respiratory tract. Pediatr Pulmonol. May 1994;17(5):331-9.;;Elhissi et al., “Formulations generated from ethanol-based proliposomes for delivery via medical nebulizers” Journal of Pharmacy and Pharmacology, Jul. 2006, 58:887-894.;;Kyriacos et al., “In Vitro Testing of Ciprofloxacin Formulations and Preliminary Study on BCS Biowaiver” Journal of Food and Drug Analysis, (2009) 17(2): 78-84.;;Majumdar et al., “Efficacies of liposome-encapsulated streptomycin and ciprofloxacin against Mycobacterium avium-M. intracellulare complex infections in human peripheral blood monocyte/macrophages” Antimicrob. Agents Chemother., (1992) 36(12):2808-2815.;;Maurer et al., “Anomalous solubility behavior of the antibiotic ciprofloxacin encapsulated in liposomes: a 1H-NMR study” Biopchimica et Biophysica Acta., (1998) 1374:9-20.;;Yim, D. et al., “The development of inhaled liposome-encapsulated ciprofloxacin to treat cystic fibrosis.” Respiratory Drug Delivery (2006) 2006:425-428.;;Serisier, DJ, et al. “Inhaled, Dual-Release Liposomal Ciprofloxacin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-2)—a Randomised, Double-Blind, Placebo-Controlled Trial. Thorax.” (2013) 68(9):812-817 doi: 10.1136/thoraxjnl-2013-203207.;;Hamblin, AJ, et al., “Efficacy of Inhaled Liposome-Encapsulated Ciprofloxacin Against Yersinis pestis.” 19th Congress of the International Society of Aerosols in Medicine (2012) 1 page.;;Bruineberg, P, et al. “Inhaled liposomal ciprofloxacin: once a day management of respiratory infections.” Respiratory Drug Delivery (2010) pp. 73-81. Editors, Richard N. Dalby, Peter R. Byron, Joanne Peart, Julie D. Suman, Stephen J. Farr, Paul M. Young. Davis Healthcare Int'l Publishing, River Grove, IL. Orlando, FL, Apr. 25-29, 2010.;;Cipolla, D, et al. “Liposomes, niosomes and proniosomes—a critical update of their (commercial) development as inhaled products.” Respiratory Drug Delivery Europe (2011) pp. 41-54. Editors, Richard N. Dalby, Peter R. Byron, Joanne Peart, Julie D. Suman, Stephen J. Farr, Paul M. Young. Davis Healthcare Int'l Publishing, River Grove, IL. Berlin, Germany, May 3-6, 2011.;;Cipolla, D. et al. “Liposomal Ciprofloxacin for Inhalation Retains Integrity Following Nebulization.” Respiratory Drug Delivery Europe (2013) pp. 237-242. Editors, Richard N. Dalby, Peter R. Byron, Joanne Peart, Julie D. Suman, Stephen J. Farr, Paul M. Young. Davis Healthcare Int'l Publishing, River Grove, IL. Berlin, Germany, May 21-24, 2013.;;Cipolla, D, et al., “Liposomal Formulations for Inhalation.” Therapeutic Delivery (2013) 4(8):1047-1072. doi: 10.4155/tde.13.71.;;Cipolla, D. et al. “Inhaled Antibiotics to Treat Lung Infection” Pharmaceutical Patent Analyst. (2013) 2(5):647-663.;;Velluto, D., C. et al. “Use of simple kinetic and reaction-order measurements for the evaluation of the mechanism of surfactant-liposome interactions.” J Phys Chem B (2011) 115(25): 8130-8137.;;Memoli et al., “Surfactant-induced leakage from liposomes: A comparison among different lecithin vesicles” Int. J. Pharm. (1999) 184(2):227-235.;;Ruiz et al., “Surfactant-induced release of liposomal contents: A survey of methods and results,” Biochim. Biophys. Acta. (1988) 937(1):127-134. (Abstract Only).",INACTIVE
20,CA,A1,CA 2752296 A1,132-350-814-207-307,2010-08-26,2010,CA 2752296 A,2010-01-26,US 15355609 P;;US 2010/0022071 W,2009-02-18,PH-MODULATED FORMULATIONS FOR PULMONARY DELIVERY,"An aerosolizable formulation comprised of a drug, a carrier and pH affecting component is disclosed. The drug is dissolved in the formulation at a concentration above which it remains in solution at neutral pH. This increases the concentration of the drug in solution making it possible to administer larger amounts of drug with the same or a smaller volume of formulation. When the formulation is aerosolized to small particles and inhaled into human lungs in small volumes (e.g. 0.05 to 0.5 mL) the fluids in the lungs neutralize the formulation causing the drug to participate out of solution. This results in the drug being delivered at a controlled rate below the rate at which drug is administered from a formulation initially at a neutral pH.",ARADIGM CORP,CIPOLLA DAVID C;;GONDA IGOR,,https://lens.org/132-350-814-207-307,Patent Application,no,0,0,20,20,0,A61K9/0078;;A61K31/43;;A61K31/545;;A61K31/65;;A61K33/24;;A61K31/496;;A61P11/00;;A61P3/14;;A61P31/00;;A61P31/04;;A61P7/00;;A61K9/0078;;A61K9/12;;A61K31/496;;A61K2121/00;;A61K33/24;;A61K31/43;;A61K31/545;;A61K31/65;;A61K33/24;;A61K9/0078;;A61K31/496;;A61K9/007;;A61K9/12,A61K9/12;;A61K33/24,,0,0,,,,INACTIVE
21,US,A1,US 2016/0120806 A1,066-501-330-603-462,2016-05-05,2016,US 201614993281 A,2016-01-12,US 201614993281 A;;US 201514619874 A;;US 201461976729 P,2014-04-08,NANOCRYSTALS FORMED IN A MICROENVIRONMENT,"A formulation is disclosed which is comprised of a first solvent having a first active ingredient dissolved therein a plurality of microenvironments dispersed in the first solvent, the microenvironment being comprised of a shell having a dimension in a range of 50 nanometers to 100, the shell comprising an internal volume comprising a second solvent having a second active ingredient dissolved therein and nanocrystals of the second active ingredient.",ARADIGM CORP,CIPOLLA DAVID C;;GONDA IGOR,ARADIGM CORPORATION (2016-02-16),https://lens.org/066-501-330-603-462,Patent Application,yes,18,15,1,16,0,A61K9/127;;A61K9/127;;A61K9/0078;;A61K9/0078;;A61K9/1277;;A61K9/1277;;A61K31/496;;A61K31/496;;A61K47/26;;A61K47/26;;Y02A50/30,A61K9/127;;A61K31/496,,2,2,033-150-287-738-644;;033-150-287-738-644,9814848;;10.1016/s0005-2736(98)00125-4;;9814848;;10.1016/s0005-2736(98)00125-4,"Maurer, N., et al in Biochimica Biophysica Acta, 1374, pp. 9-20, 1998;;Maurer, N., et al in Biochimica Biophysica Acta, 1374, pp. 9-20, 1998",DISCONTINUED
22,US,A1,US 2015/0283076 A1,093-887-977-632-102,2015-10-08,2015,US 201514619874 A,2015-02-11,US 201514619874 A;;US 201461976729 P,2014-04-08,NOVEL LIPOSOMAL FORMULATIONS THAT FORM DRUG NANOCRYSTALS AFTER FREEZE-THAW,"Methods for formulating a liposome comprised of a surfactant and a cryopreservative that can be frozen for long term stability, and upon thawing provides an immediate and sustained release delivery profile. Specific liposome formulations include anti-infectives and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.",ARADIGM CORP,CIPOLLA DAVID C;;GONDA IGOR,ARADIGM CORPORATION (2015-03-05);;GRIFOLS S.A (2020-03-31),https://lens.org/093-887-977-632-102,Patent Application,yes,7,20,13,16,0,A61K9/0078;;A61K45/06;;A61K9/127;;A61K47/26;;A61K31/496;;A61P31/00;;A61K9/0078;;A61K9/127;;A61K31/496;;A61K45/06;;A61K47/26;;A61K9/127;;A61K47/26;;A61K31/496;;A61K9/0078;;A61K45/06;;Y02A50/30,A61K9/127;;A61K31/496;;A61K47/10;;A61K47/26,,0,0,,,,INACTIVE
23,CA,C,CA 2752296 C,167-634-792-007-973,2018-09-11,2018,CA 2752296 A,2010-01-26,US 15355609 P;;US 2010/0022071 W,2009-02-18,PH-MODULATED FORMULATIONS FOR PULMONARY DELIVERY,"An aerosolizable formulation comprised of a drug, a carrier and pH affecting component is disclosed. The drug is dissolved in the formulation at a concentration above which it remains in solution at neutral pH. This increases the concentration of the drug in solution making it possible to administer larger amounts of drug with the same or a smaller volume of formulation. When the formulation is aerosolized to small particles and inhaled into human lungs in small volumes (e.g. 0.05 to 0.5 mL) the fluids in the lungs neutralize the formulation causing the drug to participate out of solution. This results in the drug being delivered at a controlled rate below the rate at which drug is administered from a formulation initially at a neutral pH.",ARADIGM CORP,CIPOLLA DAVID C;;GONDA IGOR,,https://lens.org/167-634-792-007-973,Granted Patent,no,0,0,20,20,0,A61K9/0078;;A61K31/43;;A61K31/545;;A61K31/65;;A61K33/24;;A61K31/496;;A61P11/00;;A61P3/14;;A61P31/00;;A61P31/04;;A61P7/00;;A61K9/0078;;A61K9/12;;A61K31/496;;A61K2121/00;;A61K33/24;;A61K31/43;;A61K31/545;;A61K31/65;;A61K33/24;;A61K9/0078;;A61K31/496;;A61K9/007;;A61K9/12,A61K9/72;;A61K31/496;;A61K33/24,,0,0,,,,INACTIVE
24,EP,A1,EP 2398462 A1,044-817-184-343-254,2011-12-28,2011,EP 10744110 A,2010-01-26,US 2010/0022071 W;;US 15355609 P,2009-02-18,PH-MODULATED FORMULATIONS FOR PULMONARY DELIVERY,,ARADIGM CORP,CIPOLLA DAVID C;;GONDA IGOR,,https://lens.org/044-817-184-343-254,Patent Application,yes,0,0,20,20,0,A61K9/0078;;A61K31/43;;A61K31/545;;A61K31/65;;A61K33/24;;A61K31/496;;A61P11/00;;A61P3/14;;A61P31/00;;A61P31/04;;A61P7/00;;A61K9/0078;;A61K9/12;;A61K31/496;;A61K2121/00;;A61K33/24;;A61K31/43;;A61K31/545;;A61K31/65;;A61K33/24;;A61K9/0078;;A61K31/496;;A61K9/007;;A61K9/12,A61K9/12;;A61K31/24;;A61K31/43;;A61K31/496;;A61K31/545;;A61K33/24,,0,0,,,,DISCONTINUED
25,WO,A2,WO 2017/123315 A2,124-310-316-526-165,2017-07-20,2017,US 2016/0060824 W,2016-11-07,US 201614993281 A,2016-01-12,NANOCRYSTALS FORMED IN A MICROENVIRONMENT,"A formulation is disclosed which is comprised of a first solvent having a first active ingredient dissolved therein a plurality of microenvironments dispersed in the first solvent, the microenvironment being comprised of a spherical shell having a diameter in a range of 0.5 micron to 100 microns, the shell comprising an internal volume comprising a second solvent having a second active ingredient dissolved therein and nanocrystals of the second active ingredient.",ARADIGM CORP,CIPOLLA DAVID C;;GONDA IGOR,,https://lens.org/124-310-316-526-165,Patent Application,yes,0,3,2,16,0,A61K9/127;;A61K9/0078;;A61K9/1277;;A61K31/496;;A61K45/06;;A61K47/26,A61K9/127;;A61K31/496,,0,0,,,,PENDING
26,WO,A1,WO 2010/096242 A1,087-126-624-090-068,2010-08-26,2010,US 2010/0022071 W,2010-01-26,US 15355609 P,2009-02-18,PH-MODULATED FORMULATIONS FOR PULMONARY DELIVERY,"An aerosolizable formulation comprised of a drug, a carrier and pH affecting component is disclosed. The drug is dissolved in the formulation at a concentration above which it remains in solution at neutral pH. This increases the concentration of the drug in solution making it possible to administer larger amounts of drug with the same or a smaller volume of formulation. When the formulation is aerosolized to small particles and inhaled into human lungs in small volumes (e.g. 0.05 to 0.5 mL) the fluids in the lungs neutralize the formulation causing the drug to participate out of solution. This results in the drug being delivered at a controlled rate below the rate at which drug is administered from a formulation initially at a neutral pH.",ARADIGM CORP;;CIPOLLA DAVID C;;GONDA IGOR,CIPOLLA DAVID C;;GONDA IGOR,,https://lens.org/087-126-624-090-068,Patent Application,yes,4,0,20,20,0,A61K9/0078;;A61K31/43;;A61K31/545;;A61K31/65;;A61K33/24;;A61K31/496;;A61P11/00;;A61P3/14;;A61P31/00;;A61P31/04;;A61P7/00;;A61K9/0078;;A61K9/12;;A61K31/496;;A61K2121/00;;A61K33/24;;A61K31/43;;A61K31/545;;A61K31/65;;A61K33/24;;A61K9/0078;;A61K31/496;;A61K9/007;;A61K9/12,A61K9/12;;A61K33/24,,2,1,044-851-723-958-40X,24981754;;10.1016/j.ddtec.2005.05.016,"VANBEVER.: ""Performance-Driven, Pulmonary Delivery of Systemically Acting Drugs."", DRUG DISCOVERY TODAY: TECHNOLOGIES, vol. 2, no. 1, 2005, pages 39 - 46, XP004976271;;See also references of EP 2398462A4",PENDING
27,WO,A3,WO 2017/123315 A3,149-270-297-985-836,2017-08-31,2017,US 2016/0060824 W,2016-11-07,US 201614993281 A,2016-01-12,NANOCRYSTALS FORMED IN A MICROENVIRONMENT,"A formulation is disclosed which is comprised of a first solvent having a first active ingredient dissolved therein a plurality of microenvironments dispersed in the first solvent, the microenvironment being comprised of a spherical shell having a diameter in a range of 0.5 micron to 100 microns, the shell comprising an internal volume comprising a second solvent having a second active ingredient dissolved therein and nanocrystals of the second active ingredient.",ARADIGM CORP,CIPOLLA DAVID C;;GONDA IGOR,,https://lens.org/149-270-297-985-836,Search Report,yes,4,0,2,16,0,A61K9/127;;A61K9/0078;;A61K9/1277;;A61K31/496;;A61K45/06;;A61K47/26,A61K9/00;;A61K9/12;;A61K9/127;;A61K9/133;;A61K9/19;;A61K31/18;;A61K31/245;;A61K31/395;;A61K31/49;;A61K31/496;;A61K31/65,,1,0,,,"CIPOLLA, D ET AL.: ""Formation of drug nanocrystals under nanoconfinement afforded by liposomes"", ROYAL SOCIETY OF CHEMISTRY ADVANCES, vol. 6, 8 January 2016 (2016-01-08), pages 6223 - 6233, XP055413307",PENDING
28,AU,B2,AU 2010/216348 B2,001-318-524-712-989,2015-01-22,2015,AU 2010/216348 A,2010-01-26,US 15355609 P;;US 2010/0022071 W,2009-02-18,pH-modulated formulations for pulmonary delivery,"An aerosolizable formulation comprised of a drug, a carrier and pH affecting component is disclosed. The drug is dissolved in the formulation at a concentration above which it remains in solution at neutral pH. This increases the concentration of the drug in solution making it possible to administer larger amounts of drug with the same or a smaller volume of formulation. When the formulation is aerosolized to small particles and inhaled into human lungs in small volumes (e.g. 0.05 to 0.5 mL) the fluids in the lungs neutralize the formulation causing the drug to participate out of solution. This results in the drug being delivered at a controlled rate below the rate at which drug is administered from a formulation initially at a neutral pH.",ARADIGM CORP,CIPOLLA DAVID C;;GONDA IGOR,,https://lens.org/001-318-524-712-989,Granted Patent,no,5,0,20,20,0,A61K9/0078;;A61K31/43;;A61K31/545;;A61K31/65;;A61K33/24;;A61K31/496;;A61P11/00;;A61P3/14;;A61P31/00;;A61P31/04;;A61P7/00;;A61K9/0078;;A61K9/12;;A61K31/496;;A61K2121/00;;A61K33/24;;A61K31/43;;A61K31/545;;A61K31/65;;A61K33/24;;A61K9/0078;;A61K31/496;;A61K9/007;;A61K9/12,A61K9/12;;A61K33/24,,1,1,076-423-145-398-462,10.1042/cs0740373;;3356109,"LOWRY RH, et al. Clinical Science, (1988) Vol 74, pp 373-376.",INACTIVE
29,US,A1,US 2020/0297722 A1,033-383-271-180-188,2020-09-24,2020,US 202016896132 A,2020-06-08,US 202016896132 A;;US 201615218971 A;;US 69373910 A;;US 15355609 P,2009-02-18,pH-Modulated Formulations for Pulmonary Delivery,"An aerosolizable formulation comprised of a drug, a carrier and pH affecting component is disclosed. The Drug is dissolved in the formulation at a concentration above which it remains in solution at neutral pH. This increases the concentration of the drug in solution making it possible to administer larger amounts of drug with the same or a smaller volume of formulation. When the formulation is aerosolized to small particles and inhaled into human lungs in small volumes (e.g. 0.05 to 0.5 mL) the fluids in the lungs neutralize the formulation causing the drug to participate out of solution. This results in the drug being delivered at a controlled rate below the rate at which drug is administered from a formulation initially at a neutral pH.",GRIFOLS SA,CIPOLLA DAVID C;;GONDA IGOR,ARADIGM CORPORATION (2017-02-03);;GRIFOLS S.A (2020-03-31),https://lens.org/033-383-271-180-188,Patent Application,yes,0,0,20,20,0,A61K9/0078;;A61K31/43;;A61K31/545;;A61K31/65;;A61K33/24;;A61K31/496;;A61P11/00;;A61P3/14;;A61P31/00;;A61P31/04;;A61P7/00;;A61K9/0078;;A61K9/12;;A61K31/496;;A61K2121/00;;A61K33/24;;A61K31/43;;A61K31/545;;A61K31/65;;A61K33/24;;A61K9/0078;;A61K31/496;;A61K9/007;;A61K9/12,A61K31/496;;A61K9/00;;A61K9/12;;A61K31/43;;A61K31/545;;A61K31/65;;A61K33/24,,0,0,,,,DISCONTINUED
30,US,B2,US 9968555 B2,066-274-349-042-514,2018-05-15,2018,US 201514619874 A,2015-02-11,US 201514619874 A;;US 201461976729 P,2014-04-08,Liposomal formulations that form drug nanocrystals after freeze-thaw,"Methods for formulating a liposome comprised of a surfactant and a cryopreservative that can be frozen for long term stability, and upon thawing provides an immediate and sustained release delivery profile. Specific liposome formulations include anti-infectives and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.",ARADIGM CORP,CIPOLLA DAVID C;;GONDA IGOR,ARADIGM CORPORATION (2015-03-05);;GRIFOLS S.A (2020-03-31),https://lens.org/066-274-349-042-514,Granted Patent,yes,15,0,13,16,0,A61K9/0078;;A61K45/06;;A61K9/127;;A61K47/26;;A61K31/496;;A61P31/00;;A61K9/0078;;A61K9/127;;A61K31/496;;A61K45/06;;A61K47/26;;A61K9/127;;A61K47/26;;A61K31/496;;A61K9/0078;;A61K45/06;;Y02A50/30,A61K9/127;;A61K9/00;;A61K31/496;;A61K45/06;;A61K47/26,,14,11,128-345-886-759-353;;035-121-678-040-243;;050-665-220-730-241;;007-122-013-064-944;;015-132-669-034-026;;069-271-598-076-315;;037-256-374-574-44X;;004-758-352-546-31X;;009-893-982-767-479;;057-723-944-383-350;;038-604-184-677-717,10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a3192;;12909649;;10.1099/jmm.0.05224-0;;10.4155/tde.13.71;;23919478;;10.1016/0014-5793(92)80947-f;;1426260;;10.1016/j.ejps.2010.08.010;;20800680;;pmc323309;;10.1073/pnas.83.8.2422;;16593683;;10.1016/j.bbamem.2003.12.006;;15003875;;16611229;;10.1111/j.1462-5822.2005.00667.x;;10.1016/j.jconrel.2005.10.011;;16318894;;10.1016/0168-3659(94)90257-7;;10.1007/s11095-013-1135-z;;23881305,"Bruinenberg P., “Safety, tolerability and pharmacokinetics of novel liposomal ciprofloxacin of novel liposomal ciprofloxacin formulations for inhalation in healthy volunteers and in non-cystic bronchiectasis patients”, Am. J. Respir. Crit. Care Med. (2010) 181:A3192.;;Carter G., “Characterization of biofilm formation by Mycobacterium avium strains”, J. Med. Microbiol. (2003) 52: 747-52.;;Cipolla D., “Liposomal Formulations for Inhalation”, Ther. Deliv., (2013) 4, 8, 1047-1072. doi: 10.4155/tde.13.71.;;Cipolla D., “Development and Characterization of an In Vitro Release Assay for Liposomal Ciprofloxacin for Inhalation”, J. Pharm. Sci., (2014) 103, 1, 314-327. doi: 10.1002/jps.23795.;;Lasic DD., “Gelation of liposome interior: A novel method for drug encapsulation”, FEBS Lett., (1992) 312:255-258.;;Stark B., “Long-term stability of sterically stabilized liposomes by freezing and freeze-drying: Effects of cryoprotectants on structure”, Eur. J. Pharm. Sci. 41(2010) 546-555.;;Strauss G. “Stabilization of lipid bilayer by sucrose during freezing”, PNAS (1986) 83, 2422-2426.;;Wolkers WF. “Preservation of dried liposomes in the presence of sugar and phosphate” Biochim. Biphys. Acta. 1661, 125-134.;;Yamazaki Y. “The ability to form biofilm influences Mycobacterium avium invasion and translocation of bronchial epithelial cells” Cell Microbiol. (2006) 8: 806-14.;;Zhigaltsev IV. “Formation of drug-arylsulfonate complexes inside liposomes: A novel approach to improve drug retention” J. Control Rel. 110: 378-386.;;Cipolla, et al., “Formation of drug nanocrystals under nanoconfinement afforded by liposomes,” Royal Society of Chemistry Advances (Jan. 2016) 6:6223-6233.;;ANONYMOUS: ""Nanotechnology for Cancer Therapy"", 19 December 2006, CRC PRESS, XP002772115;;Ausborn et al., “The protective effect of free and membrane-bound cryoprotectants during freezing and freeze-drying of liposomes” Journal of Controlled Release (1994) 30:105-116.;;Costa et al., “Freeze-Anneal-Thaw Cycling of Unilamellar Liposomes: Effect on Encapsulation Efficiency” Pharm Res (2014) 31:97-103.",INACTIVE
31,AU,A1,AU 2010/216348 A1,087-412-558-293-154,2011-09-08,2011,AU 2010/216348 A,2010-01-26,US 15355609 P;;US 2010/0022071 W,2009-02-18,pH-modulated formulations for pulmonary delivery,"An aerosolizable formulation comprised of a drug, a carrier and pH affecting component is disclosed. The drug is dissolved in the formulation at a concentration above which it remains in solution at neutral pH. This increases the concentration of the drug in solution making it possible to administer larger amounts of drug with the same or a smaller volume of formulation. When the formulation is aerosolized to small particles and inhaled into human lungs in small volumes (e.g. 0.05 to 0.5 mL) the fluids in the lungs neutralize the formulation causing the drug to participate out of solution. This results in the drug being delivered at a controlled rate below the rate at which drug is administered from a formulation initially at a neutral pH.",ARADIGM CORP,CIPOLLA DAVID C;;IGOR GONDA,,https://lens.org/087-412-558-293-154,Patent Application,no,0,0,20,20,0,A61K9/0078;;A61K31/43;;A61K31/545;;A61K31/65;;A61K33/24;;A61K31/496;;A61P11/00;;A61P3/14;;A61P31/00;;A61P31/04;;A61P7/00;;A61K9/0078;;A61K9/12;;A61K31/496;;A61K2121/00;;A61K33/24;;A61K31/43;;A61K31/545;;A61K31/65;;A61K33/24;;A61K9/0078;;A61K31/496;;A61K9/007;;A61K9/12,A61K9/12;;A61K33/24,,0,0,,,,INACTIVE
32,EP,A4,EP 2398462 A4,032-139-510-045-194,2012-07-25,2012,EP 10744110 A,2010-01-26,US 2010/0022071 W;;US 15355609 P,2009-02-18,PH-MODULATED FORMULATIONS FOR PULMONARY DELIVERY,,ARADIGM CORP,CIPOLLA DAVID C;;GONDA IGOR,,https://lens.org/032-139-510-045-194,Search Report,no,3,0,20,20,0,A61K9/0078;;A61K31/43;;A61K31/545;;A61K31/65;;A61K33/24;;A61K31/496;;A61P11/00;;A61P3/14;;A61P31/00;;A61P31/04;;A61P7/00;;A61K9/0078;;A61K9/12;;A61K31/496;;A61K2121/00;;A61K33/24;;A61K31/43;;A61K31/545;;A61K31/65;;A61K33/24;;A61K9/0078;;A61K31/496;;A61K9/007;;A61K9/12,A61K9/12;;A61K31/24;;A61K31/43;;A61K31/496;;A61K31/545;;A61K33/24,,1,0,,,See also references of WO 2010096242A1,DISCONTINUED
33,CN,A,CN 102395356 A,094-371-667-995-847,2012-03-28,2012,CN 201080017088 A,2010-01-26,US 2010/0022071 W;;US 15355609 P,2009-02-18,Ph-modulated formulations for pulmonary delivery,"An aerosolizable formulation comprised of a drug, a carrier and pH affecting component is disclosed. The drug is dissolved in the formulation at a concentration above which it remains in solution at neutral pH. This increases the concentration of the drug in solution making it possible to administer larger amounts of drug with the same or a smaller volume of formulation. When the formulation is aerosolized to small particles and inhaled into human lungs in small volumes (e.g. 0.05 to 0.5 mL) the fluids in the lungs neutralize the formulation causing the drug to participate out of solution. This results in the drug being delivered at a controlled rate below the rate at which drug is administered from a formulation initially at a neutral pH.",ARADIGM CORP,CIPOLLA DAVID C;;IGOR GONDA,,https://lens.org/094-371-667-995-847,Patent Application,no,0,3,20,20,0,A61K9/0078;;A61K31/43;;A61K31/545;;A61K31/65;;A61K33/24;;A61K31/496;;A61P11/00;;A61P3/14;;A61P31/00;;A61P31/04;;A61P7/00;;A61K9/0078;;A61K9/12;;A61K31/496;;A61K2121/00;;A61K33/24;;A61K31/43;;A61K31/545;;A61K31/65;;A61K33/24;;A61K9/0078;;A61K31/496;;A61K9/007;;A61K9/12,A61K9/12;;A61K33/24,,0,0,,,,DISCONTINUED
34,US,A1,US 2010/0209538 A1,129-025-010-951-563,2010-08-19,2010,US 69373910 A,2010-01-26,US 69373910 A;;US 15355609 P,2009-02-18,PH-MODULATED FORMULATIONS FOR PULMONARY DELIVERY,"An aerosolizable formulation comprised of a drug, a carrier and pH affecting component is disclosed. The drug is dissolved in the formulation at a concentration above which it remains in solution at neutral pH. This increases the concentration of the drug in solution making it possible to administer larger amounts of drug with the same or a smaller volume of formulation. When the formulation is aerosolized to small particles and inhaled into human lungs in small volumes (e.g. 0.05 to 0.5 mL) the fluids in the lungs neutralize the formulation causing the drug to participate out of solution. This results in the drug being delivered at a controlled rate below the rate at which drug is administered from a formulation initially at a neutral pH.",CIPOLLA DAVID C;;GONDA IGOR,CIPOLLA DAVID C;;GONDA IGOR,ARADIGM CORPORATION (2010-03-23),https://lens.org/129-025-010-951-563,Patent Application,yes,8,3,20,20,0,A61K9/0078;;A61K31/43;;A61K31/545;;A61K31/65;;A61K33/24;;A61K31/496;;A61P11/00;;A61P3/14;;A61P31/00;;A61P31/04;;A61P7/00;;A61K9/0078;;A61K9/12;;A61K31/496;;A61K2121/00;;A61K33/24;;A61K31/43;;A61K31/545;;A61K31/65;;A61K33/24;;A61K9/0078;;A61K31/496;;A61K9/007;;A61K9/12,A61K31/43;;A61K31/496;;A61K31/545;;A61K31/65;;A61K33/24;;A61P11/00,424/650;;514/192;;514/200;;514/152;;514/253.07,0,0,,,,DISCONTINUED
35,CN,A,CN 105362256 A,167-735-648-518-317,2016-03-02,2016,CN 201510837609 A,2010-01-26,US 15355609 P;;CN 201080017088 A,2009-02-18,PH-modulated formulations for pulmonary delivery,"An aerosolizable formulation comprised of a drug, a carrier and pH affecting component is disclosed. The drug is dissolved in the formulation at a concentration above which it remains in solution at neutral pH. This increases the concentration of the drug in solution making it possible to administer larger amounts of drug with the same or a smaller volume of formulation. When the formulation is aerosolized to small particles and inhaled into human lungs in small volumes (e.g. 0.05 to 0.5 mL) the fluids in the lungs neutralize the formulation causing the drug to participate out of solution. This results in the drug being delivered at a controlled rate below the rate at which drug is administered from a formulation initially at a neutral pH.",ARADIGM CORP,CIPOLLA DAVID C;;GONDA IGOR,,https://lens.org/167-735-648-518-317,Patent Application,no,2,2,20,20,0,A61K9/0078;;A61K31/43;;A61K31/545;;A61K31/65;;A61K33/24;;A61K31/496;;A61P11/00;;A61P3/14;;A61P31/00;;A61P31/04;;A61P7/00;;A61K9/0078;;A61K9/12;;A61K31/496;;A61K2121/00;;A61K33/24;;A61K31/43;;A61K31/545;;A61K31/65;;A61K33/24;;A61K9/0078;;A61K31/496;;A61K9/007;;A61K9/12,A61K9/72;;A61K33/24;;A61K38/12;;A61K47/12;;A61P3/14;;A61P31/04,,3,2,076-423-145-398-462;;052-517-090-658-314,10.1042/cs0740373;;3356109;;10.1023/a:1018910431216;;8058609,"R.H.LOWRY,ET AL: ""Effects of pH and osmolarity on aerosol-induced cough in normal volunteers"", 《CLINICAL SCIENCE》;;YU,ET AL: ""the effect of temperature and pH on the solubility of quinolone compounds:estimation of heat of fusion"", 《PHARMACEUTICAL RESEARCH》;;张仲扬: ""肺结核化学治疗的进展"", 《成都医药通讯》",DISCONTINUED
36,JP,A,JP 2016164183 A,189-882-220-486-092,2016-09-08,2016,JP 2016081064 A,2016-04-14,US 15355609 P,2009-02-18,PH-MODULATED FORMULATIONS FOR PULMONARY DELIVERY,"PROBLEM TO BE SOLVED: To provide an aerosolizable formulation comprising a drug, a carrier and pH affecting component.SOLUTION: The drug is dissolved in the formulation at a concentration above which it remains in solution at neutral pH. This increases the concentration of the drug in solution making it possible to administer larger amounts of drug with the same or a smaller volume of formulation. When the formulation is aerosolized to small particles and inhaled into human lungs in small volumes (e.g. 0.05 to 0.5 mL), the fluids in the lungs neutralize the formulation and the drug precipitates out of the solution. As a result, the drug is delivered at a controlled rate below the rate at which drug is administered from a formulation initially at a neutral pH. The drug is gallium nitrate, preferably a gallium salt. The pH effecting agent deviates formulation pH by 0.75 to 4.15 log units, particularly preferably by 1.0 to 2.01 log units or more away from 7.4.SELECTED DRAWING: None",ARADIGM CORP,DAVID C CIPOLLA;;IGOR GONDA,,https://lens.org/189-882-220-486-092,Patent Application,no,4,0,20,20,0,A61K9/0078;;A61K31/43;;A61K31/545;;A61K31/65;;A61K33/24;;A61K31/496;;A61P11/00;;A61P3/14;;A61P31/00;;A61P31/04;;A61P7/00;;A61K9/0078;;A61K9/12;;A61K31/496;;A61K2121/00;;A61K33/24;;A61K31/43;;A61K31/545;;A61K31/65;;A61K33/24;;A61K9/0078;;A61K31/496;;A61K9/007;;A61K9/12,A61K9/72;;A61K31/43;;A61K31/47;;A61K31/496;;A61K31/545;;A61K31/65;;A61K33/24;;A61P7/00;;A61P31/04,,1,1,010-228-844-005-930,9860806,"BERNSTEIN, L.R., PHARMACOLOGICAL REVIEWS, vol. 50, no. 4, JPN6013056229, 1998, pages 665 - 682, ISSN: 0003497272",INACTIVE
37,US,A1,US 2015/0110855 A1,086-731-717-065-178,2015-04-23,2015,US 201414506181 A,2014-10-03,US 201414506181 A;;US 201361894165 P;;US 201461949032 P,2013-10-22,INHALED SURFACTANT-MODIFIED LIPOSOMAL FORMULATIONS PROVIDING BOTH AN IMMEDIATE AND SUSTAINED RELEASE PROFILE,"Methods for formulating and compositions of immediate and sustained release liposomal products which comprise a surfactant that interacts with liposomes to effect drug release therefrom, and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.",ARADIGM CORP,CIPOLLA DAVID C;;GONDA IGOR,ARADIGM CORPORATION (2014-10-09);;GRIFOLS S.A (2020-03-31),https://lens.org/086-731-717-065-178,Patent Application,yes,10,19,10,10,0,A61K9/127;;A61K9/127;;A61K9/0078;;A61K9/0078;;A61K31/496;;A61K31/496;;A61K47/10;;A61K47/10;;A61K47/26;;A61K47/26;;A61P11/00;;A61P31/04,A61K9/127;;A61K31/496;;A61K47/10;;A61K47/24;;A61K47/26,424/450;;514/253.08,0,0,,,,INACTIVE
38,US,A,US 5457044 A,129-581-487-392-17X,1995-10-10,1995,US 14592293 A,1993-10-29,US 14592293 A,1993-10-29,Method for collection of aerosolized proteins by inert filtration,"A method for collecting an aerosolized therapeutic polypeptide of interest, such as recombinant human deoxyribonuclease I (rhDNase), is provided which enables a determination as to the effect aerosolization has on the activity and integrity of the polypeptide. An aerosol of the polypeptide is generated using a nebulizer, for example, and the polypeptide is collected in an inert filter, such as a sintered glass filter. To increase the amount of polypeptide collected, the aerosol is preferably mixed with pre-humidified dilution air at a temperature between about 40.degree. and 55.degree. C. The collected polypeptide is subjected to biochemical activity and integrity analysis compared to the activity and integrity of the control polypeptide which has not been aerosolized.",GENENTECH INC,CIPOLLA DAVID C;;GONDA IGOR,GENENTECH INC (1993-10-29),https://lens.org/129-581-487-392-17X,Granted Patent,yes,8,3,1,1,0,B01D39/201;;C07K1/34;;C12N9/22;;C12N9/22;;C07K1/34;;B01D39/201,B01D39/20;;C07K1/34;;C12N9/22,435/199;;435/19;;55/523;;95/273;;252/340,13,8,004-211-024-314-22X;;033-190-998-509-246;;025-581-483-778-453;;026-799-658-509-019;;157-834-605-228-564;;057-227-445-185-525;;058-373-248-467-12X;;091-738-606-257-508,pmc55129;;2251263;;10.1073/pnas.87.23.9188;;1548827;;10.1001/jama.1992.03480140073036;;10.1001/jama.267.14.1947;;1538726;;10.1056/nejm199203193261207;;10.1152/jappl.1990.69.5.1843;;2272977;;10.1016/0169-409x(90)90010-p;;pmc286537;;2783491;;10.1073/pnas.86.2.680;;5667195;;10.1080/00028896809342983;;1409359;;10.1023/a:1015851521551,"Niven, R. W., Delivery of Biotherapeutics by Inhalation Aerosols , Pharm Tech. , 17:72 82 (1993).;;Shak, S.; et al., Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum , Proc. Nat. Acad. Sci. , 87:9188 92 (1990).;;Aitken, M. A., et al. Recombinant human DNase Inhalation in Normal Subjects and Patients with Cystic Fibrosis: A Phase 1 Study , JAMA , 267:1947 1951 (1992).;;Hubbard, R. C.; et al. A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis , New. Eng. J. Med. 326:812 815 (1992).;;Vogelmeier, C. et al. Aerosolization of recombinant SLPI to augment antineutrophil elastase protection of pulmonary epithelium , J. Appl. Physiol. , 69:1843 1848 (1990).;;Byron, P. R., Determinants of drug and polypeptide bioavailability from aerosols deliverd to the lung , Adv. Drug Del. Rev. 5:107 132 (1990).;;Hubbard, R. C. et al., Fate of aerosolized recombinant DNA produced 1 antitrypsin: Use of epithelial surface of the lower respiratory tract to administer proteins of therapeutic importance , Proc. Nat. Acad. Sci. , 86:680 684 (1989).;;Oeswein, J. Q., et al. Aerosolization of Protein Pharmaceuticals , Proceedings of the Second Respiratory Drug Delivery Symposium , Dalby, R. N., et al., Eds.; Continuing Pharmacy Education, Univ. of Kentucky, Ky., pp. 14 49 (1991).;;Mercer, T. T., et al., Operating Characteristics of Some Compressed Air Nebulizers , Am. Ind. Hyg. Assoc. J., 29:66 78 (1968).;;Colthorpe et al., The Pharmacokinetics of Pulmonary Delivered Insulin: A Comparison of Intratracheal and Aerosol Administration to the Rabbit , Pharm. Res. 9(6):764 768 (1992).;;Clark, A. R. et al. Recombinant human (rh) proteins for inhalation therapy: rhDNase aerosols a case study , American Assn. for Aerosol Research: 12th Annual Mtg , Oak Brook, Ill., abst No. 10A4, (Oct. 11 15 , 1993).;;Cipolla, D. C. et al., Method for recovery of nebulized proteins , J. Aerosol Medicine, abstracts of the 9th Congress, Aerosols in Medicine, Garmisch Partenkirchen, Germany, vol. 6(Supp.), pp. 1,15 (Mar. 30 Apr. 3, 1993).;;Cipolla, D. C. et al., Method for recovery of nebulized proteins , 205th ACS National Meeting: Book of Abstracts, abstract No. 60, (Mar. 28 Apr. 2, 1993).",EXPIRED
39,US,A1,US 2016/0331744 A1,134-285-134-071-009,2016-11-17,2016,US 201615218971 A,2016-07-25,US 201615218971 A;;US 69373910 A;;US 15355609 P,2009-02-18,pH-MODULATED FORMULATIONS FOR PULMONARY DELIVERY,"An aerosolizable formulation comprised of a drug, a carrier and pH affecting component is disclosed. The drug is dissolved in the formulation at a concentration above which it remains in solution at neutral pH. This increases the concentration of the drug in solution making it possible to administer larger amounts of drug with the same or a smaller volume of formulation. When the formulation is aerosolized to small particles and inhaled into human lungs in small volumes (e.g. 0.05 to 0.5 mL) the fluids in the lungs neutralize the formulation causing the drug to participate out of solution. This results in the drug being delivered at a controlled rate below the rate at which drug is administered from a formulation initially at a neutral pH.",ARADIGM CORP,CIPOLLA DAVID C;;GONDA IGOR,ARADIGM CORPORATION (2017-02-03);;GRIFOLS S.A (2020-03-31),https://lens.org/134-285-134-071-009,Patent Application,yes,0,0,20,20,0,A61K9/0078;;A61K31/43;;A61K31/545;;A61K31/65;;A61K33/24;;A61K31/496;;A61P11/00;;A61P3/14;;A61P31/00;;A61P31/04;;A61P7/00;;A61K9/0078;;A61K9/12;;A61K31/496;;A61K2121/00;;A61K33/24;;A61K31/43;;A61K31/545;;A61K31/65;;A61K33/24;;A61K9/0078;;A61K31/496;;A61K9/007;;A61K9/12,A61K31/496;;A61K9/00;;A61K9/12;;A61K31/43;;A61K31/545;;A61K31/65;;A61K33/24,,0,0,,,,DISCONTINUED
40,ES,T3,ES 2054365 T3,189-283-168-190-299,1994-08-01,1994,ES 90911196 T,1990-06-27,US 37382589 A,1989-06-30,INHIBICION DE LA VIA DE LA REGLA DEL N FINAL EN CELULAS VIVAS.,"The half-life of a Type I, II and III non-compartmentalized intracellular proteins is increased in living eukaryotic cells by contacting the cells with a regulator having an amino-terminal amino acid residue which is the same or similar to the amino-terminal residue of the intracellular protein. The regulator is a dipeptide, a small polypeptide or a carboxyl-terminal derivative of an amino acid. The dipeptide or small polypeptide has an N-terminal amino acid residue which is Arg, Lys or His for the Type I protein, Phe, Leu, Trp, Tyr or Ile for the Type II protein and Ala, Ser or Thr for the Type III protein. The carboxyl-terminal derivative of an amino acid may be an amino acid modified at its C-terminus by the addition of a group selected from methyl, ethyl, propyl, butyl and isobutyl. The amino acid modified is the N-terminal amino acid residue of the dipeptide or small polypeptide for the respective Type I, II and III proteins. Compositions may be formed containing the regulator for contacting with the cells. Increasing the half-life of intracellular protein with the regulator may be used for treating diseases resulting from an abnormal breakdown of a desired protein, and for enhancing in vivo production of a desired protein.",MASSACHUSETTS INST TECHNOLOGY,BAKER ROHAN T;;GONDA DAVID K,,https://lens.org/189-283-168-190-299,Granted Patent,no,0,0,14,14,0,C07K2319/00;;C07K2319/61;;C07K2319/95;;C12N15/62;;C12N15/67;;C12N15/81;;C12P21/02;;C12Y302/01023;;C12N9/2471;;A61P43/00;;C12P21/02;;C12N15/67;;C07K2319/95;;C07K2319/00;;C12N15/62;;C07K2319/61;;C12N15/81;;C12Y302/01023;;C12N9/2471,A61P43/00;;C07K2/00;;C07K4/00;;C07K5/06;;C12N9/00;;C12N9/38;;C12N15/09;;A61K38/00;;C12N15/62;;C12N15/67;;C12N15/81;;C12P21/00;;C12P21/02;;C12R1/865,,0,0,,,,EXPIRED
41,DK,T3,DK 0479912 T3,146-809-545-433-473,1994-10-10,1994,DK 90911196 T,1990-06-27,US 37382589 A,1989-06-30,Fremgangsmåde til hæmning af N-endereglens forløb i levende celler,"The half-life of a Type I, II and III non-compartmentalized intracellular proteins is increased in living eukaryotic cells by contacting the cells with a regulator having an amino-terminal amino acid residue which is the same or similar to the amino-terminal residue of the intracellular protein. The regulator is a dipeptide, a small polypeptide or a carboxyl-terminal derivative of an amino acid. The dipeptide or small polypeptide has an N-terminal amino acid residue which is Arg, Lys or His for the Type I protein, Phe, Leu, Trp, Tyr or Ile for the Type II protein and Ala, Ser or Thr for the Type III protein. The carboxyl-terminal derivative of an amino acid may be an amino acid modified at its C-terminus by the addition of a group selected from methyl, ethyl, propyl, butyl and isobutyl. The amino acid modified is the N-terminal amino acid residue of the dipeptide or small polypeptide for the respective Type I, II and III proteins. Compositions may be formed containing the regulator for contacting with the cells. Increasing the half-life of intracellular protein with the regulator may be used for treating diseases resulting from an abnormal breakdown of a desired protein, and for enhancing in vivo production of a desired protein.",MASSACHUSETTS INST TECHNOLOGY,BAKER ROHAN T;;GONDA DAVID K,,https://lens.org/146-809-545-433-473,Granted Patent,no,0,0,14,14,0,C07K2319/00;;C07K2319/61;;C07K2319/95;;C12N15/62;;C12N15/67;;C12N15/81;;C12P21/02;;C12Y302/01023;;C12N9/2471;;A61P43/00;;C12P21/02;;C12N15/67;;C07K2319/95;;C07K2319/00;;C12N15/62;;C07K2319/61;;C12N15/81;;C12Y302/01023;;C12N9/2471,A61P43/00;;C07K2/00;;C07K4/00;;C07K5/06;;C12N9/00;;C12N9/38;;C12N15/09;;A61K38/00;;C12N15/62;;C12N15/67;;C12N15/81;;C12P21/00;;C12P21/02;;C12R1/865,,0,0,,,,EXPIRED
42,EP,B1,EP 0479912 B1,054-799-632-980-588,1994-06-01,1994,EP 90911196 A,1990-06-27,US 9003669 W;;US 37382589 A,1989-06-30,INHIBITION OF THE N-END RULE PATHWAY IN LIVING CELLS.,"The half-life of a Type I, II and III non-compartmentalized intracellular proteins is increased in living eukaryotic cells by contacting the cells with a regulator having an amino-terminal amino acid residue which is the same or similar to the amino-terminal residue of the intracellular protein. The regulator is a dipeptide, a small polypeptide or a carboxyl-terminal derivative of an amino acid. The dipeptide or small polypeptide has an N-terminal amino acid residue which is Arg, Lys or His for the Type I protein, Phe, Leu, Trp, Tyr or Ile for the Type II protein and Ala, Ser or Thr for the Type III protein. The carboxyl-terminal derivative of an amino acid may be an amino acid modified at its C-terminus by the addition of a group selected from methyl, ethyl, propyl, butyl and isobutyl. The amino acid modified is the N-terminal amino acid residue of the dipeptide or small polypeptide for the respective Type I, II and III proteins. Compositions may be formed containing the regulator for contacting with the cells. Increasing the half-life of intracellular protein with the regulator may be used for treating diseases resulting from an abnormal breakdown of a desired protein, and for enhancing in vivo production of a desired protein.",MASSACHUSETTS INST TECHNOLOGY,BAKER ROHAN T;;GONDA DAVID K,,https://lens.org/054-799-632-980-588,Granted Patent,yes,2,0,14,14,0,C07K2319/00;;C07K2319/61;;C07K2319/95;;C12N15/62;;C12N15/67;;C12N15/81;;C12P21/02;;C12Y302/01023;;C12N9/2471;;A61P43/00;;C12P21/02;;C12N15/67;;C07K2319/95;;C07K2319/00;;C12N15/62;;C07K2319/61;;C12N15/81;;C12Y302/01023;;C12N9/2471,A61P43/00;;C07K2/00;;C07K4/00;;C07K5/06;;C12N9/00;;C12N9/38;;C12N15/09;;A61K38/00;;C12N15/62;;C12N15/67;;C12N15/81;;C12P21/00;;C12P21/02;;C12R1/865,,2,0,,,"Cell, vol. 56, 24 March 1989, Cell Press, (Cambridge, MA, US), A. Bachmair et al.; pp. 1019-1032;;Science, vol. 234, 10 October 1986, (Washington, D.C., US), A. Bachmair et al.; pp. 179-186",EXPIRED
43,WO,A1,WO 2023/039266 A1,186-294-176-201-861,2023-03-16,2023,US 2022/0043262 W,2022-09-12,US 202163243198 P;;US 202163243200 P,2021-09-12,DELIVERY DEVICES AND COMPOSITIONS,"Delivery devices and formulations for aerosolization of an API including nicotine or salts thereof. Delivery devices may comprise an inhaler for delivering an API in aerosol form. The inhaler includes a container that includes an API and one or more pharmaceutically acceptable carriers; a nozzle, valve, or outlet in communication with the container to deliver an aerosol; an insert located downstream of the nozzle, valve or outlet.",NICONOX LLC,VELAGA SITARAM;;STADERMAN DAVID;;GONDA IGOR,,https://lens.org/186-294-176-201-861,Patent Application,yes,8,0,1,1,0,A61M15/06;;A61M15/009;;A61M15/0026;;A61M15/0066;;A61M2210/0625,A61M15/00;;A61M11/00;;A61M99/00,,0,0,,,,PENDING
44,US,B2,US 9844548 B2,045-340-068-078-693,2017-12-19,2017,US 201615362405 A,2016-11-28,US 201615362405 A;;US 201514675218 A;;US 201461976727 P,2014-04-08,Liposomal ciprofloxacin formulations with encapsulated ciprofloxacin nanocrystals,"Methods of treatment of NTM lung infections using formulations of liposomal ciprofloxacin. Specific liposome formulations and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.",ARADIGM CORP,GONDA IGOR;;BLANCHARD JAMES;;CIPOLLA DAVID C,ARADIGM CORPORATION (2017-11-07);;OREGON STATE UNIVERSITY (2015-05-28);;GRIFOLS S.A (2020-03-31),https://lens.org/045-340-068-078-693,Granted Patent,yes,22,2,20,20,0,A61K9/0078;;A61K31/496;;A61K9/127;;A61K9/0073;;A61P11/00;;A61P31/04;;Y02A50/30;;A61K31/496;;A61K9/127;;A61K9/0073;;A61K9/0078;;Y02A50/30;;A61K9/12;;A61K45/06,A61K9/127;;A61K9/00;;A61K9/12;;A61K31/496;;A61K45/06,,10,10,075-949-839-628-664;;101-904-038-391-443;;034-910-153-767-189;;032-708-511-260-192;;033-150-287-738-644;;024-060-783-058-765;;023-708-751-561-393;;048-157-998-339-224;;066-267-219-024-523;;048-497-642-568-879,5859039;;10.1016/s0022-2836(65)80093-6;;10.1128/aac.41.6.1288;;pmc163901;;9174185;;10.1016/0005-2736(95)00159-z;;7488619;;pmc245550;;1482150;;10.1128/aac.36.12.2808;;9814848;;10.1016/s0005-2736(98)00125-4;;10.1016/s1473-3099(08)70100-2;;18471777;;2515523;;10.1002/ppul.1950070413;;10.1002/ppul.1950170511;;8058428;;10.1016/s0168-3659(03)00358-4;;14568408;;10.1258/002367702320162405;;12144741,"Bangham, et al., “Diffusion of Univalent Ions across teh Lamellae of Swollen Phospholipids” J. Mol. Niol., 13:238-252 (1965).;;Conley, et al., “Aerosol Delivery of Liposome-Encapsulated Ciprofloxacin: Aerosol Characterization and Efficacy against Francisella tularensis Infection in Mice” Antimicrobial Agents, 41(6): 1288-1292 (Jun. 1997).;;Lasic et al., “Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery” Biochemica et Biophysica Acta (1995) 1239:145-156.;;Majumdar et al., Efficacies of liposome-encapsulated streptomycin and ciprofloxacin against Mycobacterium avium-N. intracellulare complex infections in human peripheral blood monocytes/macrophages. Antimicrob Agents Chemother (1992) 36:2808-15.;;Maurer et al., “Anomalous solubility behavior of the antibiotic ciprofloxacin encapsulated in liposomes: a 1H-NMR study” Biochemica et Biophysica Acta (1998) 1374:9-20.;;Piersimoni et al., “Pulmonary infections associated with non-tuberculous mycobacteria in immunocompetent patients” Lancet Infect Dis (2008) 8:323-334.;;Smith, et al., “Saftety of Aerosol Tobramycin administration for 3 months to patients with cystic fibrosis.” Ped. Pulmonol. (1989); 7(4):265-271.;;Weber A, et al., “Nebulizer delivery of tobramycin to the lower respiratory tract”. Pediatr Pulmonol. (May 1994); 17 (5):331-9.;;Wong, et al., “Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection” Journal of Controlled Release, 92; 265-273 (2003). Van Heeckeren, et al., Effect of Pseudomonas infection on weight loss, lung mechanics.;;Van Heeckeren, et al., “Murine Models of chronic Pseudomonas aeruginosa lung infection” Lab Anim (Jul. 2002); 36(3):291-312.",ACTIVE
45,HK,A1,HK 1219047 A1,167-351-352-768-170,2017-03-24,2017,HK 16107081 A,2012-09-07,US 15355609 P,2009-02-18,PH-MODULATED FORMULATIONS FOR PULMONARY DELIVERY PH,,ARADIGM CORP,CIPOLLA DAVID C DC;;GONDA IGOR I,,https://lens.org/167-351-352-768-170,Patent Application,no,0,0,20,20,0,A61K9/0078;;A61K31/43;;A61K31/545;;A61K31/65;;A61K33/24;;A61K31/496;;A61P11/00;;A61P3/14;;A61P31/00;;A61P31/04;;A61P7/00;;A61K9/0078;;A61K9/12;;A61K31/496;;A61K2121/00;;A61K33/24;;A61K31/43;;A61K31/545;;A61K31/65;;A61K33/24;;A61K9/0078;;A61K31/496;;A61K9/007;;A61K9/12,A61K33/24,,0,0,,,,PENDING
46,DE,T2,DE 69324784 T2,122-224-869-273-715,1999-10-21,1999,DE 69324784 T,1993-11-29,GB 9227105 A;;GB 9227106 A;;GB 9306066 A;;GB 9306065 A,1992-12-30,Verfahren zur Herstellung von Hartschaumstoffen,,ICI PLC,DE VOS RIK;;THORPE DAVID;;VAN ESSCHE GONDA,"HUNTSMAN ICI CHEMICALS LLC, SALT LAKE CITY, UTAH, (2001-03-15)",https://lens.org/122-224-869-273-715,Granted Patent,no,0,0,15,19,0,C08G18/8054;;C08G18/8054;;C07C271/28;;C07C271/28;;C08G18/8087;;C08G18/8087;;C08G2110/0025;;C08G2110/0025;;C08G2110/005;;C08G2110/005,C08G18/00;;C07C271/28;;C08G18/02;;C08G18/08;;C08G18/10;;C08G18/76;;C08G18/80;;C08G101/00;;C08J9/02;;C08J9/14;;C08L75/04,,0,0,,,,EXPIRED
47,AU,A,AU 1990/059632 A,146-836-148-431-566,1991-01-17,1991,AU 1990/059632 A,1990-06-27,US 37382589 A,1989-06-30,INHIBITION OF THE N-END RULE PATHWAY IN LIVING CELLS,"The half-life of a Type I, II and III non-compartmentalized intracellular proteins is increased in living eukaryotic cells by contacting the cells with a regulator having an amino-terminal amino acid residue which is the same or similar to the amino-terminal residue of the intracellular protein. The regulator is a dipeptide, a small polypeptide or a carboxyl-terminal derivative of an amino acid. The dipeptide or small polypeptide has an N-terminal amino acid residue which is Arg, Lys or His for the Type I protein, Phe, Leu, Trp, Tyr or Ile for the Type II protein and Ala, Ser or Thr for the Type III protein. The carboxyl-terminal derivative of an amino acid may be an amino acid modified at its C-terminus by the addition of a group selected from methyl, ethyl, propyl, butyl and isobutyl. The amino acid modified is the N-terminal amino acid residue of the dipeptide or small polypeptide for the respective Type I, II and III proteins. Compositions may be formed containing the regulator for contacting with the cells. Increasing the half-life of intracellular protein with the regulator may be used for treating diseases resulting from an abnormal breakdown of a desired protein, and for enhancing in vivo production of a desired protein.",MASSACHUSETTS INST TECHNOLOGY,BAKER ROHAN T;;GONDA DAVID K;;VARSHAVSKY ALEXANDER,,https://lens.org/146-836-148-431-566,Patent Application,no,0,0,14,14,0,C07K2319/00;;C07K2319/61;;C07K2319/95;;C12N15/62;;C12N15/67;;C12N15/81;;C12P21/02;;C12Y302/01023;;C12N9/2471;;A61P43/00;;C12P21/02;;C12N15/67;;C07K2319/95;;C07K2319/00;;C12N15/62;;C07K2319/61;;C12N15/81;;C12Y302/01023;;C12N9/2471,A61K38/00;;A61P43/00;;C07K2/00;;C07K4/00;;C07K5/06;;C12N9/00;;C12N9/38;;C12N15/09;;C12N15/62;;C12N15/67;;C12N15/81;;C12P21/00;;C12P21/02;;C12R1/865,,0,0,,,,PENDING
48,CN,A,CN 1090857 A,167-207-315-583-453,1994-08-17,1994,CN 93121527 A,1993-12-30,GB 9227105 A;;GB 9227106 A;;GB 9306066 A;;GB 9306065 A,1992-12-30,Process for rigid foams,,ICI PLC,RIK DE VOS;;DAVID THORPE;;GONDA ESSCHE VAN,,https://lens.org/167-207-315-583-453,Patent Application,no,0,0,15,19,0,C08G18/8054;;C08G18/8054;;C07C271/28;;C07C271/28;;C08G18/8087;;C08G18/8087;;C08G2110/0025;;C08G2110/0025;;C08G2110/005;;C08G2110/005,C08G18/00;;C07C271/28;;C08G18/02;;C08G18/08;;C08G18/10;;C08G18/76;;C08G18/80;;C08G101/00;;C08J9/02;;C08J9/14;;C08L75/04,,0,0,,,,DISCONTINUED
49,AU,A,AU 1998/064359 A,188-030-424-901-271,1998-09-09,1998,AU 1998/064359 A,1998-02-19,US 80404197 A;;US 9803108 W,1997-02-24,Compressible atomizer with porous nozzle and prefilter,,ARIDIGM CORP,RUBSAMEN REID;;GONDA IGOR;;FARR STEPHEN;;CIPOLLA DAVID,,https://lens.org/188-030-424-901-271,Patent Application,no,0,0,5,11,0,A61M15/0045;;A61M2205/6081;;A61M15/0043;;A61M15/0051;;A61M15/0055;;A61M11/001;;A61M11/002;;A24D3/17;;A61M15/0045;;A61M2205/6081;;A61M15/0055;;A61M15/0051;;A61M15/0043;;A61M11/001;;A61M11/002;;A24D3/17,A24D3/17;;A61M15/00,,0,0,,,,PENDING
50,US,A,US 5393799 A,023-460-267-963-255,1995-02-28,1995,US 16345993 A,1993-12-06,GB 9227105 A;;GB 9227106 A;;GB 9306065 A;;GB 9306066 A,1992-12-30,Process for rigid foams,"Process for the preparation of rigid polyurethane foam by reaction of a polyfunctional isocyanate-reactive composition with a polyisocyanate composition comprising the reaction product of a stoichiometric excess of an organic polyisocyanate and a substantially fluorinated isocyanate-reactive compound, optionally in the presence of an inert, insoluble fluorinated compound.",ICI PLC,DE VOS RIK;;THORPE DAVID;;VAN ESSCHE GONDA,HUNTSMAN ICI CHEMICALS LLC (1999-06-30);;IMPERIAL CHEMICAL INDUSTRIES PLC (1994-01-21),https://lens.org/023-460-267-963-255,Granted Patent,yes,28,6,15,19,0,C08G18/8054;;C08G18/8054;;C07C271/28;;C07C271/28;;C08G18/8087;;C08G18/8087;;C08G2110/0025;;C08G2110/0025;;C08G2110/005;;C08G2110/005,C08G18/00;;C07C271/28;;C08G18/02;;C08G18/08;;C08G18/10;;C08G18/76;;C08G18/80;;C08G101/00;;C08J9/02;;C08J9/14;;C08L75/04,521/157;;521/159,0,0,,,,EXPIRED
51,WO,A1,WO 1998/036651 A1,129-310-288-570-186,1998-08-27,1998,US 9803108 W,1998-02-19,US 80404197 A,1997-02-24,COMPRESSIBLE ATOMIZER WITH POROUS NOZZLE AND PREFILTER,"This invention is a device (1) for generating an inhaler aerosol by collapsing a wall portion (2) of a liquid (5) reservoir to force the liquid through a prefilter (301), and then through a porous nozzle (302). The porous nozzle has smaller pores than the prefilter.",ARADIGM CORP,RUBSAMEN REID;;GONDA IGOR;;FARR STEPHEN;;CIPOLLA DAVID,,https://lens.org/129-310-288-570-186,Patent Application,yes,3,46,5,11,0,A61M15/0045;;A61M2205/6081;;A61M15/0043;;A61M15/0051;;A61M15/0055;;A61M11/001;;A61M11/002;;A24D3/17;;A61M15/0045;;A61M2205/6081;;A61M15/0055;;A61M15/0051;;A61M15/0043;;A61M11/001;;A61M11/002;;A24D3/17,A24D3/17;;A61M15/00,,0,0,,,,PENDING
52,IN,B,IN 185467 B,056-113-266-140-485,2001-01-27,2001,IN 349MA1998 A,1998-02-20,US 80404197 A,1997-02-24,A disposable package for use in aerosolized delivery of a flowable formulation,,ARADIGM CORP,RUBSAMEN REID;;GONDA IGOR;;FARR STEPHEN;;CIPOLLA DAVID,,https://lens.org/056-113-266-140-485,Granted Patent,no,0,0,5,11,0,A61M15/0045;;A61M2205/6081;;A61M15/0043;;A61M15/0051;;A61M15/0055;;A61M11/001;;A61M11/002;;A24D3/17;;A61M15/0045;;A61M2205/6081;;A61M15/0055;;A61M15/0051;;A61M15/0043;;A61M11/001;;A61M11/002;;A24D3/17,A24D3/17;;A61M15/00,,0,0,,,,EXPIRED
53,EP,A1,EP 0605105 A1,019-912-858-023-724,1994-07-06,1994,EP 93309489 A,1993-11-29,GB 9227105 A;;GB 9227106 A;;GB 9306065 A;;GB 9306066 A,1992-12-30,Process for rigid foams.,"Process for the preparation of rigid polyurethane foam by reaction of a polyfunctional isocyanate-reactive composition with a polyisocyanate composition comprising the reaction product of a stoichiometric excess of an organic polyisocyanate and a substantially fluorinated isocyanate-reactive compound, optionally in the presence of an inert, insoluble fluorinated compound.",ICI PLC,DE VOS RIK;;THORPE DAVID;;VAN ESSCHE GONDA,,https://lens.org/019-912-858-023-724,Patent Application,yes,4,8,15,19,0,C08G18/8054;;C08G18/8054;;C07C271/28;;C07C271/28;;C08G18/8087;;C08G18/8087;;C08G2110/0025;;C08G2110/0025;;C08G2110/005;;C08G2110/005,C08G18/00;;C07C271/28;;C08G18/02;;C08G18/08;;C08G18/10;;C08G18/76;;C08G18/80;;C08G101/00;;C08J9/02;;C08J9/14;;C08L75/04,,3,0,,,"CHEMICAL ABSTRACTS, vol. 105, no. 9, 3 November 1986, Columbus, Ohio, US; abstract no. 154760w;;DATABASE WPI Week 8714, Derwent World Patents Index; AN 87-097897;;DATABASE WPI Week 8742, Derwent World Patents Index; AN 87-294530",EXPIRED
54,CA,A1,CA 2110894 A1,050-609-797-485-678,1994-07-01,1994,CA 2110894 A,1993-12-07,GB 9227105 A;;GB 9227106 A;;GB 9306065 A;;GB 9306066 A,1992-12-30,PROCESS FOR RIGID FOAMS,"Process For Rigid Foams Process for the preparation of rigid polyurethane foam by reaction of a polyfunctional isocyanate-reactive composition with a polyisocyanate composition comprising the reaction product of a stoichiometric excess of an organic polyisocyanate and a substantially fluorinated isocyanate-reactive compound, optionally in the presence of an inert, insoluble fluorinated compound.",ICI PLC,DE VOS RIK;;THORPE DAVID;;VAN ESSCHE GONDA,,https://lens.org/050-609-797-485-678,Patent Application,no,0,0,15,19,0,C08G18/8054;;C08G18/8054;;C07C271/28;;C07C271/28;;C08G18/8087;;C08G18/8087;;C08G2110/0025;;C08G2110/0025;;C08G2110/005;;C08G2110/005,C08G18/00;;C07C271/28;;C08G18/02;;C08G18/08;;C08G18/10;;C08G18/76;;C08G18/80;;C08G101/00;;C08J9/02;;C08J9/14;;C08L75/04,,0,0,,,,DISCONTINUED
55,CN,A,CN 1175599 A,033-337-511-669-568,1998-03-11,1998,CN 97111451 A,1997-05-16,GB 9227105 A;;GB 9227106 A;;GB 9306066 A;;GB 9306065 A,1992-12-30,Polyisocyanate compositions,,ICI PLC,VOS RIK DE;;THORPE DAVID;;ESSCHE GONDA VAN,,https://lens.org/033-337-511-669-568,Patent Application,no,0,0,15,19,0,C08G18/8054;;C08G18/8054;;C07C271/28;;C07C271/28;;C08G18/8087;;C08G18/8087;;C08G2110/0025;;C08G2110/0025;;C08G2110/005;;C08G2110/005,C08G18/00;;C07C271/28;;C08G18/02;;C08G18/08;;C08G18/10;;C08G18/76;;C08G18/80;;C08G101/00;;C08J9/02;;C08J9/14;;C08L75/04,,0,0,,,,DISCONTINUED
56,WO,A1,WO 1991/000356 A1,053-541-283-843-854,1991-01-10,1991,US 9003669 W,1990-06-27,US 37382589 A,1989-06-30,INHIBITION OF THE N-END RULE PATHWAY IN LIVING CELLS,"The invention described herein encompasses a method of influencing the metabolic stability of an intracellular protein in vivo (in intact cells and whole animals) along with compositions for affecting such regulation. The method comprises administering a regulator having an amino-terminal amino acid residue which is the same as or similar to the amino-terminal residue of the intracellular protein or group of proteins. If desired, this amino-terminal residue is chosen to be a member of the destabilizing class of amino-terminal residues, according to the N-end rule of protein degradation. The compositions of the present invention can comprise a DNA construct encoding a protein and a DNA construct encoding a regulator having the same or similar amino-terminal residue as the protein. The compositions can also comprise the regulator, having an amino-terminal residue which is the same as or similar to the amino-terminal residue of the protein and, as desired, is a member of the destabilizing class of amino-terminal residues, according to the N-end rule of protein degradation. The methods and compositions of this invention may be used for treating diseases resulting from an abnormal breakdown of a desired protein or group of proteins, and for enhancing in vivo production of a desired protein or group of proteins in biotechnological applications.",MASSACHUSETTS INST TECHNOLOGY,BAKER ROHAN T;;GONDA DAVID K;;VARSHAVSKY ALEXANDER,,https://lens.org/053-541-283-843-854,Patent Application,yes,2,8,14,14,0,C07K2319/00;;C07K2319/61;;C07K2319/95;;C12N15/62;;C12N15/67;;C12N15/81;;C12P21/02;;C12Y302/01023;;C12N9/2471;;A61P43/00;;C12P21/02;;C12N15/67;;C07K2319/95;;C07K2319/00;;C12N15/62;;C07K2319/61;;C12N15/81;;C12Y302/01023;;C12N9/2471,A61P43/00;;C07K2/00;;C07K4/00;;C07K5/06;;C12N9/00;;C12N9/38;;C12N15/09;;A61K38/00;;C12N15/62;;C12N15/67;;C12N15/81;;C12P21/00;;C12P21/02;;C12R1/865,C7A AB249;;C7A AB249;;C7A AB249;;C7A AB249;;C7A AB25Y;;C7A AB25Y;;C7A AB250;;C7A AB250;;C7A AB26X;;C7A AB26X;;C7A AB261;;C7A AB261;;C7A AB263;;C7A AB263;;C7A AB265;;C7A AB265;;C7A AB267;;C7A AB267;;C7A AB269;;C7A AB269;;C7A AB27X;;C7A AB27X;;C7A AB271;;C7A AB271;;C7A AB273;;C7A AB273;;C7A AB275;;C7A AB277;;C7A AB279;;C7A AB279;;C7A AB279;;C7A AB28Y;;C7A AB283;;C7A AB285;;C7A AB287;;C7A AB289;;C7A AB289;;C7A AB289;;C7A AB289;;C7A AB29Y;;C7A AB298;;C7A AB30X;;C7A AB301;;C7A AB303;;C7A AB305;;C7A AB307;;C7A AB309;;C7A AB309;;C7A AB309;;C7A AB309;;C7A AB319;;C7A AB319;;C7A AB319;;C7A AB319;;C7A AB32X;;C7A AB32X;;C7A AB32X;;C7A AB32X;;C7A AB32Y;;C7A AB32Y;;C7A AB32Y;;C7A AB32Y;;C7A AB320;;C7A AB320;;C7A AB320;;C7A AB349;;C7A AB349;;C7A AB349;;C7A AB349;;C7A AB35Y;;C7A AB35Y;;C7A AB35Y;;C7A AB35Y;;C7A AB361;;C7A AB361;;C7A AB361;;C7A AB361;;C7A AB363;;C7A AB363;;C7A AB363;;C7A AB363;;C7A AB365;;C7A AB365;;C7A AB365;;C7A AB365;;C7A AB367;;C7A AB367;;C7A AB367;;C7A AB367;;C7A AB369,2,2,005-431-905-859-044;;090-311-049-519-085,2538246;;10.1016/0092-8674(89)90635-1;;3018930;;10.1126/science.3018930,"Cell, Volume 56, 24 March 1989, Cell Press, (Cambridge, MA, US), A. BACHMAIR et al.: ""The Degradation Signal in a Short-Lived Protein"", pages 1019-1032;;Science, Volume 234, 10 October 1986, (Washington, D.C., US), A. BACHMAIR et al.: ""In Vivo Half-Life of a Protein is a Function of its Amino-Terminal Residu, pages 179-186",PATENTED
57,ES,T3,ES 2132198 T3,081-332-642-072-057,1999-08-16,1999,ES 93309489 T,1993-11-29,GB 9227105 A;;GB 9227106 A;;GB 9306066 A;;GB 9306065 A,1992-12-30,PROCEDIMIENTO PARA LA PRODUCCION DE ESPUMAS RIGIDAS.,"PROCESO PARA LA PREPARACION DE ESPUMAS DE POLIURETANO SOLIDAS POR REACCION DE UNA COMPOSICION REACTIVA DE ISOCIANATO POLIFUNCIONAL CON UNA COMPOSICION DE POLI-ISOCIANATO QUE COMPRENDE UN PRODUCTO DE REACCION DE EXCEDENTE ESTEQUIOMETRICO DE UN POLI-ISOCIANATO ORGANICO Y UN COMPUESTO REACTIVO DE ISOCIANATO FLUORADO, OPCIONALMENTE EN PRESENCIA DE UN COMPUESTO FLUORADO INERTE E INSOLUBLE.",ICI PLC,DE VOS RIK;;THORPE DAVID;;VAN ESSCHE GONDA,,https://lens.org/081-332-642-072-057,Granted Patent,no,0,0,15,19,0,C08G18/8054;;C08G18/8054;;C07C271/28;;C07C271/28;;C08G18/8087;;C08G18/8087;;C08G2110/0025;;C08G2110/0025;;C08G2110/005;;C08G2110/005,C08G18/00;;C07C271/28;;C08G18/02;;C08G18/08;;C08G18/10;;C08G18/76;;C08G18/80;;C08G101/00;;C08J9/02;;C08J9/14;;C08L75/04,,0,0,,,,EXPIRED
58,AU,B2,AU 665284 B2,153-632-589-031-874,1995-12-21,1995,AU 1993/052122 A,1993-12-02,GB 9227105 A;;GB 9227106 A;;GB 9306066 A;;GB 9306065 A,1992-12-30,Process for rigid foams,,ICI PLC,VOS RIK DE;;THORPE DAVID;;ESSCHE GONDA VAN,,https://lens.org/153-632-589-031-874,Granted Patent,no,2,0,15,19,0,C08G18/8054;;C08G18/8054;;C07C271/28;;C07C271/28;;C08G18/8087;;C08G18/8087;;C08G2110/0025;;C08G2110/0025;;C08G2110/005;;C08G2110/005,C08G18/00;;C07C271/28;;C08G18/02;;C08G18/08;;C08G18/10;;C08G18/76;;C08G18/80;;C08G101/00;;C08J9/02;;C08J9/14;;C08L75/04,,0,0,,,,EXPIRED
59,US,A,US 5829435 A,194-400-135-505-080,1998-11-03,1998,US 80404197 A,1997-02-24,US 80404197 A,1997-02-24,Prefilter for prevention of clogging of a nozzle in the generation of an aerosol and prevention of administration of undesirable particles,"A device, drug package and methodology for using such to generate an aerosol by moving a flowable formulation through a low resistance filter and then through a nozzle comprised of a porous membrane are disclosed. The package is comprised of a collapsible wall portion that forms a container for holding a liquid formulation which container has an opening covered by a cover portion comprising a nozzle. The membrane pores of the nozzle have a size in the range of 0.25 to 6 microns, preferably 0.5 to 6 microns. A low resistance filter, which is positioned between the flowable formulation and the nozzle, includes openings that are the same size as or smaller than the pores of the nozzle's porous membrane but includes the openings in an amount and density such that flowable formulation flows through the filter with less resistance than when the formulation moves through the porous membrane. Thus, the filter does not significantly increase the amount of pressure needed to aerosolize the formulation, prevents clogging of the porous membrane of the nozzle by any undesirable particles that may be in the formulation, prevents delivery of any such undesirable particles to the patient, and thereby improves the homogeneity of the aerosol formulation delivered to the patient, as well as the consistency and reproducibility of the aerosolized dose created.",ARADIGM CORP,RUBSAMEN REID;;GONDA IGOR;;FARR STEPHEN;;CIPOLLA DAVID,ARADIGM CORPORATION (1997-05-22),https://lens.org/194-400-135-505-080,Granted Patent,yes,16,85,5,11,0,A61M15/0045;;A61M2205/6081;;A61M15/0043;;A61M15/0051;;A61M15/0055;;A61M11/001;;A61M11/002;;A24D3/17;;A61M15/0045;;A61M2205/6081;;A61M15/0055;;A61M15/0051;;A61M15/0043;;A61M11/001;;A61M11/002;;A24D3/17,A24D3/17;;A61M15/00,128/203.21;;128/200.14;;128/203.23,0,0,,,,EXPIRED
60,CA,A1,CA 2063400 A1,092-851-151-517-406,1990-12-31,1990,CA 2063400 A,1990-06-27,US 37382589 A,1989-06-30,INHIBITION OF THE N-END RULE PATHWAY IN LIVING CELLS,"The half-life of a Type I, II and III non-compartmentalized intracellular proteins is increased in living eukaryotic cells by contacting the cells with a regulator having an amino-terminal amino acid residue which is the same or similar to the amino-terminal residue of the intracellular protein. The regulator is a dipeptide, a small polypeptide or a carboxyl-terminal derivative of an amino acid. The dipeptide or small polypeptide has an N-terminal amino acid residue which is Arg, Lys or His for the Type I protein, Phe, Leu, Trp, Tyr or Ile for the Type II protein and Ala, Ser or Thr for the Type III protein. The carboxyl-terminal derivative of an amino acid may be an amino acid modified at its C-terminus by the addition of a group selected from methyl, ethyl, propyl, butyl and isobutyl. The amino acid modified is the N-terminal amino acid residue of the dipeptide or small polypeptide for the respective Type I, II and III proteins. Compositions may be formed containing the regulator for contacting with the cells. Increasing the half-life of intracellular protein with the regulator may be used for treating diseases resulting from an abnormal breakdown of a desired protein, and for enhancing in vivo production of a desired protein.",MASSACHUSETTS INST TECHNOLOGY,BAKER ROHAN T;;GONDA DAVID K;;VARSHAVSKY ALEXANDER,,https://lens.org/092-851-151-517-406,Patent Application,no,0,0,14,14,0,C07K2319/00;;C07K2319/61;;C07K2319/95;;C12N15/62;;C12N15/67;;C12N15/81;;C12P21/02;;C12Y302/01023;;C12N9/2471;;A61P43/00;;C12P21/02;;C12N15/67;;C07K2319/95;;C07K2319/00;;C12N15/62;;C07K2319/61;;C12N15/81;;C12Y302/01023;;C12N9/2471,A61K38/00;;A61P43/00;;C07K2/00;;C07K4/00;;C07K5/06;;C12N9/00;;C12N9/38;;C12N15/09;;C12N15/62;;C12N15/67;;C12N15/81;;C12P21/00;;C12P21/02;;C12R1/865,,0,0,,,,EXPIRED
61,EP,B1,EP 0605105 B1,008-390-692-060-757,1999-05-06,1999,EP 93309489 A,1993-11-29,GB 9227105 A;;GB 9227106 A;;GB 9306065 A;;GB 9306066 A,1992-12-30,Process for rigid foams,,ICI PLC,DE VOS RIK;;THORPE DAVID;;VAN ESSCHE GONDA,,https://lens.org/008-390-692-060-757,Granted Patent,yes,4,0,15,19,0,C08G18/8054;;C08G18/8054;;C07C271/28;;C07C271/28;;C08G18/8087;;C08G18/8087;;C08G2110/0025;;C08G2110/0025;;C08G2110/005;;C08G2110/005,C08G18/00;;C07C271/28;;C08G18/02;;C08G18/08;;C08G18/10;;C08G18/76;;C08G18/80;;C08G101/00;;C08J9/02;;C08J9/14;;C08L75/04,,3,0,,,"CHEMICAL ABSTRACTS, vol. 105, no. 9, 3 November 1986, Columbus, Ohio, US; abstract no. 154760w, & JP-A-61 063 646 (SANYO CHEM. IND.);;DATABASE WPI Week 8714, Derwent Publications Ltd., London, GB; AN 87-097897 & JP-A-62 045 786 (NIPPON FUKER KK) 27 February 1987;;DATABASE WPI Week 8742, Derwent Publications Ltd., London, GB; AN 87-294530 & JP-A-62 205 181 (NIPPON HOOKER KK) 9 September 1987",EXPIRED
62,CA,C,CA 2063400 C,103-951-024-701-038,1997-07-15,1997,CA 2063400 A,1990-06-27,US 37382589 A,1989-06-30,INHIBITION OF THE N-END RULE PATHWAY IN LIVING CELLS,"The invention described herein encompasses a method of influencing the metabolic stability of an intracellular protein in vivo (in intact cells and whole animals) along with compositions for affecting such regulation. The method comprises administering a regulator having an amino-terminal amino acid residue which is the same as or similar to the amino-terminal residue of the intracellular protein or group of proteins. If desired, this amino-terminal residue is chosen to be a member of the destabilizing class of amino-terminal residues, according to the N-end rule of protein degradation. The compositions of the present invention can comprise a DNA construct encoding a protein and a DNA construct encoding a regulator having the same or similar amino-terminal residue as the protein. The compositions can also comprise the regulator, having an amino-terminal residue which is the same as or similar to the amino-terminal residue of the protein and, as desired, is a member of the destabilizing class of amino-terminal residues, according to the N-end rule of protein degradation. The methods and compositions of this invention may be used for treating diseases resulting from an abnormal breakdown of a desired protein or group of proteins, and for enhancing in vivo production of a desired protein or group of proteins in biotechnological applications.",MASSACHUSETTS INST TECHNOLOGY,BAKER ROHAN T;;GONDA DAVID K;;VARSHAVSKY ALEXANDER,,https://lens.org/103-951-024-701-038,Granted Patent,no,0,0,14,14,0,C07K2319/00;;C07K2319/61;;C07K2319/95;;C12N15/62;;C12N15/67;;C12N15/81;;C12P21/02;;C12Y302/01023;;C12N9/2471;;A61P43/00;;C12P21/02;;C12N15/67;;C07K2319/95;;C07K2319/00;;C12N15/62;;C07K2319/61;;C12N15/81;;C12Y302/01023;;C12N9/2471,A61K38/00;;A61P43/00;;C07K2/00;;C07K4/00;;C07K5/06;;C12N9/00;;C12N9/38;;C12N15/09;;C12N15/62;;C12N15/67;;C12N15/81;;C12P21/00;;C12P21/02;;C12R1/865,,0,0,,,,EXPIRED
63,US,A,US 5766927 A,078-419-032-752-657,1998-06-16,1998,US 23045394 A,1994-04-20,US 23045394 A;;US 93601992 A;;US 37382589 A,1989-06-30,Inhibition of protein degradation in living cells with dipeptides,"The half-life of a Type I, II and III non-compartmentalized intracellular proteins is increased in living eukaryotic cells by contacting the cells with a regulator having an amino-terminal amino acid residue which is the same or similar to the amino-terminal residue of the intracellular protein. The regulator is a dipeptide, a small polypeptide or a carboxyl-terminal derivative of an amino acid. The dipeptide or small polypeptide has an N-terminal amino acid residue which is Arg, Lys or His for the Type I protein, Phe, Leu, Trp, Tyr or Ile for the Type II protein and Ala, Ser or Thr for the Type III protein. The carboxyl-terminal derivative of an amino acid may be an amino acid modified at its C-terminus by the addition of a group selected from methyl, ethyl, propyl, butyl and isobutyl. The amino acid modified is the N-terminal amino acid residue of the dipeptide or small polypeptide for the respective Type I, II and III proteins. Compositions may be formed containing the regulator for contacting with the cells. Increasing the half-life of intracellular protein with the regulator may be used for treating diseases resulting from an abnormal breakdown of a desired protein, and for enhancing in vivo production of a desired protein.",MASSACHUSETTS INST TECHNOLOGY,BAKER ROHAN T;;GONDA DAVID K;;VARSHAVSKY ALEXANDER,,https://lens.org/078-419-032-752-657,Granted Patent,yes,7,25,14,14,0,C07K2319/00;;C07K2319/61;;C07K2319/95;;C12N15/62;;C12N15/67;;C12N15/81;;C12P21/02;;C12Y302/01023;;C12N9/2471;;A61P43/00;;C12P21/02;;C12N15/67;;C07K2319/95;;C07K2319/00;;C12N15/62;;C07K2319/61;;C12N15/81;;C12Y302/01023;;C12N9/2471,A61P43/00;;C07K2/00;;C07K4/00;;C07K5/06;;A61K38/00;;C12N9/00;;C12N9/38;;C12N15/09;;C12N15/62;;C12N15/67;;C12N15/81;;C12P21/00;;C12P21/02;;C12R1/865,435/255.1;;435/70.1;;435/71.1;;435/244;;435/325;;435/363;;435/366;;435/377;;514/2,15,14,011-705-453-858-069;;064-487-724-947-558;;055-646-615-064-237;;037-018-419-455-505;;028-840-490-460-34X;;029-557-383-118-162;;090-311-049-519-085;;098-217-407-243-462;;084-363-394-465-185;;078-823-400-093-70X;;005-431-905-859-044;;045-596-491-100-455;;085-846-205-582-124;;156-124-116-625-427,6330564;;10.1038/309810a0;;6095265;;pmc392068;;10.1073/pnas.81.22.7021;;2985590;;10.1016/s0021-9258(18)89033-0;;pmc390933;;10.1073/pnas.82.24.8448;;3866233;;10.1016/s0022-2836(83)80344-1;;6864804;;10.1016/s0021-9258(17)35758-7;;3005281;;3018930;;10.1126/science.3018930;;10.1038/326808a0;;3033511;;3343227;;10.1016/s0021-9258(18)69123-9;;pmc2189091;;2459295;;10.1084/jem.168.4.1211;;2538246;;10.1016/0092-8674(89)90635-1;;2538923;;10.1126/science.2538923;;2506181;;10.1016/s0021-9258(19)84762-2;;2334397;;10.1042/bj2670343;;pmc1131293,"K. Nagai and H.C. Thogersen, Nature 309:810 812 (1984).;;Hershko et al., Proc. Natl. Acad. Sci. USA 81:7021 7025 (1985).;;Tsunasawa et al., J. Biol. Chem. 260:5382 5391 (1985).;;Boissel et al., Proc. Natl. Acad. Sci. USA 82:8448 8452 (1985).;;Thornton et al., J. Mol. Biol. 167:443 460 (1983).;;Ferber et al., J. Biol. Chem. 261:3128 3134 (1986).;;Bachmair et al., Science 234:179 186 (1986).;;Ferber et al., Nature 326:808 811 (1988).;;Reiss et al., J. Biol. Chem. 263:2693 2698 (1988).;;Townsend et al., J. Exp. Med. 168:1211 1224 (1988).;;Bachmair and Varshavsky, Cell 56:1019 1032 (1989).;;Chau et al., Science 243:1576 1583 (1989).;;Gonda et al., J. Biol. Chem. 264:16700 16712 (1989).;;Miller et al., Biotechnology 1:698 704 (1989).;;Kopitz et al., Biochem. J. 267:343 348 (1990).",EXPIRED
64,AT,T1,AT E106449 T1,155-523-767-155-627,1994-06-15,1994,AT 90911196 T,1990-06-27,US 37382589 A,1989-06-30,HEMMUNG DES REAKTIONSWEGS FÜR DIE N-ENDE-REGEL IN LEBENDEN ZELLEN.,"The half-life of a Type I, II and III non-compartmentalized intracellular proteins is increased in living eukaryotic cells by contacting the cells with a regulator having an amino-terminal amino acid residue which is the same or similar to the amino-terminal residue of the intracellular protein. The regulator is a dipeptide, a small polypeptide or a carboxyl-terminal derivative of an amino acid. The dipeptide or small polypeptide has an N-terminal amino acid residue which is Arg, Lys or His for the Type I protein, Phe, Leu, Trp, Tyr or Ile for the Type II protein and Ala, Ser or Thr for the Type III protein. The carboxyl-terminal derivative of an amino acid may be an amino acid modified at its C-terminus by the addition of a group selected from methyl, ethyl, propyl, butyl and isobutyl. The amino acid modified is the N-terminal amino acid residue of the dipeptide or small polypeptide for the respective Type I, II and III proteins. Compositions may be formed containing the regulator for contacting with the cells. Increasing the half-life of intracellular protein with the regulator may be used for treating diseases resulting from an abnormal breakdown of a desired protein, and for enhancing in vivo production of a desired protein.",MASSACHUSETTS INST TECHNOLOGY,BAKER ROHAN T;;GONDA DAVID K;;VARSHAVSKY ALEXANDER,,https://lens.org/155-523-767-155-627,Granted Patent,no,0,0,14,14,0,C07K2319/00;;C07K2319/61;;C07K2319/95;;C12N15/62;;C12N15/67;;C12N15/81;;C12P21/02;;C12Y302/01023;;C12N9/2471;;A61P43/00;;C12P21/02;;C12N15/67;;C07K2319/95;;C07K2319/00;;C12N15/62;;C07K2319/61;;C12N15/81;;C12Y302/01023;;C12N9/2471,A61K38/00;;A61P43/00;;C07K2/00;;C07K4/00;;C07K5/06;;C12N9/00;;C12N9/38;;C12N15/09;;C12N15/62;;C12N15/67;;C12N15/81;;C12P21/00;;C12P21/02;;C12R1/865,,0,0,,,,DISCONTINUED
65,MX,A,MX 9307835 A,035-041-248-619-255,1994-06-30,1994,MX 9307835 A,1993-12-10,GB 9227105 A;;GB 9227106 A;;GB 9306066 A;;GB 9306065 A,1992-12-30,PROCEDIMIENTO PARA LA PREPARACION DE ESPUMAS RIGIDAS.,"La presente invención se refiere a un procedimiento para la preparación de espuma de poliuretano rígida mediante la reacción de una composición reactivo de isocianato polifuncional, con una composición de poliisocianato, que comprende el producto de la reacción de un exceso estequiométrico, de un poliisocianato orgánico y un compuesto reactivo de isocianato substancialmente fluorado, opcionalmente en la presencia de un compuesto fluorado insoluble inerte.",ICI PLC,VOS RIK DE;;THORPE DAVID;;ESSCHE GONDA VAN,,https://lens.org/035-041-248-619-255,Patent Application,no,0,0,15,19,0,C08G18/8054;;C08G18/8054;;C07C271/28;;C07C271/28;;C08G18/8087;;C08G18/8087;;C08G2110/0025;;C08G2110/0025;;C08G2110/005;;C08G2110/005,C08G18/00;;C07C271/28;;C08G18/02;;C08G18/08;;C08G18/10;;C08G18/76;;C08G18/80;;C08G101/00;;C08J9/02;;C08J9/14;;C08L75/04,,0,0,,,,EXPIRED
66,EP,A1,EP 0479912 A1,124-683-298-033-579,1992-04-15,1992,EP 90911196 A,1990-06-27,US 9003669 W;;US 37382589 A,1989-06-30,INHIBITION OF THE N-END RULE PATHWAY IN LIVING CELLS.,"The half-life of a Type I, II and III non-compartmentalized intracellular proteins is increased in living eukaryotic cells by contacting the cells with a regulator having an amino-terminal amino acid residue which is the same or similar to the amino-terminal residue of the intracellular protein. The regulator is a dipeptide, a small polypeptide or a carboxyl-terminal derivative of an amino acid. The dipeptide or small polypeptide has an N-terminal amino acid residue which is Arg, Lys or His for the Type I protein, Phe, Leu, Trp, Tyr or Ile for the Type II protein and Ala, Ser or Thr for the Type III protein. The carboxyl-terminal derivative of an amino acid may be an amino acid modified at its C-terminus by the addition of a group selected from methyl, ethyl, propyl, butyl and isobutyl. The amino acid modified is the N-terminal amino acid residue of the dipeptide or small polypeptide for the respective Type I, II and III proteins. Compositions may be formed containing the regulator for contacting with the cells. Increasing the half-life of intracellular protein with the regulator may be used for treating diseases resulting from an abnormal breakdown of a desired protein, and for enhancing in vivo production of a desired protein.",MASSACHUSETTS INST TECHNOLOGY,BAKER ROHAN T;;GONDA DAVID K;;VARSHAVSKY ALEXANDER,,https://lens.org/124-683-298-033-579,Patent Application,yes,0,2,14,14,0,C07K2319/00;;C07K2319/61;;C07K2319/95;;C12N15/62;;C12N15/67;;C12N15/81;;C12P21/02;;C12Y302/01023;;C12N9/2471;;A61P43/00;;C12P21/02;;C12N15/67;;C07K2319/95;;C07K2319/00;;C12N15/62;;C07K2319/61;;C12N15/81;;C12Y302/01023;;C12N9/2471,A61P43/00;;C07K2/00;;C07K4/00;;C07K5/06;;C12N9/00;;C12N9/38;;C12N15/09;;A61K38/00;;C12N15/62;;C12N15/67;;C12N15/81;;C12P21/00;;C12P21/02;;C12R1/865,,0,0,,,,EXPIRED
67,DE,D1,DE 69324784 D1,013-887-325-179-937,1999-06-10,1999,DE 69324784 T,1993-11-29,GB 9227105 A;;GB 9227106 A;;GB 9306066 A;;GB 9306065 A,1992-12-30,Verfahren zur Herstellung von Hartschaumstoffen,,ICI PLC,DE VOS RIK;;THORPE DAVID;;VAN ESSCHE GONDA,"HUNTSMAN ICI CHEMICALS LLC, SALT LAKE CITY, UTAH, (2001-03-15)",https://lens.org/013-887-325-179-937,Granted Patent,no,0,0,15,19,0,C08G18/8054;;C08G18/8054;;C07C271/28;;C07C271/28;;C08G18/8087;;C08G18/8087;;C08G2110/0025;;C08G2110/0025;;C08G2110/005;;C08G2110/005,C08G18/00;;C07C271/28;;C08G18/02;;C08G18/08;;C08G18/10;;C08G18/76;;C08G18/80;;C08G101/00;;C08J9/02;;C08J9/14;;C08L75/04,,0,0,,,,EXPIRED
68,AU,A,AU 1993/052122 A,122-341-529-148-742,1994-07-14,1994,AU 1993/052122 A,1993-12-02,GB 9227105 A;;GB 9227106 A;;GB 9306066 A;;GB 9306065 A,1992-12-30,Process for rigid foams,,ICI PLC,VOS RIK DE;;THORPE DAVID;;ESSCHE GONDA VAN,,https://lens.org/122-341-529-148-742,Patent Application,no,0,0,15,19,0,C08G18/8054;;C08G18/8054;;C07C271/28;;C07C271/28;;C08G18/8087;;C08G18/8087;;C08G2110/0025;;C08G2110/0025;;C08G2110/005;;C08G2110/005,C08G18/00;;C07C271/28;;C08G18/02;;C08G18/08;;C08G18/10;;C08G18/76;;C08G18/80;;C08G101/00;;C08J9/02;;C08J9/14;;C08L75/04,,0,0,,,,EXPIRED
69,US,A,US 5074404 A,054-228-831-932-387,1991-12-24,1991,US 70217391 A,1991-05-15,US 70217391 A,1991-05-15,Vibration isolator having adjustability feature,An isolator for use on a vibratory parts feeder incorporates a locating plate rotatable through three hundred sixty degrees in a horizontal plain to allow mounting adjustment and parts feeder micro alignment.,FMC CORP,GONDA WILLIAM V;;BRENCE DAVID A;;SLEPPY PAUL I,FMC CORPORATION A DE CORPORATION (1991-07-09);;FMC TECHNOLOGIES INC (2001-11-26),https://lens.org/054-228-831-932-387,Granted Patent,yes,6,8,1,1,0,B65G27/08;;B65G27/08;;B65G2207/24;;B65G2207/24,B65G27/08,198/757;;198/760;;198/767,0,0,,,,EXPIRED
70,US,S,US D0439150 S,112-192-599-867-073,2001-03-20,2001,US 11550699 F,1999-12-15,US 11550699 F,1999-12-15,Bottle with pump,,UNILEVER HOME & PERSONAL CARE,GONDA FRANK EDWARD;;LAUBACH DAVID SCOTT;;ROSS MICHAEL EDWARD,UNILEVER HOME & PERSONAL CARE USA DIVISION OF CONOPCO INC (2000-01-18),https://lens.org/112-192-599-867-073,Design Right,yes,8,5,1,1,0,,,D 9300;;0901,0,0,,,,EXPIRED
71,US,S,US D0438804 S,142-962-656-669-564,2001-03-13,2001,US 11550799 F,1999-12-15,US 11550799 F,1999-12-15,Bottle,,UNILEVER HOME & PERSONAL CARE,GONDA FRANK EDWARD;;LAUBACH DAVID SCOTT;;ROSS MICHAEL EDWARD,UNILEVER HOME & PERSONAL CARE USA DIVISION OF CONOPCO INC (2000-01-18),https://lens.org/142-962-656-669-564,Design Right,yes,8,6,1,1,0,,,D 9542;;0901,0,0,,,,EXPIRED
72,GR,T3,GR 3033094 T3,060-669-725-210-066,2000-08-31,2000,GR 20000400783 T,2000-03-29,US 52515090 A;;US 9103366 W,1990-05-17,METHODS FOR TRANS-DESTABILIZATION OF SPECIFIC PROTEINS IN VIVO.,"This invention pertains to a method of metabolically destabilizing a protein or peptide of interest in vivo provided that the protein or peptide contains a second determinant of the N-end rule-based degradation signal and provided that another (targeting) protein or peptide can be identified that specifically interacts with the protein or peptide of interest. The methods of the invention comprise contacting the protein or peptide of interest with the targeting protein or peptide which contains a destabilizing amino-terminal amino acid according to the N-end rule of protein degradation but lacking a second determinant of the N-end rule-based degradation signal. Because nearly all proteins specifically interact with other proteins, this is a broadly applicable method for metabolically destabilizing a protein or peptide of interest in vivo.",MASSACHUSETTS INST TECHNOLOGY,VARSHAVSKY ALEXANDER;;JOHNSON ERICA S;;GONDA DAVID K;;HOCHSTRASSER MARK,,https://lens.org/060-669-725-210-066,Granted Patent,no,0,0,14,14,0,C07K1/107;;C07K14/00;;C07K14/395;;C07K2319/00;;C07K2319/61;;C07K2319/80;;C07K2319/95;;C12N15/11;;C07K14/00;;C07K1/107;;C07K14/395;;C07K2319/00;;C07K2319/61;;C07K2319/80;;C12N15/11;;C07K2319/95,C07K1/107;;C07K14/00;;C07K14/395;;C07K19/00;;C12N15/09;;C12N15/11;;C12P21/02;;C12R1/865,,0,0,,,,EXPIRED
73,CA,A1,CA 2079584 A1,000-512-126-062-768,1991-11-18,1991,CA 2079584 A,1991-05-14,US 52515090 A,1990-05-17,Methods for Trans-Destabilization of Specific Proteins in Vivo,"This invention pertains to a method of metabolically destabilizing a protein or peptide of interest in vivo provided that the protein or peptide contains a second determinant of the N-end rule-based degradation signal and provided that another (targeting) protein or peptide can be identified that specifically interacts with the protein or peptide of interest. The methods of the invention comprise contacting the protein or peptide of interest with the targeting protein or peptide which contains a destabilizing amino-terminal amino acid according to the N-end rule of protein degradation but lacking a second determinant of the N-end rule-based degradation signal. Because nearly all proteins specifically interact with other proteins, this is a broadly applicable method for metabolically destabilizing a protein or peptide of interest in vivo.",MASSACHUSETTS INST TECHNOLOGY,VARSHAVSKY ALEXANDER J;;JOHNSON ERICA;;GONDA DAVID K;;HOCHSTRASSER MARK,,https://lens.org/000-512-126-062-768,Patent Application,no,0,0,14,14,0,C07K1/107;;C07K14/00;;C07K14/395;;C07K2319/00;;C07K2319/61;;C07K2319/80;;C07K2319/95;;C12N15/11;;C07K14/00;;C07K1/107;;C07K14/395;;C07K2319/00;;C07K2319/61;;C07K2319/80;;C12N15/11;;C07K2319/95,C07K1/107;;C07K14/00;;C07K14/395;;C07K19/00;;C12N15/09;;C12N15/11;;C12P21/02;;C12R1/865,,0,0,,,,EXPIRED
74,CA,C,CA 2079584 C,034-791-074-049-85X,1999-04-13,1999,CA 2079584 A,1991-05-14,US 52515090 A,1990-05-17,METHODS FOR TRANS-DESTABILIZATION OF SPECIFIC PROTEINS IN VIVO,"This invention pertains to the metabolic destabilization a protein or peptide of interest in vivo. The protein or peptide of interest contains a second determinant of the N-end rule-based degradation signa l. The methods of the invention comprise contacting the protein or peptide of interest with a targeting protein or peptid e which interacts specifically with the protein or peptide of interest. The targeting peptide or protein contains a destabilizing amino-ter minal amino acid according to the N-end rule of protein degradation, but lacks a second determinant of the N-end rule-based degr adation signal. A requirement of the methods is that it is necessary to identify a peptide or protein which interacts specifical ly with the protein or peptide of interest. Because nearly all proteins specifically interact with other proteins, this is a broadly applicable method for metabolically destabilizing a protein or peptide of interest in vivo.",MASSACHUSETTS INST TECHNOLOGY,VARSHAVSKY ALEXANDER J;;JOHNSON ERICA;;GONDA DAVID K;;HOCHSTRASSER MARK,,https://lens.org/034-791-074-049-85X,Granted Patent,no,0,0,14,14,0,C07K1/107;;C07K14/00;;C07K14/395;;C07K2319/00;;C07K2319/61;;C07K2319/80;;C07K2319/95;;C12N15/11;;C07K14/00;;C07K1/107;;C07K14/395;;C07K2319/00;;C07K2319/61;;C07K2319/80;;C12N15/11;;C07K2319/95,C07K1/107;;C07K14/00;;C07K14/395;;C07K19/00;;C12N15/09;;C12N15/11;;C12P21/02;;C12R1/865,,0,0,,,,EXPIRED
75,US,A,US 5770152 A,012-286-256-147-99X,1998-06-23,1998,US 74961096 A,1996-11-18,US 74961096 A,1996-11-18,Collapsible container for measuring particles in a sample fluid,"A device and method for the detection of small particles in a fluid. The device is a collapsible sample container having a opening which is covered, at least in part, by a porous membrane having a plurality (e.g., 100) of pores therein having a pore diameter equal to or smaller than the diameter of the particles to be detected (e.g., 01. to 100 microns). A means for collapsing the container to extrude the liquid sample through the membrane pores is provided along with a means for detecting pressure during the extrusion. The size and number of particles in the liquid is calculated by relating the extrusion pressure required to a pre-calibrated standard. When a constant pressure is applied the rate at which fluid is extruded decreases as the pores of the membrane become clogged with particles. The greater number of particles in the sample tested the greater the number of pores which will become clogged with particles which causes an increase in the amount of time or pressure needed to extrude a given volume of the sample through the porous membrane. The number of pores per unit area and pore size can be varied depending on the probable size and concentration of the particles in the liquid be tested.",ARADIGM CORP,SCHUSTER JEFFREY A;;LLOYD PETER M;;GONDA IGOR;;CIPOLLA DAVID,ARADIGM CORPORATION (1997-02-24),https://lens.org/012-286-256-147-99X,Granted Patent,yes,21,29,1,1,0,G01N15/0618;;G01N15/0618;;G01N7/10;;G01N7/10;;Y10T436/101666;;Y10T436/101666;;Y10T436/25375;;Y10T436/25375;;Y10T436/255;;Y10T436/255,G01N7/10;;G01N15/06,422/73;;422/68.1;;422/82.13;;422/101;;436/10;;436/69;;436/70;;436/148;;436/177;;436/178;;73/61.71;;73/61.72;;73/61.73;;73/863.64;;73/864.62;;73/864.81,1,0,,,"The United States Pharmacopeia, The National Formulary, 1995. Particulate Matter in Injections, United States Pharmacopeial Convention, Inc., Rockville,MD, pp. 1813 1819",EXPIRED
76,AT,T1,AT E188994 T1,029-261-550-704-458,2000-02-15,2000,AT 91910688 T,1991-05-14,US 52515090 A;;US 9103366 W,1990-05-17,METHODEN ZUR TRANS-DESTABILISIERUNG VON SPEZIFISCHEN PROTEINEN IN VIVO,"This invention pertains to a method of metabolically destabilizing a protein or peptide of interest in vivo provided that the protein or peptide contains a second determinant of the N-end rule-based degradation signal and provided that another (targeting) protein or peptide can be identified that specifically interacts with the protein or peptide of interest. The methods of the invention comprise contacting the protein or peptide of interest with the targeting protein or peptide which contains a destabilizing amino-terminal amino acid according to the N-end rule of protein degradation but lacking a second determinant of the N-end rule-based degradation signal. Because nearly all proteins specifically interact with other proteins, this is a broadly applicable method for metabolically destabilizing a protein or peptide of interest in vivo.",MASSACHUSETTS INST TECHNOLOGY,VARSHAVSKY ALEXANDER;;JOHNSON ERICA S;;GONDA DAVID K;;HOCHSTRASSER MARK,,https://lens.org/029-261-550-704-458,Granted Patent,no,0,0,14,14,0,C07K1/107;;C07K14/00;;C07K14/395;;C07K2319/00;;C07K2319/61;;C07K2319/80;;C07K2319/95;;C12N15/11;;C07K14/00;;C07K1/107;;C07K14/395;;C07K2319/00;;C07K2319/61;;C07K2319/80;;C12N15/11;;C07K2319/95,C07K1/107;;C07K14/00;;C07K14/395;;C07K19/00;;C12N15/09;;C12N15/11;;C12P21/02;;C12R1/865,,0,0,,,,DISCONTINUED
77,EP,A1,EP 3129004 A1,087-669-678-909-877,2017-02-15,2017,EP 15775997 A,2015-03-31,US 201461976727 P;;US 2015/0023668 W,2014-04-08,LIPOSOMAL CIPROFLOXACIN FORMULATIONS WITH ACTIVITY AGAINST NON-TUBERCULOUS MYCOBACTERIA,,ARADIGM CORP;;UNIV OREGON STATE,GONDA IGOR;;BLANCHARD JAMES;;CIPOLLA DAVID C;;BERMUDEZ LUIS EDUARDO MOREIRA,,https://lens.org/087-669-678-909-877,Patent Application,yes,0,0,20,20,0,A61K9/0078;;A61K31/496;;A61K9/127;;A61K9/0073;;A61P11/00;;A61P31/04;;Y02A50/30;;A61K31/496;;A61K9/127;;A61K9/0073;;A61K9/0078;;Y02A50/30;;A61K9/12;;A61K45/06,A61K9/127,,0,0,,,,DISCONTINUED
78,US,A1,US 2015/0283133 A1,153-570-878-249-756,2015-10-08,2015,US 201514675218 A,2015-03-31,US 201514675218 A;;US 201461976727 P,2014-04-08,LIPOSOMAL CIPROFLOXACIN FORMULATIONS WITH ACTIVITY AGAINST NON-TUBERCULOUS MYCOBACTERIA,"Methods of treatment of NTM lung infections using formulations of liposomal ciprofloxacin. Specific liposome formulations and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.",ARADIGM CORP;;UNIV OREGON STATE,GONDA IGOR;;BLANCHARD JAMES;;CIPOLLA DAVID C;;BERMUDEZ LUIZ EDUARDO MOREIRA,ARADIGM CORPORATION (2015-04-16);;OREGON STATE UNIVERSITY (2015-05-28);;GRIFOLS S.A (2020-03-31),https://lens.org/153-570-878-249-756,Patent Application,yes,2,23,20,20,0,A61K9/0078;;A61K31/496;;A61K9/127;;A61K9/0073;;A61P11/00;;A61P31/04;;Y02A50/30;;A61K31/496;;A61K9/127;;A61K9/0073;;A61K9/0078;;Y02A50/30;;A61K9/12;;A61K45/06,A61K31/496;;A61K9/00;;A61K9/12;;A61K9/127;;C12Q1/04,,7,4,024-060-783-058-765;;033-150-287-738-644;;034-910-153-767-189;;066-724-015-906-939,10.1016/s1473-3099(08)70100-2;;18471777;;9814848;;10.1016/s0005-2736(98)00125-4;;10.1016/0005-2736(95)00159-z;;7488619;;10.1039/c5ra25898g,"Piersimoni et al. (2008). ""Pulmonary infections associated with non-tuberculous mycobacteria in immunocompetent patients."" Lancet Infect Dis, 8: 323-334.;;Maurer et al. (1998). ""Anomalous solubility behavior of the antibiotic ciprofloxacin encapsulated in liposomes: a 1H-NMR study."" Biochimica et Biophysica Acta, 1374: 9-20.;;Lasic et al. (1995). ""Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery."" Biochemica et Biophysica Acta, 1239: 145-156.;;Piersimoni et al. (2008). “Pulmonary infections associated with non-tuberculous mycobacteria in immunocompetent patients.” Lancet Infect Dis, 8: 323-334.;;Maurer et al. (1998). “Anomalous solubility behavior of the antibiotic ciprofloxacin encapsulated in liposomes: a 1H-NMR study.” Biochimica et Biophysica Acta, 1374: 9-20.;;Lasic et al. (1995). “Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery.” Biochemica et Biophysica Acta, 1239: 145-156.;;Cipolla et al. (2016). ""Formation of drug nanocrystals under nanoconfinement afforded by liposomes."" RSC Advances, 6: 6223-6233.",ACTIVE
79,US,B2,US 9532986 B2,072-169-770-971-15X,2017-01-03,2017,US 201514675218 A,2015-03-31,US 201514675218 A;;US 201461976727 P,2014-04-08,Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria,"Methods of treatment of NTM lung infections using formulations of liposomal ciprofloxacin. Specific liposome formulations and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.",ARADIGM CORP;;UNIV OREGON STATE,GONDA IGOR;;BLANCHARD JAMES;;CIPOLLA DAVID C;;BERMUDEZ LUIZ EDUARDO MOREIRA,ARADIGM CORPORATION (2015-04-16);;OREGON STATE UNIVERSITY (2015-05-28);;GRIFOLS S.A (2020-03-31),https://lens.org/072-169-770-971-15X,Granted Patent,yes,21,0,20,20,0,A61K9/0078;;A61K31/496;;A61K9/127;;A61K9/0073;;A61P11/00;;A61P31/04;;Y02A50/30;;A61K31/496;;A61K9/127;;A61K9/0073;;A61K9/0078;;Y02A50/30;;A61K9/12;;A61K45/06,A61K9/127;;A61K9/00;;A61K31/496,,12,12,024-060-783-058-765;;034-910-153-767-189;;033-150-287-738-644;;066-724-015-906-939;;075-949-839-628-664;;101-904-038-391-443;;023-708-751-561-393;;048-157-998-339-224;;066-267-219-024-523;;058-433-709-835-418;;048-497-642-568-879;;032-708-511-260-192,10.1016/s1473-3099(08)70100-2;;18471777;;10.1016/0005-2736(95)00159-z;;7488619;;9814848;;10.1016/s0005-2736(98)00125-4;;10.1039/c5ra25898g;;5859039;;10.1016/s0022-2836(65)80093-6;;10.1128/aac.41.6.1288;;pmc163901;;9174185;;2515523;;10.1002/ppul.1950070413;;10.1002/ppul.1950170511;;8058428;;10.1016/s0168-3659(03)00358-4;;14568408;;10.1164/ajrccm.161.1.9903019;;10619831;;10.1258/002367702320162405;;12144741;;pmc245550;;1482150;;10.1128/aac.36.12.2808,"Piersimoni et al. (2008). ""Pulmonary infections associated with non-tuberculous mycobacteria in immunocompetent patients."" Lancet Infect Dis, 8: 323-334.;;Lasic et al. (1995). ""Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery."" Biochemica et Biophysica Acta, 1239: 145-156.;;Maurer et al. (1998). ""Anomalous solubility behavior of the antibiotic ciprofloxacin encapsulated in liposomes: a 1H-NMR study."" Biochimica et Biophysica Acta, 1374: 9-20.;;Cipolla et al. (2016). ""Formation of drug nanocrystals under nanoconfinement afforded by liposomes."" RSC Advances, 6: 6223-6233.;;Bangham, et al., ""Diffusion of Univalent Ions across teh Lamellae of Swollen Phospholipids"" J. Mol. Niol., 13:238-252 (1965).;;Conley, et al., ""Aerosol Delivery of Liposome-Encapsulated Ciprofloxacin: Aerosol Characterization and Efficacy against Francisella tularensis Infection in Mice"" Antimicrobial Agents, 41(6): 1288-1292 (Jun. 1997).;;Smith, et al., ""Saftety of Aerosol Tobramycin administration for 3 months to patients with cystic fibrosis."" Ped. Pulmonol. (1989); 7(4):265-271.;;Weber A, et al., ""Nebulizer delivery of tobramycin to the lower respiratory tract"". Pediatr Pulmonol. (May 1994); 17 (5):331-9.;;Wong, et al., ""Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection"" Journal of Controlled Release, 92; 265-273 (2003).;;Van Heeckeren, et al., ""Effect of Pseudomonas infection on weight loss, lung mechanics, and cytokines in mice."" Am J Respir Crit Care Med. (Jan. 2000); 161(1):271.;;Van Heeckeren, et al., ""Murine Models of chronic Pseudomonas aeruginosa lung infection"" Lab Anim (Jul. 2002); 36(3):291-312.;;Majumdar et al., Efficacies of liposome-encapsulated streptomycin and ciprofloxacin against Mycobacterium avium-N. intracellulare complex infections in human peripheral blood monocytes/macrophages. Antimicrob Agents Chemother (1992) 36:2808-15.",ACTIVE
80,EP,A1,EP 2330893 A1,060-538-880-761-351,2011-06-15,2011,EP 09816849 A,2009-09-24,US 2009/0058217 W;;US 10001708 P,2008-09-25,DEEP LUNG PULMONARY DELIVERY OF TREPROSTINIL,,ARADIGM CORP,CIPOLLA DAVID C;;GONDA IGOR;;OTULANA TUNDE;;MORISHIGE RICHARD;;BRUINENBERG PAUL,,https://lens.org/060-538-880-761-351,Patent Application,yes,0,0,9,9,0,A61K9/0078;;A61K9/0078;;A61K31/19;;A61K9/12;;A61K31/191;;A61K31/191;;A61K31/192;;A61P7/02;;A61P9/04;;A61P9/10;;A61P9/12;;A61P11/00;;A61P11/08;;A61P13/12;;A61P15/00;;A61P17/00;;A61P17/06;;A61P29/00;;A61P35/00;;A61P43/00,A61K31/557;;A61K9/12;;A61P11/08,,0,0,,,,DISCONTINUED
81,US,A,US 5122463 A,041-813-029-665-600,1992-06-16,1992,US 52515090 A,1990-05-17,US 52515090 A,1990-05-17,METHODS FOR TRANS-DESTABILIZATION OF SPECIFIC PROTEINS IN VIVO AND DNA MOLECULES USEFUL THEREFOR,"This invention pertains to a method of metabolically destabilizing a protein or peptide of interest in vivo provided that the protein or peptide contains a second determinant of the N-end rule-based degradation signal and provided that another (targeting) protein or peptide can be identified that specifically interacts with the protein or peptide of interest. The methods of the invention comprise contacting the protein or peptide of interest with the targeting protein or peptide which contains a destabilizing amino-terminal amino acid according to the N-end rule of protein degradation but lacking a second determinant of the N-end rule-based degradation signal. Because nearly all proteins specifically interact with other proteins, this is a broadly applicable method for metabolically destabilizing a protein or peptide of interest in vivo.",MASSACHUSETTS INST TECHNOLOGY,VARSHAVSKY ALEXANDER J;;JOHNSON ERICA S;;GONDA DAVID K;;HOCHSTRASSER MARK,MASSACHUSETTS INSTITUTE OF TECHNOLOGY A CORP. OF MA (1990-07-10),https://lens.org/041-813-029-665-600,Granted Patent,yes,2,46,14,14,0,C07K1/107;;C07K14/00;;C07K14/395;;C07K2319/00;;C07K2319/61;;C07K2319/80;;C07K2319/95;;C12N15/11;;C07K14/00;;C07K1/107;;C07K14/395;;C07K2319/00;;C07K2319/61;;C07K2319/80;;C12N15/11;;C07K2319/95,C07K1/107;;C07K14/00;;C07K14/395;;C07K19/00;;C12N15/09;;C12N15/11;;C12P21/02;;C12R1/865,435/172.3;;435/69.7;;536/27,16,15,081-726-332-359-812;;011-705-453-858-069;;064-487-724-947-558;;055-646-615-064-237;;037-018-419-455-505;;028-840-490-460-34X;;029-557-383-118-162;;090-311-049-519-085;;098-217-407-243-462;;084-363-394-465-185;;078-823-400-093-70X;;005-431-905-859-044;;045-596-491-100-455;;085-846-205-582-124;;062-612-834-714-365,pmc286952;;10.1073/pnas.86.8.2540;;2539593;;6330564;;10.1038/309810a0;;6095265;;pmc392068;;10.1073/pnas.81.22.7021;;2985590;;10.1016/s0021-9258(18)89033-0;;pmc390933;;10.1073/pnas.82.24.8448;;3866233;;10.1016/s0022-2836(83)80344-1;;6864804;;10.1016/s0021-9258(17)35758-7;;3005281;;3018930;;10.1126/science.3018930;;10.1038/326808a0;;3033511;;3343227;;10.1016/s0021-9258(18)69123-9;;pmc2189091;;2459295;;10.1084/jem.168.4.1211;;2538246;;10.1016/0092-8674(89)90635-1;;2538923;;10.1126/science.2538923;;2506181;;10.1016/s0021-9258(19)84762-2;;2654934;;pmc287064;;10.1073/pnas.86.9.3060,"P.N.A.S. vol. 86:2540 2544, Apr. 1989, Butt et al. Ubiquitin fusion augments the yield of cloned gene products, in Eschlerichia coli.;;K. Nagai and H. C. Thogersen, Nature 309:810 812 (1984).;;Hershko et al., Proc. Natl. Acad. Sci. USA 81:7021 7025 (1985).;;Tsunasawa et al., J. Biol. Chem. 260:5382 5391 (1985).;;Boissel et al., Proc. Natl. Acad. Sci. USA 82:8448 8452 (1985).;;Thornton et al., J. Mol. Biol. 167:443 460 (1983).;;Ferber et al., J. Biol. Chem. 261:3128 3134 (1986).;;Bachmair et al., Science 234:179 186 (1986).;;Ferber et al., Nature 326:808 811 (1988).;;Reiss et al., J. Biol. Chem. 263:2693 2698 (1988).;;Townsend et al., J. Exp. Med. 168:1211 1224 (1988).;;Bachmair and Varshavsky, Cell 56:1019 1032 (1989).;;Chau et al., Science 243:1576 1583 (1989).;;Gonda et al., J. Biol. Chem. 264:16700 16712 (1989).;;Miller et al., Biotechnology 1:698 704 (1989).;;Hall and Frieden, Proc. Natl. Acad. Sci. USA 86:3060 3064 (1989).",EXPIRED
82,JP,A,JP 2015129177 A,056-924-240-109-85X,2015-07-16,2015,JP 2015044671 A,2015-03-06,US 10001708 P,2008-09-25,DEEP LUNG PULMONARY DELIVERY OF TREPROSTINIL,"PROBLEM TO BE SOLVED: To provide Treprostinil formulations which affects vasodilation, and increases the efficacy at lower doses due to the sustained presence of drugs at the site of action in the deep lung which contributes to lowering blood pressure.SOLUTION: By administration of aerosolized Treprostinil formulation containing Treprostinil Na represented by the following formula, the pulmonary deposition of Treprostinil can be made more homogeneously, and thereby, the deep lung delivery is enabled. The aerosolized formulation has an aerodynamic diameter of particles or droplets of 10 microns or less, and the administration results in depositing the Treprostinil in a deep lung, such that a ratio of central/peripheral lung deposits of the formulation is in a range of 1 to 2.0.",ARADIGM CORP,DAVID C CIPOLLA;;IGOR GONDA;;TUNDE OTULANA;;MORISHIGE RICHARD;;PAUL BRUINENBERG,,https://lens.org/056-924-240-109-85X,Patent Application,no,1,0,9,9,0,A61K9/0078;;A61K9/0078;;A61K31/19;;A61K9/12;;A61K31/191;;A61K31/191;;A61K31/192;;A61P7/02;;A61P9/04;;A61P9/10;;A61P9/12;;A61P11/00;;A61P11/08;;A61P13/12;;A61P15/00;;A61P17/00;;A61P17/06;;A61P29/00;;A61P35/00;;A61P43/00,A61K31/5578;;A61K9/12;;A61P9/12,,0,0,,,,PENDING
83,CN,A,CN 107072944 A,187-468-180-377-097,2017-08-18,2017,CN 201580030672 A,2015-03-31,US 201461976727 P;;US 2015/0023668 W,2014-04-08,Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria,"Methods of treatment of NTM lung infections using formulations of liposomal ciprofloxacin. Specific liposome formulations and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.",ARADIGM CORP;;UNIV OREGON STATE,GONDA IGOR;;BLANCHARD JAMES;;CIPOLLA DAVID C;;BERMUDEZ LUIS EDUARDO MOREIRA,,https://lens.org/187-468-180-377-097,Patent Application,no,8,2,20,20,0,A61K9/0078;;A61K31/496;;A61K9/127;;A61K9/0073;;A61P11/00;;A61P31/04;;Y02A50/30;;A61K31/496;;A61K9/127;;A61K9/0073;;A61K9/0078;;Y02A50/30;;A61K9/12;;A61K45/06,A61K9/127,,3,1,038-014-909-043-851,10.1021/am500097f;;24511877,"余家会等主编: ""《纳米生物医药》"", 31 December 2011, 华东理工大学出版社;;WANG ET AL.: ""MC540 and Upconverting Nanocrystal Coloaded Polymeric Liposome for Near-Infrared Light-Triggered Photodynamic Therapy and cell Fluorescent Imaging"", 《ACS APPLIED MATERIALS & INTERFACES》;;罗国培: ""PLGA/poloxamer纳米微粒包裹MBD1-siRNA质粒治疗胰腺癌的实验研究"", 《中国博士学位论文全文数据库 医药卫生科技辑》",INACTIVE
84,US,A1,US 2019/0328731 A1,197-549-829-889-132,2019-10-31,2019,US 201916506675 A,2019-07-09,US 201916506675 A;;US 201715821193 A;;US 201615362405 A;;US 201514675218 A;;US 201461976727 P,2014-04-08,LIPOSOMAL CIPROFLOXACIN FORMULATIONS WITH ACTIVITY AGAINST NON-TUBERCULOUS MYCOBACTERIA,"Methods of treatment of NTM lung infections using formulations of liposomal ciprofloxacin. Specific liposome formulations and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.",ARADIGM CORP;;UNIV OREGON STATE,GONDA IGOR;;BLANCHARD JAMES;;CIPOLLA DAVID C;;BERMUDEZ LUIZ EDUARDO MOREIRA,ARADIGM CORPORATION (2017-11-07);;OREGON STATE UNIVERSITY (2015-05-28);;GRIFOLS S.A (2020-03-31),https://lens.org/197-549-829-889-132,Patent Application,yes,1,0,20,20,0,A61K9/0078;;A61K31/496;;A61K9/127;;A61K9/0073;;A61P11/00;;A61P31/04;;Y02A50/30;;A61K31/496;;A61K9/127;;A61K9/0073;;A61K9/0078;;Y02A50/30;;A61K9/12;;A61K45/06,A61K31/496;;A61K9/00;;A61K9/12;;A61K9/127;;A61K45/06,,0,0,,,,DISCONTINUED
85,US,A1,US 2020/0323845 A1,075-242-798-578-867,2020-10-15,2020,US 202016914122 A,2020-06-26,US 202016914122 A;;US 201916506675 A;;US 201715821193 A;;US 201615362405 A;;US 201514675218 A;;US 201461976727 P,2014-04-08,LIPOSOMAL CIPROFLOXACIN FORMULATIONS WITH ACTIVITY AGAINST NON-TUBERCULOUS MYCOBACTERIA,"Methods of treatment of NTM lung infections using formulations of liposoma ciprofloxacin. Specific liposome formulations and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.",GRIFOLS SA,GONDA IGOR;;BLANCHARD JAMES;;CIPOLLA DAVID C;;BERMUDEZ LUIZ EDUARDO MOREIRA,,https://lens.org/075-242-798-578-867,Patent Application,yes,0,0,20,20,0,A61K9/0078;;A61K31/496;;A61K9/127;;A61K9/0073;;A61P11/00;;A61P31/04;;Y02A50/30;;A61K31/496;;A61K9/127;;A61K9/0073;;A61K9/0078;;Y02A50/30;;A61K9/12;;A61K45/06,A61K31/496;;A61K9/00;;A61K9/12;;A61K9/127;;A61K45/06,,0,0,,,,ACTIVE
86,CA,A1,CA 2737350 A1,081-374-025-017-808,2010-04-01,2010,CA 2737350 A,2009-09-24,US 10001708 P;;US 2009/0058217 W,2008-09-25,DEEP LUNG PULMONARY DELIVERY OF TREPROSTINIL,"Administration of aerosolized Treprostinil formulations may provide a more homogeneous lung deposition of treprostinil, whereby making deep lung delivery possible.",ARADIGM CORP,CIPOLLA DAVID C;;GONDA IGOR;;OTULANA TUNDE;;MORISHIGE RICHARD;;BRUINENBERG PAUL,,https://lens.org/081-374-025-017-808,Patent Application,no,0,0,9,9,0,A61K9/0078;;A61K9/0078;;A61K31/19;;A61K9/12;;A61K31/191;;A61K31/191;;A61K31/192;;A61P7/02;;A61P9/04;;A61P9/10;;A61P9/12;;A61P11/00;;A61P11/08;;A61P13/12;;A61P15/00;;A61P17/00;;A61P17/06;;A61P29/00;;A61P35/00;;A61P43/00,A01N37/10;;A01K31/19,,0,0,,,,DISCONTINUED
87,EP,A4,EP 2330893 A4,180-189-211-740-324,2013-01-09,2013,EP 09816849 A,2009-09-24,US 2009/0058217 W;;US 10001708 P,2008-09-25,DEEP LUNG PULMONARY DELIVERY OF TREPROSTINIL,,ARADIGM CORP,CIPOLLA DAVID C;;GONDA IGOR;;OTULANA TUNDE;;MORISHIGE RICHARD;;BRUINENBERG PAUL,,https://lens.org/180-189-211-740-324,Search Report,no,3,0,9,9,0,A61K9/0078;;A61K9/0078;;A61K31/19;;A61K9/12;;A61K31/191;;A61K31/191;;A61K31/192;;A61P7/02;;A61P9/04;;A61P9/10;;A61P9/12;;A61P11/00;;A61P11/08;;A61P13/12;;A61P15/00;;A61P17/00;;A61P17/06;;A61P29/00;;A61P35/00;;A61P43/00,A61K31/557;;A61K9/12;;A61P11/08,,3,2,135-530-757-322-225;;017-947-104-065-298,16141385;;10.1152/japplphysiol.00083.2005;;10.1109/ias.2004.1348527,"SANDIFER BRETT L ET AL: ""Potent effects of aerosol compared with intravenous treprostinil on the pulmonary circulation"", JOURNAL OF APPLIED PHYSIOLOGY, AMERICAN PHYSIOLOGICAL SOCIETY, US, vol. 99, no. 6, 1 December 2005 (2005-12-01), pages 2363 - 2368, XP002454664, ISSN: 8750-7587, DOI: 10.1152/JAPPLPHYSIOL.00083.2005;;SAINI D ET AL: ""Effect of electrostatic charge and size distributions on respirable aerosol deposition in lung model"", INDUSTRY APPLICATIONS CONFERENCE, 2004. 39TH IAS ANNUAL MEETING. CONFE RENCE RECORD OF THE 2004 IEEE SEATTLE, WA, USA 3-7 OCT. 2004, PISCATAWAY, NJ, USA,IEEE, vol. 2, 3 October 2004 (2004-10-03), pages 948 - 952, XP010735121, ISBN: 978-0-7803-8486-6, DOI: 10.1109/IAS.2004.1348527;;See also references of WO 2010036798A1",DISCONTINUED
88,CN,A,CN 102164487 A,006-366-217-230-427,2011-08-24,2011,CN 200980137941 A,2009-09-24,US 2009/0058217 W;;US 10001708 P,2008-09-25,Deep lung pulmonary delivery of treprostinil,"Administration of aerosolized Treprostinil formulations may provide a more homogeneous lung deposition of treprostinil, whereby making deep lung delivery possible.",ARADIGM CORP,CIPOLLA DAVID C;;IGOR GONDA;;TUNDE OTULANA;;RICHARD MORISHIGE;;PAUL BRUINENBERG,,https://lens.org/006-366-217-230-427,Patent Application,no,0,0,9,9,0,A61K9/0078;;A61K9/0078;;A61K31/19;;A61K9/12;;A61K31/191;;A61K31/191;;A61K31/192;;A61P7/02;;A61P9/04;;A61P9/10;;A61P9/12;;A61P11/00;;A61P11/08;;A61P13/12;;A61P15/00;;A61P17/00;;A61P17/06;;A61P29/00;;A61P35/00;;A61P43/00,A01N37/10;;A01K31/19,,0,0,,,,DISCONTINUED
89,EP,A4,EP 3129004 A4,181-379-983-034-204,2017-11-15,2017,EP 15775997 A,2015-03-31,US 201461976727 P;;US 2015/0023668 W,2014-04-08,LIPOSOMAL CIPROFLOXACIN FORMULATIONS WITH ACTIVITY AGAINST NON-TUBERCULOUS MYCOBACTERIA,,ARADIGM CORP;;UNIV OREGON STATE,GONDA IGOR;;BLANCHARD JAMES;;CIPOLLA DAVID C;;BERMUDEZ LUIS EDUARDO MOREIRA,,https://lens.org/181-379-983-034-204,Search Report,no,5,0,20,20,0,A61K9/0078;;A61K31/496;;A61K9/127;;A61K9/0073;;A61P11/00;;A61P31/04;;Y02A50/30;;A61K31/496;;A61K9/127;;A61K9/0073;;A61K9/0078;;Y02A50/30;;A61K9/12;;A61K45/06,A61K9/127,,1,0,,,See also references of WO 2015157038A1,DISCONTINUED
90,WO,A1,WO 2018/186998 A1,044-775-778-578-234,2018-10-11,2018,US 2018/0022031 W,2018-03-12,US 201762481984 P,2017-04-05,LIPOSOMAL ANTI-INFECTIVE FORMULATIONS TO INHIBIT NON-TUBERCULOUS MYCOBACTERIA (NTM) MICROAGGREGATE FORMATION AND ESTABLISHMENT OF NTM BIOFILM,"Methods of treatment to prevent NTM microaggregate formation using formulations of liposomal ciprofloxacin. Specific liposome formulations and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.",ARADIGM CORP;;UNIV OREGON STATE,GONDA IGOR;;BLANCHARD JAMES;;CIPOLLA DAVID C;;BERMUDEZ LUIZ EDUARDO MOREIRA,,https://lens.org/044-775-778-578-234,Patent Application,yes,2,0,2,2,0,A61K9/0073;;A61K9/127;;A61K9/0073;;A61K9/127;;A61K31/496;;A61K31/496;;A61K31/7036;;A61K31/7036,A61K31/7048;;A61K9/127,,4,2,030-313-935-038-14X;;101-904-038-391-443,26364883;;pmc4720240;;10.1080/21505594.2015.1088633;;10.1128/aac.41.6.1288;;pmc163901;;9174185,"LEITE: ""Understanding Mycobacterium avium subspecies hominissuis microaggregate mediated pathogenesis"", VIRULENCE, vol. 6, no. 7, October 2015 (2015-10-01), pages 675 - 676, XP055550772;;""Pulmonary surfactant"", WIKIPEDIA, 2 April 2017 (2017-04-02), pages 1 - 6, XP055550776;;BERMUDEZ ET AL.: ""Liposome-Ciprofloxacin Inhibits Mycobacterium Avium Subs Hominissuis (mah) Microaggregate Formation In A Dose And Time Dependent Manner"", AM J RESPIR CRIT CARE MED, 2016, pages 1;;CONLEY ET AL.: ""Aerosol Delivery of Liposome-Encapsulated Ciprofloxacin: Aerosol Characterization and Efficacy against Francisella tularensis Infection in Mice"", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 41, no. 6, June 1997 (1997-06-01), pages 1288 - 1292, XP055550781",PENDING
91,AU,A1,AU 2015/244275 A1,199-263-799-465-329,2016-10-06,2016,AU 2015/244275 A,2015-03-31,US 201461976727 P;;US 2015/0023668 W,2014-04-08,Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria,"Methods of treatment of NTM lung infections using formulations of liposomal ciprofloxacin. Specific liposome formulations and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.",UNIV OREGON STATE;;ARADIGM CORP,GONDA IGOR;;BLANCHARD JAMES;;CIPOLLA DAVID C;;BERMUDEZ LUIS EDUARDO MOREIRA,,https://lens.org/199-263-799-465-329,Patent Application,no,0,0,20,20,0,A61K9/0078;;A61K31/496;;A61K9/127;;A61K9/0073;;A61P11/00;;A61P31/04;;Y02A50/30;;A61K31/496;;A61K9/127;;A61K9/0073;;A61K9/0078;;Y02A50/30;;A61K9/12;;A61K45/06,A61K9/127,,0,0,,,,INACTIVE
92,EP,B1,EP 0532587 B1,028-863-243-165-118,2000-01-19,2000,EP 91910688 A,1991-05-14,US 9103366 W;;US 52515090 A,1990-05-17,METHODS FOR TRANS-DESTABILIZATION OF SPECIFIC PROTEINS IN VIVO,"This invention pertains to a method of metabolically destabilizing a protein or peptide of interest in vivo provided that the protein or peptide contains a second determinant of the N-end rule-based degradation signal and provided that another (targeting) protein or peptide can be identified that specifically interacts with the protein or peptide of interest. The methods of the invention comprise contacting the protein or peptide of interest with the targeting protein or peptide which contains a destabilizing amino-terminal amino acid according to the N-end rule of protein degradation but lacking a second determinant of the N-end rule-based degradation signal. Because nearly all proteins specifically interact with other proteins, this is a broadly applicable method for metabolically destabilizing a protein or peptide of interest in vivo.",MASSACHUSETTS INST TECHNOLOGY,VARSHAVSKY ALEXANDER J;;JOHNSON ERICA S;;GONDA DAVID K;;HOCHSTRASSER MARK,,https://lens.org/028-863-243-165-118,Granted Patent,yes,0,0,14,14,0,C07K1/107;;C07K14/00;;C07K14/395;;C07K2319/00;;C07K2319/61;;C07K2319/80;;C07K2319/95;;C12N15/11;;C07K14/00;;C07K1/107;;C07K14/395;;C07K2319/00;;C07K2319/61;;C07K2319/80;;C12N15/11;;C07K2319/95,C07K1/107;;C07K14/00;;C07K14/395;;C07K19/00;;C12N15/09;;C12N15/11;;C12P21/02;;C12R1/865,,2,2,085-846-205-582-124;;147-103-086-349-206,2506181;;10.1016/s0021-9258(19)84762-2;;10.1038/346287a0;;2165217,"JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 264, no. 28, 05 October 1989, Baltimore, MD (US); D.K. GONDA et al., pp. 16700-16712;;NATURE, vol. 364, 19 July 1990, London (GB); E.S. JOHNSON et al., pp., 287-291",EXPIRED
93,CA,A1,CA 2943049 A1,052-787-081-500-371,2015-10-15,2015,CA 2943049 A,2015-03-31,US 201461976727 P;;US 2015/0023668 W,2014-04-08,LIPOSOMAL CIPROFLOXACIN FORMULATIONS WITH ACTIVITY AGAINST NON-TUBERCULOUS MYCOBACTERIA,"Methods of treatment of NTM lung infections using formulations of liposomal ciprofloxacin. Specific liposome formulations and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.",ARADIGM CORP;;UNIV OREGON STATE,GONDA IGOR;;BLANCHARD JAMES;;CIPOLLA DAVID C;;BERMUDEZ LUIS EDUARDO MOREIRA,,https://lens.org/052-787-081-500-371,Patent Application,no,0,0,20,20,0,A61K9/0078;;A61K31/496;;A61K9/127;;A61K9/0073;;A61P11/00;;A61P31/04;;Y02A50/30;;A61K31/496;;A61K9/127;;A61K9/0073;;A61K9/0078;;Y02A50/30;;A61K9/12;;A61K45/06,A61K9/127,,0,0,,,,DISCONTINUED
94,US,A1,US 2021/0007985 A1,184-184-564-219-473,2021-01-14,2021,US 201816603045 A,2018-03-12,US 201816603045 A;;US 201762481984 P;;US 2018/0022031 W,2017-04-05,LIPOSOMAL ANTI-INFECTIVE FORMULATIONS TO INHIBIT NON-TUBERCULOUS MYCOBACTERIA (NTM) MICROAGGREGATE FORMATION AND ESTABLISHMENT OF NTM BIOFILM,"Methods of treatment to prevent NTM microaggregate formation using formulations of liposomal ciprofloxacin. Specific liposome formulations and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.",ARADIGM CORP;;OREGON STATE UNIVERESITY;;UNIV OREGON STATE,GONDA IGOR;;BLANCHARD JAMES;;CIPOLLA DAVID C;;BERMUDEZ LUIZ EDUARDO MOREIRA,ARADIGM CORPORATION (2019-11-06);;OREGON STATE UNIVERSITY (2020-04-21);;GRIFOLS S.A (2020-02-28),https://lens.org/184-184-564-219-473,Patent Application,yes,0,0,2,2,0,A61K9/0073;;A61K9/127;;A61K9/0073;;A61K9/127;;A61K31/496;;A61K31/496;;A61K31/7036;;A61K31/7036,A61K9/127;;A61K31/496,,0,0,,,,DISCONTINUED
95,US,A1,US 2017/0071934 A1,198-416-147-569-323,2017-03-16,2017,US 201615362405 A,2016-11-28,US 201615362405 A;;US 201514675218 A;;US 201461976727 P,2014-04-08,LIPOSOMAL CIPROFLOXACIN FORMULATIONS WITH ACTIVITY AGAINST NON-TUBERCULOUS MYCOBACTERIA,"Methods of treatment of NTM lung infections using formulations of liposomal ciprofloxacin. Specific liposome formulations and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.",ARADIGM CORP;;UNIV OREGON STATE,GONDA IGOR;;BLANCHARD JAMES;;CIPOLLA DAVID C;;BERMUDEZ LUIZ EDUARDOO MOREIRA,ARADIGM CORPORATION (2017-11-07);;OREGON STATE UNIVERSITY (2015-05-28);;GRIFOLS S.A (2020-03-31),https://lens.org/198-416-147-569-323,Patent Application,yes,2,0,20,20,0,A61K9/0078;;A61K31/496;;A61K9/127;;A61K9/0073;;A61P11/00;;A61P31/04;;Y02A50/30;;A61K31/496;;A61K9/127;;A61K9/0073;;A61K9/0078;;Y02A50/30;;A61K9/12;;A61K45/06,A61K31/496;;A61K9/12;;A61K9/127;;A61K45/06,,0,0,,,,ACTIVE
96,AU,B2,AU 2015/244275 B2,003-831-964-618-531,2019-08-29,2019,AU 2015/244275 A,2015-03-31,US 201461976727 P;;US 2015/0023668 W,2014-04-08,Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria,"Methods of treatment of NTM lung infections using formulations of liposomal ciprofloxacin. Specific liposome formulations and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.",ARADIGM CORP;;UNIV OREGON STATE,GONDA IGOR;;BLANCHARD JAMES;;CIPOLLA DAVID C;;BERMUDEZ LUIS EDUARDO MOREIRA,,https://lens.org/003-831-964-618-531,Granted Patent,no,5,0,20,20,0,A61K9/0078;;A61K31/496;;A61K9/127;;A61K9/0073;;A61P11/00;;A61P31/04;;Y02A50/30;;A61K31/496;;A61K9/127;;A61K9/0073;;A61K9/0078;;Y02A50/30;;A61K9/12;;A61K45/06,A61K9/127,,0,0,,,,INACTIVE
97,US,B2,US 11116765 B2,084-028-588-858-456,2021-09-14,2021,US 202016914122 A,2020-06-26,US 202016914122 A;;US 201916506675 A;;US 201715821193 A;;US 201615362405 A;;US 201514675218 A;;US 201461976727 P,2014-04-08,Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria,"Methods of treatment of NTM lung infections using formulations of liposomal ciprofloxacin. Specific liposome formulations and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.",GRIFOLS SA,GONDA IGOR;;BLANCHARD JAMES;;CIPOLLA DAVID C;;BERMUDEZ LUIZ EDUARDO MOREIRA,,https://lens.org/084-028-588-858-456,Granted Patent,yes,51,0,20,20,0,A61K9/0078;;A61K31/496;;A61K9/127;;A61K9/0073;;A61P11/00;;A61P31/04;;Y02A50/30;;A61K31/496;;A61K9/127;;A61K9/0073;;A61K9/0078;;Y02A50/30;;A61K9/12;;A61K45/06,A61K31/496;;A61K9/00;;A61K9/12;;A61K9/127;;A61K45/06,,29,25,057-723-944-383-350;;075-949-839-628-664;;128-345-886-759-353;;035-121-678-040-243;;050-665-220-730-241;;066-724-015-906-939;;101-904-038-391-443;;038-604-184-677-717;;077-425-842-356-028;;007-122-013-064-944;;034-910-153-767-189;;032-708-511-260-192;;033-150-287-738-644;;024-060-783-058-765;;023-708-751-561-393;;015-132-669-034-026;;069-271-598-076-315;;058-433-709-835-418;;048-497-642-568-879;;048-974-626-954-111;;048-157-998-339-224;;037-256-374-574-44X;;066-267-219-024-523;;004-758-352-546-31X;;009-893-982-767-479,10.1016/0168-3659(94)90257-7;;5859039;;10.1016/s0022-2836(65)80093-6;;10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a3192;;12909649;;10.1099/jmm.0.05224-0;;10.4155/tde.13.71;;23919478;;10.1039/c5ra25898g;;10.1128/aac.41.6.1288;;pmc163901;;9174185;;10.1007/s11095-013-1135-z;;23881305;;10.1164/rccm.201003-0395oc;;20833823;;10.1016/0014-5793(92)80947-f;;1426260;;10.1016/0005-2736(95)00159-z;;7488619;;pmc245550;;1482150;;10.1128/aac.36.12.2808;;9814848;;10.1016/s0005-2736(98)00125-4;;10.1016/s1473-3099(08)70100-2;;18471777;;2515523;;10.1002/ppul.1950070413;;10.1016/j.ejps.2010.08.010;;20800680;;pmc323309;;10.1073/pnas.83.8.2422;;16593683;;10.1164/ajrccm.161.1.9903019;;10619831;;10.1258/002367702320162405;;12144741;;9449259;;pmc105454;;10.1128/aac.42.1.45;;10.1002/ppul.1950170511;;8058428;;10.1016/j.bbamem.2003.12.006;;15003875;;10.1016/s0168-3659(03)00358-4;;14568408;;16611229;;10.1111/j.1462-5822.2005.00667.x;;10.1016/j.jconrel.2005.10.011;;16318894,"ANONYMOUS: ""Nanotechnology for Cancer Therapy"", 19 December 2006, CRC PRESS, XP002772115;;Ausborn et al., “The protective effect of free and membrane-bound cryoprotectants during freezing and freeze-drying of liposomes” Journal of Controlled Release (1994) 30:105-116.;;Bangham, et al., “Diffusion of Univalent Ions across the Lamellae of Swollen Phospholipids” J. Mol. Niol., 13:238-252 (1965).;;Bruinenberg P., et al., “Safety, tolerability and pharmacokinetics of novel liposomal ciprofloxacin formulations for inhalation in healthy volunteers and in non-cystic bronchiectasis patients” Am. J. Respir. Crit. Care Med. 181;2010: A3192 / www.atsjournals.org.;;Carter G., et al., “Characterization of biofilm formation by clinical isolates of Mycobacterium avium”, Journal of Medical Microbiology (2003) 52:747-52.;;Cipolla D., et al., “Liposomal Formulations for Inhalation”, Ther. Deliv., (2013) 4(8)1047-1072. doi: 10.4155/tde.13.71.;;Cipolla D., et al., “Development and Characterization of an In Vitro Release Assay for Liposomal Ciprofloxacin for Inhalation”, J. Pharm. Sci., (2014) 103:314-327. doi: 10.1002/ios.23795.;;Cipolla, et al., “Formation of drug nanocrystals under nanoconfinement afforded by liposomes,” RSC Adv. (Jan. 2016) 6:6223-6233.;;Conley, et al., “Aerosol Delivery of Liposome-Encapsulated Ciprofloxacin: Aerosol Characterization and Efficacy against Francisella tularensis Infection in Mice” Antimicrobial Aaents 41(6): 1288-1292 (Jun. 1997).;;Costa, et al., “Freeze-Anneal-Thaw Cycling of Unilamellar Liposomes: Effect on Encapsulation Efficiency” Pharm. Res. (2014) 31:97-103.;;Koh, et al., “Clinical Significance of Differentiation of Mycobacterium massiliense from Mycobacterium abscessus” American Journal of Respiratory and Critical Care Medicine (2011) 183:405-410.;;Kokyu (Respiration) (2013) 32(7):619-623.;;Kurashima, “Mycobacterium abscessas” Igaku no Ayumi (Progress in Medicine) (Mar. 8, 2014) 248(10):792-798.;;Lasic, et al., “Gelation of liposome interior: A novel method for drug encapsulation” FEBS Lett., (1992) 312:255-258.;;Lasic et al., “Transmembrane gradient drive phase transitions within vesicles: lessons for drug delivery” Biochimica et Biophysica Acta (1995) 1239:145-156.;;Majumdar et al., Efficacies of liposome-encapsulated streptomycin and ciprofloxacin against Mycobacterium avium—N. intracellulare complex infections in human peripheral blood monocvtes/macroohaaes. Antimicrob Aaents Chemother (1992) 36:2808-15.;;Maurer et al., “Anomalous solubility behavior of the antibiotic ciprofloxacin encapsulated in liposomes: a 1H-NMR study.” Biochimica et Biophysica Acta (1998) 1374:9-20.;;Piersimoni et al., “Pulmonary infections associated with non-tuberculous mycobacteria in immunocompetent patients” Lancet Infect. Dis. (2008) 8:323-334.;;Smith, et al., “Safety of Aerosol Tobramycin administration for 3 months to patients with cystic fibrosis.” Ped. Pulmonol. (1989); 7(4):265-271.;;Stark, et al., “Long-term stability of sterically stabilized liposomes by freezing and freeze-drying: Effects of cryoprotectants on structure”, Eur. J. Pharm. Sci. 41(2010) 546-555.;;Strauss, et al., “Stabilization of lipid bilayer vesicles by sucrose during freezing”, Proc. Natl. Acad. Sci. USA (1986) 83:2422-2426.;;Van Heeckeren, et al., “Effect of Pseudomonas infection on weight loss, lung mechanics, and cytokines in mice.” Am J Respir Grit Care Med. (Jan. 2000); 161(1):271.;;Van Heeckeren, et al., “Murine Models of chronic Pseudomonas aeruginosa lung infection” Lab Anim (Jul. 2002}; 36(3):291-312.;;Webb, et al., “Antibacterial Efficacy against an In Vivo Salmonella typhimurium Infection Model and Pharmacokinetics of a Liposomal Ciprofloxacin Formulation”, Antimicrobial Agents and Chemotherapy (Jan. 1998) 42(1):45-52.;;Weber A, et al., “Nebulizer delivery of tobramycin to the lower respiratory tract”. Pediatr Pulmonol. (May 1994}; 17 (5):331-9.;;Wolkers, et al.,“Preservation of dried liposomes in the presence of sugar and phosphate”, Biochim. Biphys. Acta. (2004) 1661:125-134.;;Wong, et al., “Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection” Journal of Controlled Release, 92; 265-273 (2003}.;;Yamazaki, et al., “The ability to form biofilm influences Mycobacterium avium invasion and translocation of bronchial epithelial cells”, Cellular Microbiology (2006) 8(5):806-14.;;Zhigaltsev, et al., “Formation of drug-arylsulfonate complexes inside liposomes: A novel approach to improve drug retention”, J. Control Rel. 110 (2006): 378-386.",ACTIVE
98,WO,A1,WO 2015/157038 A1,156-195-466-454-574,2015-10-15,2015,US 2015/0023668 W,2015-03-31,US 201461976727 P,2014-04-08,LIPOSOMAL CIPROFLOXACIN FORMULATIONS WITH ACTIVITY AGAINST NON-TUBERCULOUS MYCOBACTERIA,"Methods of treatment of NTM lung infections using formulations of liposomal ciprofloxacin. Specific liposome formulations and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.",ARADIGM CORP;;UNIV OREGON STATE,GONDA IGOR;;BLANCHARD JAMES;;CIPOLLA DAVID C;;BERMUDEZ LUIS EDUARDO MOREIRA,,https://lens.org/156-195-466-454-574,Patent Application,yes,23,1,20,20,0,A61K9/0078;;A61K31/496;;A61K9/127;;A61K9/0073;;A61P11/00;;A61P31/04;;Y02A50/30;;A61K31/496;;A61K9/127;;A61K9/0073;;A61K9/0078;;Y02A50/30;;A61K9/12;;A61K45/06,A61K9/127,,62,45,048-673-484-109-027;;075-949-839-628-664;;100-159-123-243-871;;012-252-886-612-459;;032-540-097-522-655;;032-540-097-522-655;;154-415-293-408-578;;032-933-505-288-325;;031-426-424-414-729;;128-345-886-759-353;;029-148-589-814-422;;035-121-678-040-243;;067-024-524-311-940;;050-665-220-730-241;;101-904-038-391-443;;096-430-335-321-467;;012-210-322-057-335;;012-650-141-047-778;;135-866-219-244-046;;022-758-786-690-485;;019-988-630-331-801;;036-582-222-376-548;;083-698-431-720-922;;076-312-210-864-326;;003-924-759-694-183;;012-062-928-890-733;;110-934-436-932-405;;117-414-976-171-550;;032-708-511-260-192;;086-931-563-365-931;;085-282-321-416-333;;083-903-071-523-844;;008-565-993-389-128;;045-559-172-047-180;;011-205-311-656-508;;116-973-337-420-471;;023-708-751-561-393;;048-497-642-568-879;;058-433-709-835-418;;048-157-998-339-224;;066-267-219-024-523;;005-355-449-252-481;;086-952-662-851-508;;004-758-352-546-31X;;012-361-294-266-137,22312016;;pmc3360574;;10.1164/rccm.201111-2016oc;;5859039;;10.1016/s0022-2836(65)80093-6;;10934074;;10.1164/ajrccm.162.2.9910086;;10.1086/587906;;18422455;;10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a3214;;10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a3214;;10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a3191;;10.1164/rccm.201002-0310oc;;20538958;;pmc2970866;;10.1016/s1569-1993(09)60196-x;;10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a3192;;10.1016/s1569-1993(11)60130-6;;12909649;;10.1099/jmm.0.05224-0;;10.7326/0003-4819-113-5-358;;2382918;;10.4155/tde.13.71;;23919478;;10.1128/aac.41.6.1288;;pmc163901;;9174185;;10.1146/annurev.micro.49.1.711;;10.1146/annurev.mi.49.100195.003431;;8561477;;10.1128/aac.36.7.1567;;1387303;;pmc191622;;8354928;;10.1093/infdis/168.3.793;;10.1586/17476348.2.4.479;;20477211;;8419592;;10.1016/s0022-3476(05)83478-x;;16807259;;10.1183/09031936.06.00149805;;9524452;;10.1177/08959374970110010701;;pmc4068435;;24637682;;10.1128/aac.02555-13;;pmc171452;;10.1128/aac.33.2.176;;2719461;;10.1128/cmr.6.3.266;;pmc358286;;8358707;;10.1586/eri.12.88;;pmc3562728;;23106280;;10.1111/j.1462-5822.2007.01067.x;;10.1093/jac/37.suppl_c.1;;8818841;;pmc245550;;1482150;;10.1128/aac.36.12.2808;;10.1111/j.1469-0691.2010.03307.x;;20636426;;pmc2978799;;18305202;;10.1093/jac/dkn059;;2293210;;10.1023/a:1015924124180;;10.1128/aac.39.9.2104;;pmc162889;;8540724;;10.1128/aac.45.11.3262-3266.2001;;pmc90822;;11600396;;pmc4770250;;10.1136/thoraxjnl-2013-203207;;23681906;;10.1056/nejm199608083350602;;8676931;;2515523;;10.1002/ppul.1950070413;;10.1258/002367702320162405;;12144741;;10.1164/ajrccm.161.1.9903019;;10619831;;10.1002/ppul.1950170511;;8058428;;10.1016/s0168-3659(03)00358-4;;14568408;;10.3109/10731190009118586;;11009114;;10.1136/thorax.57.3.212;;pmc1746273;;11867823;;16611229;;10.1111/j.1462-5822.2005.00667.x;;10.1164/arrd.1973.108.3.547;;4745250,"""Peptide and Protein Drug Delivery"", 1991, MARCEL DEKKER, INC., pages: 247 - 301;;BERGOGNE-BEREZIN E: ""Pharmacokinetics of fluoroquinolones in respiratory tissues and fluids"", QUINOLONES BULL, vol. 10, 1993, pages 29 - 18;;ADJEMIAN JOLIVIER KNSEITZ AEHOLLAND SMPREVOTS DR: ""Prevalence of nontuberculosis mycobacterial lung disease in US Medicare beneficiaries"", AM J RESPIR CRIT CARE MED, vol. 185, 2012, pages 881 - 886;;BANGHAM ADSTANDISH MMWATKINS JC: ""Diffusion of univalent ions across the lamellae of swollen phospholipids"", J MOL BIOL., vol. 13, no. 1, 1965, pages 238 - 252, XP008039387, DOI: 10.1016/S0022-2836(65)80093-6;;BARKER AFCOUCH LFEIL SBGOTFRIED MHILOWITE JMEYER KCO'DONNELL ASAHN SASMITH LJSTEWART JO: ""Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis"", AM J RESPIR CRIT CARE MED, vol. 162, 2000, pages 481 - 5;;BERMUDEZ LEMOTAMEDI NKOLONOSKI P. CHEE CBAIMUKANOVA GBILDFELL RWANG GPHAN LTYOUNG LS: ""The efficacy of clarithromycin and the bicyclolide EDP-420 against Mycobacterium avium in a mouse model of pulmonary infection"", J INFECT DIS, vol. 197, 2008, pages 1506 - 10;;BERMUDEZ LEBLANCHARD JDHAUCK LGONDA I: ""Treatment of Mycobacterium avium subsp hominissuis (MAH) lung infection with liposome-encapsulated ciprofloxacin resulted in significant decrease in bacterial load in the lung"", AMERICAN THORACIC SOCIETY (ATS) INTERNATIONAL CONFERENCE, 2015;;BILTON DP BRUINENBERG POTULANA B: ""Inhaled liposomal ciprofloxacin hydrochloride significantly reduces sputum Pseudomonas aeruginosa density in CF and non-CF bronchiectasis"", AMERICAN THORACIC SOCIETY (ATS) INTERNATIONAL CONFERENCE, SAN DIEGO, CA;;AM J RESPIR CRIT CARE MED, vol. 179, 2009, pages A3214;;BILTON DBRUINENBERG POTULANA BMORISHIGE RBLANCHARD JDESOYZA ASERISIER D: ""Inhaled liposomal ciprofloxacin hydrochloride significantly reduces sputum Pseudomonas aeruginosa density in CF and non-CF bronchiectasis"", EUROPEAN RESPIRATORY SOCIETY (ERS) CONFERENCE, 2009;;BILTON DDE SOYZA AHAYWARD CBRUINENBERG P: ""Effect of a 28-day course of two different doses of once a day liposomal ciprofloxacin for inhalation on sputum Pseudomonas aeruginosa density in non-CF bronchiectasis"", AMERICAN THORACIC SOCIETY (ATS) INTERNATIONAL CONFERENCE;;PREVOTS RDSHAW PASTRICKLAND DJACKSON LARAEBEL MABLOSKY MAMONTES DE OCA RSHEA YRSEITZ AEHOLLAND SM: ""Nontuberculosis mycobacterial lung disease prevalence at four integrated health care delivery systems"", AM J RESPIR CRIT CARE MED, vol. 182, 2010, pages A3192 - 976;;BILTON DSERISIER DJDESOYZA AWOLF RBRUINENBERG P: ""Multicenter, randomized, double-blind, placebo-controlled study (ORBIT 1) to evaluate the efficacy, safety, and tolerability of once daily ciprofloxacin for inhalation in the management of Pseudomonas aeruginosa infections in patients with non-cystic fibrosis bronchiectasis"", EUROPEAN RESPIRATORY SOCIETY ANNUAL CONGRESS, 2011;;BLANCHARD JD: ""Pulmonary drug delivery as a first response to bioterrorism"", RESPIRATORY DRUG DELIVERY X, 2006, pages 73 - 82;;BLANCHARD JDANELISHVILI LGONDA IBERMUDEZ L: ""Liposomal ciprofloxacin preparation is active against Mycobacterium avium subsp hominissuis and Mycobacterium abscessus in macrophages and in biofilm"", AMERICAN THORACIC SOCIETY (ATS) INTERNATIONAL CONFERENCE, 2014;;BRUINENBERG POTULANA BBLANCHARD JMORISHIGE RCIPOLLA DWILSON JSERISIER D: ""The effect of once-a-day, inhaled liposomal ciprofloxacin hydrochloride for inhalation on bacterial density in cystic fibrosis patients with chronic P. aeruginosa infection"", NORTH AMERICAN CYSTIC FIBROSIS CONFERENCE, 2008;;PED PULMON, vol. 43, 2008, pages 401;;BRUINENBERG POTULANA BBLANCHARD JCIPOLLA DWILSON JSERISIER D: ""Pharmacokinetics and antibacterial activity of inhaled liposomal ciprofloxacin hydrochloride in healthy volunteers and in cystic fibrosis (CF) patients"", 32ND EUROPEAN CYSTIC FIBROSIS CONFERENCE;;J CYSTIC FIBROSIS, vol. 8, 2009, pages S49;;BRUINENBERG PBLANCHARD JCIPOLLA DSERISIER D: ""Safety, tolerability and pharmacokinetics of novel liposomal ciprofloxacin formulations for inhalation in healthy volunteers and in non-cystic bronchiectasis patients"", AMERICAN THORACIC SOCIETY (ATS) INTERNATIONAL CONFERENCE;;BRUINENBERG, PBLANCHARD JDCIPOLLA DCDAYTON FMUDUMBA SGONDA I: ""Inhaled liposomal ciprofloxacin: once a day management of respiratory infections"", RESPIRATORY DRUG DELIVERY, 2010, pages 73 - 81;;BRUINENBERG PSERISIER DBLANCHARD JCIPOLLA DGONDA I: ""Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis"", EUROPEAN RESPIRATORY SOCIETY ANNUAL CONGRESS, 2010;;BRUINENBERG PSERISIER DCIPOLLA DBLANCHARD J: ""Safety, tolerability pharmacokinetics and antimicrobial activity of inhaled liposomal ciprofloxacin formulations in humans"", NORTH AMERICAN CYSTIC FIBROSIS CONFERENCE, vol. 45, 2010;;BRUINENBERG PSERISIER DCIPOLLA DBLANCHARD J: ""Safety, tolerability, and pharmacokinetics of novel liposomal ciprofloxacin formulations in healthy volunteers (HV) and non-cystic fibrosis bronchiectasis (BE) patients"", J CYSTIC FIBROSIS, vol. 10, 2011, pages S29;;CARTER GDRUMMOND DBERMUDEZ LE: ""Characterization of biofilm formation by Mycobacterium avium strains"", J MED MICROBIOL, vol. 52, 2003, pages 747 - 52;;CHIU JNUSSBAUM JBOZZETTE STILLES JGYOUNG LSLEEDOM JHESELTINE PNMCCUTCHAN JA: ""Treatment of disseminated Mycobacterium avium complex infection in AIDS with amikacin, ethambutol and ciprofloxacin"", ANN INTERN MED, vol. 113, 1990, pages 358 - 61;;CIPOLLA DCDAYTON FFULZELE SGABATAN EMUDUMBA SYIM DWU HZWOLINSKI R: ""Vitro Properties and Aerosol Performance. Respiratory Drug Delivery"", 25 April 2010, DAVIS HEALTHCARE INT'L PUBLISHING, article ""Inhaled Liposomal Ciprofloxacin"", pages: 409 - 414;;CIPOLLA DREDELMEIER TEASTMAN S.BRUINENBERG PGONDA I.: ""Respiratory Drug Delivery Europe"", 21 May 2013, DAVIS HEALTHCARE INT'L PUBLISHING, article ""Liposomes, niosomes and proniosomes - a critical update of their (commercial) development as inhaled products"", pages: 237 - 242;;CIPOLLA DGONDA ICHAN H-K: ""Liposomal Formulations for Inhalation"", THERAPEUTIC DELIVERY, vol. 4, no. 8, pages 1047 - 1072, XP009194915, DOI: 10.4155/tde.13.71;;CONLEY JYANG HWILSON TBLASETTI KDI NINNO VSCHNELL GWONG JP: ""Aerosol delivery of liposome encapsulated ciprofloxacin: aerosol characterization and efficacy against Francisella tuleransis infection in mice"", ANTIMICROB AGENTS CHEMOTHER, vol. 41, 1997, pages 1288 - 92;;COSTERTON JWLEWANDOWSKI ZCALDWELL DEKORBER DRLAPPIN-SCOTT HM.: ""Microbial biofilms"", ANNU REV MICROBIOL, vol. 49, 1995, pages 711 - 45, XP002919540, DOI: 10.1146/annurev.mi.49.100195.003431;;DE LALLA FMASERATI RSCARPELLINI PMARONE PNICOLIN RCACCAMO FRIGOLI R: ""Clarithromycin-ciprofloxacin-amikacin for therapy of Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS"", ANTIMICROB AGENTS CHEMOTHER, vol. 36, 1992, pages 1567 - 9, XP002536416;;DI NINNO VLCHERWONOGRODZKY JWWONG JP: ""Liposome-encapsulated ciprofloxacin is effective in the protection and treatment of Balb/c mice against Francisella tularensis"", J INFECT DIS, vol. 168, 1993, pages 793 - 794;;FIEL SB: ""Aerosolized antibiotics in cystic fibrosis: current and future trends"", EXPERT REV RESPIR MED, vol. 2, 2008, pages 479 - 487;;FITZSIMMONS SC: ""The changing epidemiology of cystic fibrosis"", J PEDIATR, vol. 122, no. 1, January 1993 (1993-01-01), pages 1 - 9;;FOWLER SJFRENCH JSCRANTON NJFOWERAKER JCONDLIFFE AHAWORTH CSEXLEY ARBILTON D: ""Nontuberculous mycobacteria in bronchiectasis: prevalence and patient characteristics"", EUR RESPIR J, vol. 28, 2006, pages 1204 - 10;;GILBERT PDAS JFOLEY I.: ""Biofilm susceptibility to antimicrobials"", ADV DENT RES, vol. 11, no. 1, April 1997 (1997-04-01), pages 160 - 7;;HAMBLIN KABLANCHARD JDATKINS HS: ""Efficacy of liposome-encapsulated ciprofloxacin against Francisella tularensis Schu S4 strain"", INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (ICACC, 2011;;HAMBLIN KAARMSTRONG SJKAY BBARNES KBDAVIES CWONG JPBLANCHARD JDHARDING SVSIMPSON AJHATKINS HS: ""Liposome-encapsulation of ciprofloxacin improves protection against highly resistant Francisella tularensis Schu S4 strain"", ANTIMICROB AGENTS CHEMOTHER, 2014;;INDERLIED CKOLONOSKI PWU MYOUNG L: ""Amikacin, ciprofloxacin, and imipenem treatment for disseminated Mycobacterium avium complex infection of beige mice"", ANTIMICROB AGENTS CHEMOTHER, vol. 33, 1989, pages 176 - 80;;INDERLIED CBKEMPER CABERMUDEZ LE: ""The Mycobacterium avium complex"", CLIN MICRO REV, vol. 6, 1993, pages 266 - 310;;ISLAM MSRICHARDS JPOJHA AK: ""Targeting drug tolerance in mycobacteria: a perspective from mycobacterial biofilms"", EXPERT REV ANTI INFECT THER, vol. 10, no. 9, 2012, pages 1055 - 1066;;JORDAO LBLECK CKMAYORGA LGRIFFTHS GANES E: ""On the killing of mycobacteria by macrophages"", CELL MICROBIOL, vol. 10, 2008, pages 529 - 48;;LODE HBORNER KKOEPPE PSCHABERG T.: ""Azithromycin--review of key chemical, pharmacokinetic and microbiological features"", J ANTIMICROB CHEMOTHER, vol. 37, 1996, pages 1 - 8, XP008078035, DOI: 10.1093/jac/37.1.1;;MAJUMDAR SFLASHER DFRIEND DSNASSOS PYAJKO DHADLEY WKDIIZGIINE N: ""Efficacies of liposome-encapsulated streptomycin and ciprofloxacin against Mycobacterium avium-M. intracellulare complex infections in human peripheral blood monocytes/macrophages"", ANTIMICROB AGENTS CHEMOTHER, vol. 36, 1992, pages 2808 - 15;;MCNABE MTENNANT RDANELISHVILI LYOUNG LBERMUDEZ LE: ""Mycobacterium avium ssp. hominissuis biofilm is composed of distinct phenotypes and influenced by the presence of antimicrobials"", CLIN MICROBIOL INFECT, vol. 17, no. 5, 2012, pages 697 - 703;;MEERS PNEVILLE MMALININ VSCOTTO AWSARDARYAN GKURUMUNDA RMACKINSON CJAMES GFISHER SPERKINS WR: ""Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomanas aeruginosa lung infections"", J ANTIMICROB CHEMOTHER, vol. 61, 2008, pages 859 - 68, XP002632705, DOI: 10.1093/jac/dkn059;;NIVEN RNSCHREIER H: ""Nebulization of Liposomes: I. Effects of Lipid Composition"", PHARM RES, vol. 7, 1990, pages 1127 - 1133, XP009031185, DOI: 10.1023/A:1015924124180;;OH YKNIX DESTRAUBINGER RM: ""Formulation and efficacy of liposome-encapsulated antibiotics for therapy of intracellular Mycobacterium avium infection"", ANTIMICROB AGENTS CHEMOTHER, vol. 39, 1995, pages 2104 - 11, XP002065382;;POLONIO REMERMEL LAPAQUETTE GESPERRY JF.: ""Eradication of biofilm-forming Staphylococcus epidermidis (RP62A) by a combination of sodium salicylate and vancomycin"", ANTIMICROB AGENTS CHEMOTHER, vol. 45, no. 11, November 2001 (2001-11-01), pages 3262 - 6, XP055460071, DOI: 10.1128/AAC.45.11.3262-3266.2001;;SERISIER DJBILTON DDE SOYZA ATHOMPSON PJKOLBE JGREVILLE HWCIPOLLA DBRUINENBERG PGONDA I: ""Inhaled, Dual-Release Liposomal Ciprofloxacin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-2) - a Randomised, Double-Blind"", PLACEBO-CONTROLLED TRIAL. THORAX, vol. 68, no. 9, 2013, pages 812 - 817, XP055576959, DOI: 10.1136/thoraxjnl-2013-203207;;SHAFRAN SDSINGER JZAROWNY DPPHILLIPS PSALIT IWALMSLEY SLFONG IWGILL MJRACHLIS ARLALONDE RG: ""A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS, rifampin, ethambutol, and clarithromycin, versus rifampin, ethambutol, clofazimine and ciprofloxacin"", N ENGL J MED, vol. 335, 1996, pages 377 - 83, XP000987186, DOI: 10.1056/NEJM199608083350602;;SMITH ALRAMSEY BWHEDGES DLHACK BWILLIAMS-WARREN JWEBER AGORE EJREDDING GJ: ""Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis"", PED PULMONOL, vol. 7, no. 4, 1989, pages 265 - 271, XP001107253;;VAN HEECKEREN AMSCHLUCHTER MD.: ""Murine models of chronic Pseudomonas aeruginosa lung infection"", LAB ANIM, vol. 36, no. 3, July 2002 (2002-07-01), pages 291 - 312;;EROKWU BHAXHIU MAFERKOL TW: ""Effect of Pseudomonas infection on weight loss, lung mechanics, and cytokines in mice"", AM J RESPIR CRIT CARE MED, vol. 161, no. 1, January 2000 (2000-01-01), pages 271 - 9;;WEBER ASMITH AWILLIAMS-WARREN JRAMSEY BCOVERT DS.: ""Nebulizer delivery of tobramycin to the lower respiratory tract"", PEDIATR PULMONOL, vol. 17, no. 5, May 1994 (1994-05-01), pages 331 - 9;;WONG JPYANG HBLASETTI KLSCHNELL GCONLEY JSCHOFIELD LN: ""Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection"", J CONTROL RELEASE, vol. 92, 2003, pages 265 - 73, XP004467641, DOI: 10.1016/S0168-3659(03)00358-4;;WONG JPSCHNELL GSIMPSON MSARAVOLAC E: ""Effects of liposome-encapsulated ciprofloxacin on phagocytosis, nitric oxide, and intracellular killing of Staphylcoccus aureus by murine macrophages"", ARTIFIC CELLS BLOOD SUBSTIT IMMOBIL BIOTECHNOL, vol. 28, 2000, pages 415 - 28, XP055659636, DOI: 10.3109/10731190009118586;;WOLTER JSEENEY SBELL SBOWLER SMASEL PMCCORMACK J.: ""Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial"", THORAX, vol. 57, 2002, pages 212 - 216;;YAMAZAKI YDANELISHVILI LWU MHIDAKA EKATSUYAMA TSTANG BPETROFSKY MBILDFELL RBERMUDEZ L: ""The ability to form biofilm influences Mycobacterium avium invasion and translocation of bronchial epithelial cells"", CELL MICROBIOL, vol. 8, 2006, pages 806 - 14;;YEAGER HRALEIGH JW: ""Pulmonary disease due to Mycobacterium intracellulare"", AM REV RESP DIS, vol. 108, 1973, pages 547 - 52;;See also references of EP 3129004A4",PENDING
99,DK,T3,DK 0532587 T3,165-793-136-411-033,2000-04-17,2000,DK 91910688 T,1991-05-14,US 52515090 A;;US 9103366 W,1990-05-17,Fremgangsmåder til trans-destabilisering af specifikke proteiner in vivo,"This invention pertains to a method of metabolically destabilizing a protein or peptide of interest in vivo provided that the protein or peptide contains a second determinant of the N-end rule-based degradation signal and provided that another (targeting) protein or peptide can be identified that specifically interacts with the protein or peptide of interest. The methods of the invention comprise contacting the protein or peptide of interest with the targeting protein or peptide which contains a destabilizing amino-terminal amino acid according to the N-end rule of protein degradation but lacking a second determinant of the N-end rule-based degradation signal. Because nearly all proteins specifically interact with other proteins, this is a broadly applicable method for metabolically destabilizing a protein or peptide of interest in vivo.",MASSACHUSETTS INST TECHNOLOGY,VARSHAVSKY ALEXANDER J;;JOHNSON ERICA S;;GONDA DAVID K;;HOCHSTRASSER MARK,,https://lens.org/165-793-136-411-033,Granted Patent,no,0,0,14,14,0,C07K1/107;;C07K14/00;;C07K14/395;;C07K2319/00;;C07K2319/61;;C07K2319/80;;C07K2319/95;;C12N15/11;;C07K14/00;;C07K1/107;;C07K14/395;;C07K2319/00;;C07K2319/61;;C07K2319/80;;C12N15/11;;C07K2319/95,C07K1/107;;C07K14/00;;C07K14/395;;C07K19/00;;C12N15/09;;C12N15/11;;C12P21/02;;C12R1/865,,0,0,,,,EXPIRED
100,WO,A1,WO 2010/036798 A1,143-325-577-169-208,2010-04-01,2010,US 2009/0058217 W,2009-09-24,US 10001708 P,2008-09-25,DEEP LUNG PULMONARY DELIVERY OF TREPROSTINIL,"Administration of aerosolized Treprostinil formulations may provide a more homogeneous lung deposition of treprostinil, whereby making deep lung delivery possible.",ARADIGM CORP;;CIPOLLA DAVID C;;GONDA IGOR;;OTULANA TUNDE;;MORISHIGE RICHARD;;BRUINENBERG PAUL,CIPOLLA DAVID C;;GONDA IGOR;;OTULANA TUNDE;;MORISHIGE RICHARD;;BRUINENBERG PAUL,,https://lens.org/143-325-577-169-208,Patent Application,yes,2,10,9,9,0,A61K9/0078;;A61K9/0078;;A61K31/19;;A61K9/12;;A61K31/191;;A61K31/191;;A61K31/192;;A61P7/02;;A61P9/04;;A61P9/10;;A61P9/12;;A61P11/00;;A61P11/08;;A61P13/12;;A61P15/00;;A61P17/00;;A61P17/06;;A61P29/00;;A61P35/00;;A61P43/00,A01N37/10;;A01K31/19,,1,0,,,See also references of EP 2330893A4,PENDING
101,US,A1,US 2018/0092912 A1,015-732-179-802-554,2018-04-05,2018,US 201715821193 A,2017-11-22,US 201715821193 A;;US 201615362405 A;;US 201514675218 A;;US 201461976727 P,2014-04-08,LIPOSOMAL CIPROFLOXACIN FORMULATIONS WITH ACTIVITY AGAINST NON-TUBERCULOUS MYCOBACTERIA,"Methods of treatment of NTM lung infections using formulations of liposomal ciprofloxacin. Specific liposome formulations and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.",ARADIGM CORP;;UNIV OREGON STATE,GONDA IGOR;;BLANCHARD JAMES;;CIPOLLA DAVID C;;BERMUDEZ LUIZ EDUARDO MOREIRA,ARADIGM CORPORATION (2017-11-07);;OREGON STATE UNIVERSITY (2015-05-28);;GRIFOLS S.A (2020-02-28),https://lens.org/015-732-179-802-554,Patent Application,yes,2,0,20,20,0,A61K9/0078;;A61K31/496;;A61K9/127;;A61K9/0073;;A61P11/00;;A61P31/04;;Y02A50/30;;A61K31/496;;A61K9/127;;A61K9/0073;;A61K9/0078;;Y02A50/30;;A61K9/12;;A61K45/06,A61K31/496;;A61K9/00;;A61K9/12;;A61K9/127;;A61K45/06,,0,0,,,,INACTIVE
102,US,B2,US 10376508 B2,021-562-220-037-806,2019-08-13,2019,US 201715821193 A,2017-11-22,US 201715821193 A;;US 201615362405 A;;US 201514675218 A;;US 201461976727 P,2014-04-08,Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria,"Methods of treatment of NTM lung infections using formulations of liposomal ciprofloxacin. Specific liposome formulations and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.",ARADIGM CORP;;UNIV OREGON STATE,GONDA IGOR;;BLANCHARD JAMES;;CIPOLLA DAVID C;;BERMUDEZ LUIZ EDUARDO MOREIRA,ARADIGM CORPORATION (2017-11-07);;OREGON STATE UNIVERSITY (2015-05-28);;GRIFOLS S.A (2020-02-28),https://lens.org/021-562-220-037-806,Granted Patent,yes,33,0,20,20,0,A61K9/0078;;A61K31/496;;A61K9/127;;A61K9/0073;;A61P11/00;;A61P31/04;;Y02A50/30;;A61K31/496;;A61K9/127;;A61K9/0073;;A61K9/0078;;Y02A50/30;;A61K9/12;;A61K45/06,A61K31/496;;A61K9/00;;A61K9/12;;A61K9/127;;A61K45/06,,13,11,077-425-842-356-028;;075-949-839-628-664;;101-904-038-391-443;;034-910-153-767-189;;032-708-511-260-192;;033-150-287-738-644;;024-060-783-058-765;;023-708-751-561-393;;048-157-998-339-224;;066-267-219-024-523;;048-497-642-568-879,10.1164/rccm.201003-0395oc;;20833823;;5859039;;10.1016/s0022-2836(65)80093-6;;10.1128/aac.41.6.1288;;pmc163901;;9174185;;10.1016/0005-2736(95)00159-z;;7488619;;pmc245550;;1482150;;10.1128/aac.36.12.2808;;9814848;;10.1016/s0005-2736(98)00125-4;;10.1016/s1473-3099(08)70100-2;;18471777;;2515523;;10.1002/ppul.1950070413;;10.1002/ppul.1950170511;;8058428;;10.1016/s0168-3659(03)00358-4;;14568408;;10.1258/002367702320162405;;12144741,"Kurashima, “Mycobacterium abscessus” Igaku no Ayumi (Progress in Medicine) (Mar. 8, 2014) 248(10):792-798.;;Koh, et al., “Clinical Significance of Differentiation of Mycobacterium massiliense from Mycobacterium abscessus” American Journal of Respiratory and Critical Care Medicine (2011) 183:405-410.;;Kokyu (Respiration) (2013) 32(7):619-623.;;Bangham, et al., “Diffusion of Univalent Ions across teh Lamellae of Swollen Phospholipids” J. Mol. Niol., 13:238-252 (1965).;;Conley, et al., “Aerosol Delivery of Liposome-Encapsulated Ciprofloxacin: Aerosol Characterization and Efficacy against Francisella tularensis Infection in Mice” Antimicrobial Agents, 41(6): 1288-1292 (Jun. 1997).;;Lasic et al., “Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery” Biochemica et Biophysica Acta (1995) 1239:145-156.;;Majumdar et al., Efficacies of liposome-encapsulated streptomycin and ciprofloxacin against Mycobacterium avium-N. intracellulare complex infections in human peripheral blood monocytes/macrophages. Antimicrob Agents Chemother (1992) 36:2808-15.;;Maurer et al., “Anomalous solubility behavior of the antibiotic ciprofloxacin encapsulated in liposomes: a 1 H-NMR study” Biochemica et Biophysica Acta (1998) 1374:9-20.;;Piersimoni et al., “Pulmonary infections associated with non-tuberculous mycobacteria in immunocompetent patients” Lancet Infect Dis (2008) 8:323-334.;;Smith, et al., “Saftety of Aerosol Tobramycin administration for 3 months to patients with cystic fibrosis.” Ped. Pulmonol. (1989); 7(4):265-271.;;Weber A, et al., “Nebulizer delivery of tobramycin to the lower respiratory tract”. Pediatr Pulmonol. (May 1994); 17 (5):331-9.;;Wong, et al., “Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection” Journal of Controlled Release, 92; 265-273 (2003). Van Heeckeren, et al., Effect of Pseudomonas infection on weight loss, lung mechanics.;;Van Heeckeren, et al., “Murine Models of chronic Pseudomonas aeruginosa lung infection” Lab Anim (Jul. 2002); 36(3):291-312.",INACTIVE
103,US,S,US D0401507 S,087-987-585-595-059,1998-11-24,1998,US 6974397 F,1997-04-17,US 6974397 F,1997-04-17,Combined bottle and cap,,LEVER BROTHERS COMPANY DIV OF CONOPCO INC,GONDA FRANK;;LAUBACH DAVID SCOTT;;LATHROP GREGORY ALAN;;KRUSE JOYCE LYNN,LEVER BROTHER COMPANY DIVISION OF CONOPCO INC (1997-04-22),https://lens.org/087-987-585-595-059,Design Right,yes,48,18,1,1,0,,,D 9529;;0901,2,0,,,"Harper's Bazaar, Apr. 1986, p. 121, ""Nivea Sun"" lotion bottle.;;Washington Post Coupon Section, Nov. 24, 1991, ""Jergens"" lotion bottle.",EXPIRED
104,ES,T3,ES 2140390 T3,137-451-252-357-868,2000-03-01,2000,ES 91910688 T,1991-05-14,US 52515090 A,1990-05-17,METODOS PARA LA TRANS-DESESTABILIZACION DE PROTEINAS IN VIVO.,"This invention pertains to a method of metabolically destabilizing a protein or peptide of interest in vivo provided that the protein or peptide contains a second determinant of the N-end rule-based degradation signal and provided that another (targeting) protein or peptide can be identified that specifically interacts with the protein or peptide of interest. The methods of the invention comprise contacting the protein or peptide of interest with the targeting protein or peptide which contains a destabilizing amino-terminal amino acid according to the N-end rule of protein degradation but lacking a second determinant of the N-end rule-based degradation signal. Because nearly all proteins specifically interact with other proteins, this is a broadly applicable method for metabolically destabilizing a protein or peptide of interest in vivo.",MASSACHUSETTS INST TECHNOLOGY,VARSHAVSKY ALEXANDER J;;JOHNSON ERICA S;;GONDA DAVID K;;HOCHSTRASSER MARK,,https://lens.org/137-451-252-357-868,Granted Patent,no,0,0,14,14,0,C07K1/107;;C07K14/00;;C07K14/395;;C07K2319/00;;C07K2319/61;;C07K2319/80;;C07K2319/95;;C12N15/11;;C07K14/00;;C07K1/107;;C07K14/395;;C07K2319/00;;C07K2319/61;;C07K2319/80;;C12N15/11;;C07K2319/95,C07K1/107;;C07K14/00;;C07K14/395;;C07K19/00;;C12N15/09;;C12N15/11;;C12P21/02;;C12R1/865,,0,0,,,,EXPIRED
105,KR,A,KR 20110081204 A,145-618-565-442-002,2011-07-13,2011,KR 20117008976 A,2009-09-24,US 10001708 P,2008-09-25,DEEP LUNG PULMONARY DELIVERY OF TREPROSTINIL,,ARADIGM CORP,CIPOLLA DAVID C;;GONDA IGOR;;OTULANA TUNDE;;MORISHIGE RICHARD;;BRUINENBERG PAUL,,https://lens.org/145-618-565-442-002,Patent Application,no,0,0,9,9,0,A61K9/0078;;A61K9/0078;;A61K31/19;;A61K9/12;;A61K31/191;;A61K31/191;;A61K31/192;;A61P7/02;;A61P9/04;;A61P9/10;;A61P9/12;;A61P11/00;;A61P11/08;;A61P13/12;;A61P15/00;;A61P17/00;;A61P17/06;;A61P29/00;;A61P35/00;;A61P43/00,A61K9/12;;A61K31/192;;A61P11/00,,0,0,,,,DISCONTINUED
106,WO,A1,WO 1991/018096 A1,102-180-144-297-27X,1991-11-28,1991,US 9103366 W,1991-05-14,US 52515090 A,1990-05-17,METHODS FOR TRANS-DESTABILIZATION OF SPECIFIC PROTEINS IN VIVO,"This invention pertains to the metabolic destabilization a protein or peptide of interest in vivo. The protein or peptide of interest contains a second determinant of the N-end rule-based degradation signal. The methods of the invention comprise contacting the protein or peptide of interest with a targeting protein or peptide which interacts specifically with the protein or peptide of interest. The targeting peptide or protein contains a destabilizing amino-terminal amino acid according to the N-end rule of protein degradation, but lacks a second determinant of the N-end rule-based degradation signal. A requirement of the methods is that it is necessary to identify a peptide or protein which interacts specifically with the protein or peptide of interest. Because nearly all proteins specifically interact with other proteins, this is a broadly applicable method for metabolically destabilizing a protein or peptide of interest in vivo.",MASSACHUSETTS INST TECHNOLOGY,VARSHAVSKY ALEXANDER J;;JOHNSON ERICA S;;GONDA DAVID K;;HOCHSTRASSER MARK,,https://lens.org/102-180-144-297-27X,Patent Application,yes,1,4,14,14,0,C07K1/107;;C07K14/00;;C07K14/395;;C07K2319/00;;C07K2319/61;;C07K2319/80;;C07K2319/95;;C12N15/11;;C07K14/00;;C07K1/107;;C07K14/395;;C07K2319/00;;C07K2319/61;;C07K2319/80;;C12N15/11;;C07K2319/95,C07K1/107;;C07K14/00;;C07K14/395;;C07K19/00;;C12N15/09;;C12N15/11;;C12P21/02;;C12R1/865,,5,5,085-846-205-582-124;;005-431-905-859-044;;062-612-834-714-365;;147-103-086-349-206;;110-722-627-560-902,2506181;;10.1016/s0021-9258(19)84762-2;;2538246;;10.1016/0092-8674(89)90635-1;;2654934;;pmc287064;;10.1073/pnas.86.9.3060;;10.1038/346287a0;;2165217;;10.1016/0092-8674(90)90481-s;;2111732,"JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 264, No. 28, 5 October 1989, Baltimore, US, GONDA D.K. et al., ""Universality and Structure of the N-end Rule"", pages 16700-16712.;;CELL, Vol. 56, No. 6, 24 March 1989, Cambridge, NA, US, pages 1019-1032, BACHMAIR & VARSHAVSKY, ""The Degradation Signal in a Short-Lived Protein"".;;PROC. NATL. ACAD. SCI. U.S.A., Vol. 86, May 1989, Washington, US, pages 3060-3064, HALL J.G. et FRIEDEN C., ""Protein Fragments as Probes in the Study of Protein Folding Mechanisms: Differential Effects of Dihydrofolate Reductase Fragments on the Refolding of the Intact Protein"".;;NATURE, Vol. 346, 19 July 1990, London, GB, pages 287-291, JOHNSON E.S. et al., ""Cis-Trans Recognition and Subunit-Specific Degradation of Short-Lived Proteins"".;;CELL, Vol. 61, 18 May 1990, Cambridge, NA, US, pages 697-708, HOCHSTRASSER & VARSHAVSKY: ""In Vivo Degradation of a Transcriptional Regulator: the Yeast alpha2 Repressor"".",PATENTED
107,US,A1,US 2012/0177693 A1,034-362-086-987-266,2012-07-12,2012,US 200913120015 A,2009-09-24,US 200913120015 A;;US 10001708 P;;US 2009/0058217 W,2008-09-25,DEEP LUNG PULMONARY DELIVERY OF TREPROSTINIL,"Administration of aerosolized Treprostinil formulations may provide a more homogeneous lung deposition of treprostinil, whereby making deep lung delivery possible.",CIPOLLA DAVID C;;GONDA IGOR;;OTULANA BABATUNDE;;MORISHIGE RICHARD;;BRUINENBERG PAUL R;;ARADIGM CORP,CIPOLLA DAVID C;;GONDA IGOR;;OTULANA BABATUNDE;;MORISHIGE RICHARD;;BRUINENBERG PAUL R,ARADIGM CORPORATION (2011-04-20),https://lens.org/034-362-086-987-266,Patent Application,yes,2,29,9,9,0,A61K9/0078;;A61K9/0078;;A61K31/19;;A61K9/12;;A61K31/191;;A61K31/191;;A61K31/192;;A61P7/02;;A61P9/04;;A61P9/10;;A61P9/12;;A61P11/00;;A61P11/08;;A61P13/12;;A61P15/00;;A61P17/00;;A61P17/06;;A61P29/00;;A61P35/00;;A61P43/00,A61K31/192;;A61K9/12;;A61P9/12;;A61P11/00,424/400;;514/569,3,0,,,"Ghofrani, Cardiovascular Research, 72, 2006;;Farr, International Journal of Pharmaceutics, 198, 2000;;Pulmonary Delivery, ONdrugDelivery, 2006",DISCONTINUED
108,US,B1,US 6223942 B1,074-221-107-278-349,2001-05-01,2001,US 12329698 A,1998-07-28,US 12329698 A,1998-07-28,Container and closure,"A container for dispensing two products kept separate prior to application, for example, surfactant and skin benefit agent. The container comprising two chambers, adhered to each other. Although the chambers are essentially identical when viewed from their respective distal walls, they are adhered to each other at an offset so that from any view, both chambers can be seen. Preferably, the chambers include in their proximal walls complementary raised and recessed portions, e.g., protuberances and depressions, which assist the alignment of the chambers in an offset. A closure preferably comprises a peripheral flange and a wall extending transversely of the flange and including at least two product egress openings. Product egress channels on the underside of the transverse wall may lead to the product egress openings. Preferably attached to the closure base, for example by a hinge, is a closure cover. In accordance with one aspect of the invention, both the closure base transverse wall and the closure cover include one or more drainage openings. The drainage openings are not in communication with the product exit openings of the chambers, but instead serve to permit drainage of any liquid which may otherwise be present in the closure, given that the closure will receive the exteriors of the chambers, but not in a liquid tight arrangement.",LEVER BROTHERS CO,MARKEY KEVIN JOSEPH;;GONDA FRANK EDWARD;;TURBETT JAMES LYNN;;LAUBACH DAVID SCOTT,LEVER BROTHERS COMPANY DIVISION OF CONOPCO INC (1998-10-28),https://lens.org/074-221-107-278-349,Granted Patent,yes,36,66,1,15,0,B65D21/0204;;B65D21/0205;;B65D81/3288;;B65D21/0205;;B65D81/3288;;B65D21/0204,B65D21/02;;B65D81/32,222/94;;222/485;;222/556,0,0,,,,EXPIRED
109,EP,A1,EP 0532587 A1,121-743-943-106-607,1993-03-24,1993,EP 91910688 A,1991-05-14,US 9103366 W;;US 52515090 A,1990-05-17,METHODS FOR TRANS-DESTABILIZATION OF SPECIFIC PROTEINS IN VIVO.,"This invention pertains to a method of metabolically destabilizing a protein or peptide of interest in vivo provided that the protein or peptide contains a second determinant of the N-end rule-based degradation signal and provided that another (targeting) protein or peptide can be identified that specifically interacts with the protein or peptide of interest. The methods of the invention comprise contacting the protein or peptide of interest with the targeting protein or peptide which contains a destabilizing amino-terminal amino acid according to the N-end rule of protein degradation but lacking a second determinant of the N-end rule-based degradation signal. Because nearly all proteins specifically interact with other proteins, this is a broadly applicable method for metabolically destabilizing a protein or peptide of interest in vivo.",MASSACHUSETTS INST TECHNOLOGY,VARSHAVSKY ALEXANDER J ONE LON;;JOHNSON ERICA S;;GONDA DAVID K;;HOCHSTRASSER MARK,,https://lens.org/121-743-943-106-607,Patent Application,yes,0,0,14,14,0,C07K1/107;;C07K14/00;;C07K14/395;;C07K2319/00;;C07K2319/61;;C07K2319/80;;C07K2319/95;;C12N15/11;;C07K14/00;;C07K1/107;;C07K14/395;;C07K2319/00;;C07K2319/61;;C07K2319/80;;C12N15/11;;C07K2319/95,C07K1/107;;C07K14/00;;C07K14/395;;C07K19/00;;C12N15/09;;C12N15/11;;C12P21/02;;C12R1/865,,0,0,,,,EXPIRED
110,DE,T2,DE 69906104 T2,087-814-740-430-786,2003-10-30,2003,DE 69906104 T,1999-07-26,EP 9905346 W;;US 12329698 A;;US 29372999 A,1998-07-28,BEHÄLTER UND VERSCHLUSS,,UNILEVER NV,MARKEY JOSEPH;;GONDA FRANK EDWARD;;TURBETT JAMES LYNN;;LAUBACH DAVID SCOTT;;RAINEY DEAN,,https://lens.org/087-814-740-430-786,Granted Patent,no,0,0,13,15,0,B65D21/0204;;B65D21/0205;;B65D81/3288,B65D21/02;;B65D47/06;;B65D51/24;;B65D81/32,,0,0,,,,EXPIRED
111,DE,D1,DE 69906104 D1,117-953-009-434-952,2003-04-24,2003,DE 69906104 T,1999-07-26,EP 9905346 W;;US 12329698 A;;US 29372999 A,1998-07-28,BEHÄLTER UND VERSCHLUSS,,UNILEVER NV,MARKEY JOSEPH;;GONDA FRANK EDWARD;;TURBETT JAMES LYNN;;LAUBACH DAVID SCOTT;;RAINEY DEAN,,https://lens.org/117-953-009-434-952,Granted Patent,no,0,0,13,15,0,B65D21/0204;;B65D21/0205;;B65D81/3288,B65D21/02;;B65D47/06;;B65D51/24;;B65D81/32,,0,0,,,,EXPIRED
112,EP,A2,EP 1115619 A2,126-023-194-029-718,2001-07-18,2001,EP 99944296 A,1999-07-26,EP 9905346 W;;US 12329698 A;;US 29372999 A,1998-07-28,CONTAINER AND CLOSURE,,UNILEVER PLC;;UNILEVER NV,MARKEY KEVIN JOSEPH;;GONDA FRANK EDWARD;;TURBETT JAMES LYNN;;LAUBACH DAVID SCOTT;;RAINEY DEAN,,https://lens.org/126-023-194-029-718,Patent Application,yes,0,0,13,15,0,B65D21/0204;;B65D21/0205;;B65D81/3288,B65D21/02;;B65D47/06;;B65D51/24;;B65D81/32,,0,0,,,,EXPIRED
113,MY,A,MY 117052 A,169-981-279-392-355,2004-04-30,2004,MY PI9903152 A,1999-07-27,US 12329698 A;;US 29372999 A,1998-07-28,CONTAINER AND CLOSURE,"A CONTAINER (10) FOR DISPENSING TWO PRODUCTS KEPT SEPARATE PRIOR TO APPLICATION, FOR EXAMPLE, SURFACTANT AND SKIN BENEFIT AGENT. THE CONTAINER (10) COMPRISING TWO CHAMBERS (14, 14""), ADHERED TO EACH OTHER. ALTHOUGH THE CHAMBERS (14, 14'''''''') ARE ESSENTIALLY IDENTICAL WHEN VIEWED FROM THEIR RESPECTIVE DISTAL WALLS (40, 40''''''''), THEY ARE ADHERED TO EACH OTHER AT AN OFFSET SO THAT FROM ANY VIEW, BOTH CHAMBERS (14, 14'''''''') CAN BE SEEN. PREFERABLY, THE CHAMBERS (14, 14'''''''') INCLUDE IN THEIR PROXIMAL WALLS (30, 30'''''''') COMPLEMENTARY RAISED AND RECESSED PORTIONS, E.G., PROTUBERANCES AND DEPRESSIONS, WHICH ASSIST THE ALIGNMENT OF THE CHAMBERS (14, 14'''''''') IN AN OFFSET. A CLOSURE (12) PREFERABLY COMPRISES A PERIPHERAL FLANGE AND A WALL EXTENDING TRANSVERSELY OF THEFLANGE AND INCLUDING AT LEAST TWO PRODUCT EGRESS OPENINGS (60, 62). PRODUCT EGRESS CHANNELS (92, 94) ON THE UNDERSIDE (90) OF THE TRANSVERSE WALL MAY LEAD TO THE PRODUCT EGRESS OPENINGS (60,62). PREFERABLY ATTACHED TO THE CLOSURE BASE (120), FOR EXAMPLE BY A HINGE, IS A CLOSURE COVER. IN ACCORDANCE WITH ONE ASPECT OF THE INVENTION, BOTH THE CLOSURE BASE TRANSVERSE WALL AND THE CLOSURE COVER INCLUDE ONE OR MORE DRAINAGE OPENINGS (68,70). THE DRAINAGE OPENINGS (68, 70) ARE NOT IN COMMUNICATION WITH THE PRODUCT EXIT OPENINGS OF THE CHAMBERS (14, 14''''''''), BUT INSTEAD SERVE TO PERMIT DRAINAGE OF ANY LIQUID WHICH MAY OTHERWISE BE PRESENT IN THE CLOSURE, GIVEN THAT THE CLOSURE WILL RECEIVE THE EXTERIORS OF THE CHAMBERS, BUT NOT IN A LIQUID TIGHT ARRANGEMENT.(FIG. 3)",UNILEVER PLC,MARKEY KEVIN JOSEPH;;GONDA FRANK EDWARD;;TURBETT JAMES LYNN;;LAUBACH DAVID SCOTT;;RAINEY DEAN,,https://lens.org/169-981-279-392-355,Granted Patent,no,0,0,13,15,0,B65D21/0204;;B65D21/0205;;B65D81/3288,B65D35/22;;B65D21/02;;B65D47/06;;B65D51/24;;B65D81/32,,0,0,,,,EXPIRED
114,WO,A3,WO 2000/006456 A3,051-476-076-233-892,2000-08-03,2000,EP 9905346 W,1999-07-26,US 12329698 A;;US 29372999 A,1998-07-28,CONTAINER AND CLOSURE,"A container comprising a first and a second product chamber (14, 14'), each chamber comprising a distal wall (40, 40') and a proximal wall (30, 30'), the chambers being adhered to each other at the first and second chamber proximal walls, the first and second chamber distal walls being sufficiently flexible to permit product dispensing by application of manual pressure thereto, the chambers being similarly shaped so that the chambers could be disposed back to back along the proximal walls in a front view such that the distal wall of the first chamber will essentially obscure the second chamber and the distal wall of the second chamber will essentially obscure the first chamber, the chambers being adhered along the proximal walls in the container in an offset such that the first chamber does not obscure the second chamber from any direction and the second chamber does not obscure the first chamber from any direction.",UNILEVER PLC;;UNILEVER NV;;LEVER HINDUSTAN LTD,MARKEY KEVIN JOSEPH;;GONDA FRANK EDWARD;;TURBETT JAMES LYNN;;LAUBACH DAVID SCOTT;;RAINEY DEAN,,https://lens.org/051-476-076-233-892,Search Report,yes,8,0,13,15,0,B65D21/0204;;B65D21/0205;;B65D81/3288,B65D21/02;;B65D47/06;;B65D51/24;;B65D81/32,,0,0,,,,PATENTED
115,ES,T3,ES 2195608 T3,000-573-791-473-494,2003-12-01,2003,ES 99944296 T,1999-07-26,US 12329698 A;;US 29372999 A,1998-07-28,ENVASE Y CIERRE.,"Un envase (10), que comprende una primera y una segunda cámara de producto (14, 14¿), comprendiendo cada cámara una pared distal (40, 40¿) y una pared proximal (30, 30¿), estando las cámaras adheridas entre sí en la primera y segunda pared proximal de la cámara, siendo la primera y la segunda pared distal de la cámara lo suficientemente flexibles como para permitir el dispensado de producto mediante la aplicación de una presión manual sobre éstas, presentando las cámaras una forma similar de modo que las cámaras podrían disponerse espalda con espalda a lo largo de las paredes proximales, en una vista frontal tal que la pared distal de la primera cámara ocultará esencialmente a la segunda cámara, y la pared distal de la segunda cámara ocultará esencialmente a la primera cámara, caracterizado porque las cámaras se adhieren a lo largo de las paredes proximales en el envase con un desplazamiento tal que la primera cámara no oculta a la segunda desde ninguna dirección, y la segunda cámara no oculta a la primera cámara desde ninguna dirección.",UNILEVER PLC;;UNILEVER NV,MARKEY KEVIN JOSEPH;;GONDA FRANK EDWARD;;TURBETT JAMES LYNN;;LAUBACH DAVID SCOTT;;RAINEY DEAN,,https://lens.org/000-573-791-473-494,Granted Patent,no,0,0,13,15,0,B65D21/0204;;B65D21/0205;;B65D81/3288,B65D21/02;;B65D47/06;;B65D51/24;;B65D81/32,,0,0,,,,EXPIRED
116,WO,A2,WO 2001/041038 A2,199-484-889-534-438,2001-06-07,2001,US 0042322 W,2000-11-29,US 44965999 A,1999-11-30,FINDING HOMOLOGS OF KNOWN GENES,"Homologs are found by generating candidate nucleic acid sequences using a profile, and displaying the candidate nucleic acid sequences using a graphical display having a first window for graphically displaying values for at least two parameters of the candidate nucleic acid sequences and a second window for displaying textual information relating to the values displayed in the first window. The generating of candidate nucleic acid sequences comprises searching an EST database using the profile to produce hits, and searching the hits against an EST database using a nucleic acid sequence similarity algorithm to produce the candidate nucleic acid sequences. The graphical display further includes a third window for providing a control panel relating to the values displayed in the first window, and the control panel enables selection of the parameters being graphically displayed in the first window.",BAYER AG,BIGWOOD DOUGLAS WAYNE;;HART JOHN T;;GONDA DAVID KEITH;;CERRO JOSEPH ALAN;;CONG LUAN,,https://lens.org/199-484-889-534-438,Patent Application,yes,0,1,4,4,0,G16B30/00;;G16B45/00;;G16B30/10;;G16B30/10,G16B30/10;;G16B45/00,,0,0,,,,PENDING
117,AU,A,AU 2001/041375 A,095-937-403-341-758,2001-06-12,2001,AU 2001/041375 A,2000-11-29,US 44965999 A;;US 0042322 W,1999-11-30,Finding homologs of known genes,,BAYER AG,BIGWOOD DOUGLAS WAYNE;;HART JOHN T;;GONDA DAVID KEITH;;CERRO JOSEPH ALAN;;CONG LUAN,,https://lens.org/095-937-403-341-758,Patent Application,no,0,0,4,4,0,G16B30/00;;G16B45/00;;G16B30/10;;G16B30/10,G16B30/10;;G16B45/00,,0,0,,,,DISCONTINUED
118,WO,A9,WO 2001/041038 A9,057-107-036-233-921,2002-08-15,2002,US 0042322 W,2000-11-29,US 44965999 A,1999-11-30,FINDING HOMOLOGS OF KNOWN GENES,"Homologs are found by generating candidate nucleic acid sequences using a profile, and displaying the candidate nucleic acid sequences using a graphical display having a first window for graphically displaying values for at least two parameters of the candidate nucleic acid sequences and a second window for displaying textual information relating to the values displayed in the first window. The generating of candidate nucleic acid sequences comprises searching an EST database using the profile to produce hits, and searching the hits against an EST database using a nucleic acid sequence similarity algorithm to produce the candidate nucleic acid sequences. The graphical display further includes a third window for providing a control panel relating to the values displayed in the first window, and the control panel enables selection of the parameters being graphically displayed in the first window.",BAYER AG,BIGWOOD DOUGLAS WAYNE;;HART JOHN T;;GONDA DAVID KEITH;;CERRO JOSEPH ALAN;;CONG LUAN,,https://lens.org/057-107-036-233-921,Patent Application,no,0,0,4,4,0,G16B30/00;;G16B45/00;;G16B30/10;;G16B30/10,G16B30/10;;G16B45/00,,0,0,,,,PENDING
119,WO,A3,WO 2001/041038 A3,174-597-181-986-256,2002-10-17,2002,US 0042322 W,2000-11-29,US 44965999 A,1999-11-30,METHOD FOR FINDING HOMOLOGS OF KNOWN GENES,"Homologs are found by generating candidate nucleic acid sequences using a profile, and displaying the candidate nucleic acid sequences using a graphical display having a first window for graphically displaying values for at least two parameters of the candidate nucleic acid sequences and a second window for displaying textual information relating to the values displayed in the first window. The generating of candidate nucleic acid sequences comprises searching an EST database using the profile to produce hits, and searching the hits against an EST database using a nucleic acid sequence similarity algorithm to produce the candidate nucleic acid sequences. The graphical display further includes a third window for providing a control panel relating to the values displayed in the first window, and the control panel enables selection of the parameters being graphically displayed in the first window.",BAYER AG,BIGWOOD DOUGLAS WAYNE;;HART JOHN T;;GONDA DAVID KEITH;;CERRO JOSEPH ALAN;;CONG LUAN,,https://lens.org/174-597-181-986-256,Search Report,yes,0,0,4,4,0,G16B30/00;;G16B45/00;;G16B30/10;;G16B30/10,G16B30/10;;G16B45/00,,5,2,019-804-299-972-983;;020-737-035-981-454,10.1093/bioinformatics/14.9.755;;9918945;;10.1109/visual.1996.567796,"EDDY S R: ""Profile hidden Markov models"", BIOINFORMATICS, vol. 14, 1998, pages 755 - 763, XP002194730, Retrieved from the Internet <URL:ftp://ftp.genetics.wustl.edu/pub/eddy/papers/hmmreview-bioinformatics-98.pdf> [retrieved on 20020325];;CHI E H ET AL: ""Flexible Information Visualization of Multivariate Data from Biological Sequence Similarity Searches"", IEEE VISUALIZATION '96, 1996, pages 133 - 140, XP002194731, Retrieved from the Internet <URL:http://www.cbc.umn.edu/~shoop/papers/vis96color.pdf> [retrieved on 20020325];;ISELI C ET AL: ""ESTSCAN: A PROGRAM FOR DETECTING, EVALUATING, AND RECONSTRUCTING POTENTIAL CODING REGIONS IN EST SEQUENCES"", PROCEEDINGS OF THE INTERNATIONAL CONFERENCE ON INTELLIGENT SYSTEMS FOR MOLECULAR BIOLOGY, 6 August 1999 (1999-08-06) - 10 August 1999 (1999-08-10), pages 138 - 148, XP001008293;;CHI E H ET AL: ""Visualization of Biological Sequence Similarity Search Results"", IEEE VISUALIZATION '95, 1995, pages 44 - 51, XP002194732, Retrieved from the Internet <URL:http://www.cbc.umn.edu/~shoop/papers/vis95.pdf> [retrieved on 20020325];;SHOOP E ET AL: ""Implementation and Testing of an Automated EST Processing and Similarity Analysis System"", PROCEEDINGS OF THE 28TH ANNUAL IEEE HAWAII INTERNATIONAL CONFERENCE ON SYSTEM SCIENCES, vol. 5, 1995, pages 52 - 61, XP002194733, Retrieved from the Internet <URL:http://www.cbc.umn.edu/~shoop/papers/est_processing.final.frame5.pdf> [retrieved on 20020325]",PENDING
120,US,S,US D0375454 S,172-597-575-161-203,1996-11-12,1996,US 3904495 F,1995-05-19,US 3904495 F,1995-05-19,Bottle,,LEVER BROTHERS COMPANY DIV OF CONOPCO INC,LATHROP GREGORY A;;GERHART MARK D;;GNADT DAVID F;;MARKEY KEVIN J;;GONDA FRANK E;;LAUBACH DAVID S,LEVER BROTHERS COMPANY DIVISION OF CONOPCO INC (1995-05-10),https://lens.org/172-597-575-161-203,Design Right,yes,18,2,1,1,0,,,D 9300,1,0,,,"Spray Technology & Marketing, Aug. 1992, p. 25, Dispensing Pump.",EXPIRED
121,AT,T1,AT E234760 T1,020-005-624-871-073,2003-04-15,2003,AT 99944296 T,1999-07-26,EP 9905346 W;;US 12329698 A;;US 29372999 A,1998-07-28,BEHÄLTER UND VERSCHLUSS,,UNILEVER NV,MARKEY KEVIN JOSEPH;;GONDA FRANK EDWARD;;TURBETT JAMES LYNN;;LAUBACH DAVID SCOTT;;RAINEY DEAN,,https://lens.org/020-005-624-871-073,Granted Patent,no,0,0,13,15,0,B65D21/0204;;B65D21/0205;;B65D81/3288,B65D21/02;;B65D47/06;;B65D51/24;;B65D81/32,,0,0,,,,DISCONTINUED
122,EP,B1,EP 1115619 B1,027-994-873-668-741,2003-03-19,2003,EP 99944296 A,1999-07-26,EP 9905346 W;;US 12329698 A;;US 29372999 A,1998-07-28,CONTAINER AND CLOSURE,,UNILEVER PLC;;UNILEVER NV,MARKEY KEVIN JOSEPH;;GONDA FRANK EDWARD;;TURBETT JAMES LYNN;;LAUBACH DAVID SCOTT;;RAINEY DEAN,,https://lens.org/027-994-873-668-741,Granted Patent,yes,8,0,13,15,0,B65D21/0204;;B65D21/0205;;B65D81/3288,B65D21/02;;B65D47/06;;B65D51/24;;B65D81/32,,0,0,,,,EXPIRED
123,WO,A2,WO 2000/006456 A2,198-381-167-081-934,2000-02-10,2000,EP 9905346 W,1999-07-26,US 12329698 A;;US 29372999 A,1998-07-28,CONTAINER AND CLOSURE,"A container comprising a first and a second product chamber (14, 14'), each chamber comprising a distal wall (40, 40') and a proximal wall (30, 30'), the chambers being adhered to each other at the first and second chamber proximal walls, the first and second chamber distal walls being sufficiently flexible to permit product dispensing by application of manual pressure thereto, the chambers being similarly shaped so that the chambers could be disposed back to back along the proximal walls in a front view such that the distal wall of the first chamber will essentially obscure the second chamber and the distal wall of the second chamber will essentially obscure the first chamber, the chambers being adhered along the proximal walls in the container in an offset such that the first chamber does not obscure the second chamber from any direction and the second chamber does not obscure the first chamber from any direction.",UNILEVER PLC;;UNILEVER NV;;LEVER HINDUSTAN LTD,MARKEY KEVIN JOSEPH;;GONDA FRANK EDWARD;;TURBETT JAMES LYNN;;LAUBACH DAVID SCOTT;;RAINEY DEAN,,https://lens.org/198-381-167-081-934,Patent Application,yes,25,2,13,15,0,B65D21/0204;;B65D21/0205;;B65D81/3288,B65D21/02;;B65D47/06;;B65D51/24;;B65D81/32,,0,0,,,,PATENTED
124,US,S,US D0372199 S,138-851-833-408-95X,1996-07-30,1996,US 3835095 F,1995-05-04,US 3835095 F,1995-05-04,Combined bottle and closure,,LEVER BROTHERS COMPANY DIV OF CONOPCO INC,LATHROP GREGORY A;;GERHART MARK D;;GNADT DAVID F;;MARKEY KEVIN J;;GONDA FRANK E;;LAUBACH DAVID S,LEVER BROTHERS COMPANY DIVISION OF CONOPCO INC (1995-04-03),https://lens.org/138-851-833-408-95X,Design Right,yes,19,7,1,1,0,,,D 9558,2,0,,,"Vogue, Dec. 1993, p. 206, Sothy's ""Vitality Serum"" bottle.;;Vogue, Dec. 1993, p. 46, Max Factor ""Color and Light"" makeup bottle.",EXPIRED
125,US,S,US D0372198 S,024-767-899-350-425,1996-07-30,1996,US 3834295 F,1995-05-04,US 3834295 F,1995-05-04,Bottle,,LEVER BROTHERS COMPANY DIV OF CONOPCO INC,LATHROP GREGORY A;;GERHART MARK D;;GNADT DAVID F;;MARKEY KEVIN J;;GONDA FRANK E;;LAUBACH DAVID S,,https://lens.org/024-767-899-350-425,Design Right,yes,18,2,1,1,0,,,D 9558,2,0,,,"Vogue, Dec. 1993, p. 206, Sothy's ""Vitality Serum"" bottle.;;Vogue, Dec. 1993, p. 46, Max Factor ""Color and Light"" makeup bottle.",EXPIRED
126,US,S,US D0376320 S,068-804-145-345-677,1996-12-10,1996,US 038399,1995-05-04,,,Combined bottle and cap,,,Lathrop; Gregory A.;;Gerhart; Mark D.;;Gnadt; David F.;;Markey; Kevin J.;;Gonda; Frank E.;;Laubach; David S.,LEVER BROTHERS COMPANY DIVISION OF CONCOPCO INC (1995-04-03),https://lens.org/068-804-145-345-677,Design Right,yes,10,25,1,1,0,,,D 9558,2,0,,,"Vogue, Dec., 1993, p. 206, Sothy's ""Vitality Serum"" bottle.;;Vogue, Dec., 1993, p. 46, Max Factor ""Color and Light"" makeup bottle.",UNKNOWN
127,US,S,US D0372859 S,035-162-236-167-133,1996-08-20,1996,US 3905295 F,1995-05-19,US 3905295 F,1995-05-19,Bottle,,LEVER BROTHERS COMPANY DIV OF CONOPCO INC,LATHROP GREGORY A;;GERHART MARK D;;GNADT DAVID F;;MARKEY KEVIN J;;GONDA FRANK E;;LAUBACH DAVID S,LEVER BROTHERS COMPANY DIVISION OF CONOPCO INC (1995-05-10),https://lens.org/035-162-236-167-133,Design Right,yes,18,10,1,1,0,,,D 9300,1,0,,,"Spray Technology & Marketing, Aug. 1992, p. 25, Dispensing Pump.",EXPIRED
128,US,S,US D0380159 S,066-841-757-916-83X,1997-06-24,1997,US 3840095 F,1995-05-04,US 3840095 F,1995-05-04,Bottle,,LEVER BROTHERS COMPANY DIV OF CONOPCO INC,LATHROP GREGORY ALAN;;GERHART MARK DOUGLAS;;GNADT DAVID FREDERIC;;MARKEY KEVIN JOSEPH;;GONDA FRANK EDWARD;;LAUBACH DAVID SCOTT,LEVER BROTHERS COMPANY DIVISION OF CONOPCO INC (1995-04-03),https://lens.org/066-841-757-916-83X,Design Right,yes,18,1,1,1,0,,,D 9558;;0901,0,0,,,,EXPIRED
129,US,S,US D0375052 S,105-232-761-866-248,1996-10-29,1996,US 3929095 F,1995-05-19,US 3929095 F,1995-05-19,Bottle,,LEVER BROTHERS COMPANY DIV OF CONOPCO INC,LATHROP GREGORY A;;GERHART MARK D;;GNADT DAVID F;;MARKEY KEVIN J;;GONDA FRANK E;;LAUBACH DAVID S,LEVER BROTHERS COMPANY DIVISION OF CONOPCO INC (1995-05-10),https://lens.org/105-232-761-866-248,Design Right,yes,20,4,1,1,0,,,D 9558,2,0,,,"Vogue, Dec. 1993, p. 206, Sothy's ""Vitality Serum"" bottle.;;Vogue, Dec. 1993, p. 46, Max Factor ""Color And Light"" makeup bottle.",EXPIRED
130,US,S,US D0370409 S,090-620-181-538-397,1996-06-04,1996,US 3904695 F,1995-05-19,US 3904695 F,1995-05-19,Bottle,,LEVER BROTHERS COMPANY DIV OF CONOPCO INC,LATHROP GREGORY A;;GERHART MARK D;;GNADT DAVID F;;MARKEY KEVIN J;;GONDA FRANK E;;LAUBACH DAVID S,LEVER BROTHERS COMPANY DIVISION OF CONOPCO INC (1995-05-10),https://lens.org/090-620-181-538-397,Design Right,yes,18,9,1,1,0,,,D 9300,1,0,,,"Spray Technology & Marketing, Aug. 1992, p. 25, Dispensing Pump.",EXPIRED
131,US,S,US D0372873 S,154-345-652-378-972,1996-08-20,1996,US 3928995 F,1995-05-19,US 3928995 F,1995-05-19,Combined bottle and cap,,LEVER BROTHERS COMPANY DIV OF CONOPCO INC,LATHROP GREGORY A;;GERHART MARK D;;GNADT DAVID F;;MARKEY KEVIN J;;GONDA FRANK E;;LAUBACH DAVID S,LEVER BROTHERS COMPANY DIVISION OF CONOPCO INC (1995-05-10),https://lens.org/154-345-652-378-972,Design Right,yes,20,19,1,1,0,,,D 9558,3,0,,,"Beauty Fashion, Jun. 1984, p. 113, Revlon ""Oriental Hair Cure"" bottle cap.;;Vogue, Dec. 1993, p. 206, Sothy's ""Vitality Serum"" bottle.;;Vogue Dec. 1993, p. 46, Max Factor ""Color and Light"" makeup bottle.",EXPIRED
132,US,S,US D0375051 S,198-339-660-429-35X,1996-10-29,1996,US 3905395 F,1995-05-19,US 3905395 F,1995-05-19,Bottle,,LEVER BROTHERS COMPANY DIV OF CONOPCO INC,LATHROP GREGORY A;;GERHART MARK D;;GNADT DAVID F;;MARKEY KEVIN J;;GONDA FRANK E;;LAUBACH DAVID S,LEVER BROTHERS COMPANY DIVISION OF CONOPCO INC (1995-05-10),https://lens.org/198-339-660-429-35X,Design Right,yes,20,25,1,1,0,,,D 9558,2,0,,,"Vogue, Dec. 1993, p. 206, Sothy's ""Vitality Serum"" bottle.;;Vogue, Dec. 1993, p. 46, Max Factor ""Color and Light"" makeup bottle.",EXPIRED
133,US,S,US D0372860 S,143-843-984-186-988,1996-08-20,1996,US 3939495 F,1995-05-19,US 3939495 F,1995-05-19,Bottle,,LEVER BROTHERS COMPANY DIV OF CONOPCO INC,LATHROP GREGORY A;;GERHART MARK D;;GNADT DAVID F;;MARKEY KEVIN J;;GONDA FRANK E;;LAUBACH DAVID S,LEVER BROTHERS COMPANY DIVISION OF CONOPCO INC (1995-05-10),https://lens.org/143-843-984-186-988,Design Right,yes,18,11,1,1,0,,,D 9300,1,0,,,"Spray Technology & Marketing, Aug. 1992, p. 25, Dispensing Pump.",EXPIRED
134,US,S,US D0372200 S,178-407-342-121-751,1996-07-30,1996,US 3904795 F,1995-05-19,US 3904795 F,1995-05-19,Bottle,,LEVER BROTHERS COMPANY DIV OF CONOPCO INC,LATHROP GREGORY A;;GERHART MARK D;;GNADT DAVID F;;MARKEY KEVIN J;;GONDA FRANK E;;LAUBACH DAVID S,LEVER BROTHERS COMPANY DIVISION OF CONOPCO INC (1995-05-10),https://lens.org/178-407-342-121-751,Design Right,yes,20,2,1,1,0,,,D 9558,2,0,,,"Vogue, Dec. 1993, p. 206, Sothy's ""Vitality Serum"" bottle.;;Vogue, Dec. 1993, p. 46, Max Factor ""Color and Light"" makeup bottle.",EXPIRED
135,US,S,US D0371740 S,064-752-435-083-014,1996-07-16,1996,US 3698295 F,1995-03-31,US 3698295 F,1995-03-31,Bottle,,LEVER BROTHERS COMPANY DIV OF CONOPCO INC,LATHROP GREGORY A;;GERHART MARK D;;GNADT DAVID F;;BROWN ARNOLD;;GONDA FRANK E;;HAUBERT HARRY H,LEVER BROTHERS COMPANY DIVISION OF CONOPCO INC (1995-05-31),https://lens.org/064-752-435-083-014,Design Right,yes,35,7,1,1,0,,,D 9528,0,0,,,,EXPIRED
136,US,S,US D0373535 S,078-077-172-460-878,1996-09-10,1996,US 3698795 F,1995-03-31,US 3698795 F,1995-03-31,Combined bottle and cap,,LEVER BROTHERS COMPANY DIV OF CONOPCO INC,LATHROP GREGORY A;;GERHART MARK D;;GNADT DAVID F;;BROWN ARNOLD;;GONDA FRANK E;;HAUBERT HARRY H,HENKEL IP & HOLDING GMBH (2017-03-08);;THE SUN PRODUCTS CORPORATION (2009-06-16);;LEVER BROTHERS COMPANY DIVISION OF CONOPCO INC (1995-05-31);;SPOTLESS U.S. ACQUISITIONS LLC (2008-09-08),https://lens.org/078-077-172-460-878,Design Right,yes,33,17,1,1,0,,,D 9528,0,0,,,,EXPIRED
137,US,S,US D0374179 S,088-188-765-821-143,1996-10-01,1996,US 3698095 F,1995-03-31,US 3698095 F,1995-03-31,Combined bottle and cap,,LEVER BROTHERS COMPANY DIV OF CONOPCO INC,LATHROP GREGORY A;;GERHART MARK D;;GNADT DAVID F;;BROWN ARNOLD;;GONDA FRANK E;;HAUBERT HARRY H,HENKEL IP & HOLDING GMBH (2017-03-08);;THE SUN PRODUCTS CORPORATION (2009-06-16);;LEVER BROTHERS COMPANY DIVISION OF CONOPCO INC (1995-05-31);;SPOTLESS U.S. ACQUISITIONS LLC (2008-09-08),https://lens.org/088-188-765-821-143,Design Right,yes,33,14,1,1,0,,,D 9528,0,0,,,,EXPIRED
138,US,S,US D0373534 S,127-670-433-132-411,1996-09-10,1996,US 3697895 F,1995-03-31,US 3697895 F,1995-03-31,Combined bottle and cap,,LEVER BOTHERS COMPANY DIV OF CONOPCO INC,LATHROP GREGORY A;;GERHART MARK D;;GNADT DAVID F;;BROWN ARNOLD;;GONDA FRANK E;;HAUBERT HARRY H,HENKEL IP & HOLDING GMBH (2017-03-08);;THE SUN PRODUCTS CORPORATION (2009-06-16);;LEVER BROTHERS COMPANY DIVISION OF CONOPCO INC (1995-05-31);;SPOTLESS U.S. ACQUISITIONS LLC (2008-09-08),https://lens.org/127-670-433-132-411,Design Right,yes,33,3,1,1,0,,,D 9528,0,0,,,,EXPIRED
139,US,S,US D0373533 S,080-292-846-700-502,1996-09-10,1996,US 3697795 F,1995-03-31,US 3697795 F,1995-03-31,Combined bottle and cap,,LEVER BROTHERS COMPANY DIV OF CONOPCO INC,LATHROP GREGORY A;;GERHART MARK D;;GNADT DAVID F;;BROWN ARNOLD;;GONDA FRANK E;;HAUBERT HARRY H,HENKEL IP & HOLDING GMBH (2017-03-08);;THE SUN PRODUCTS CORPORATION (2009-06-16);;LEVER BROTHERS COMPANY DIVISION OF CONOPCO INC (1995-05-31);;SPOTLESS U.S. ACQUISITIONS LLC (2008-09-08),https://lens.org/080-292-846-700-502,Design Right,yes,33,12,1,1,0,,,D 9528,0,0,,,,EXPIRED
140,US,S,US D0376761 S,097-399-589-805-967,1996-12-24,1996,US 3698895 F,1995-03-31,US 3698895 F,1995-03-31,Combined bottle and cap,,LEVER BROTHERS COMPANY DIV OF CONOPCO INC,LATHROP GREGORY A;;GERHART MARK D;;GNADT DAVID F;;BROWN ARNOLD;;GONDA FRANK E;;HAUBERT HARRY H,HENKEL IP & HOLDING GMBH (2017-03-08);;THE SUN PRODUCTS CORPORATION (2009-06-16);;LEVER BROTHERS COMPANY DIVISION OF CONOPCO INC (1995-05-31);;SPOTLESS U.S. ACQUISITIONS LLC (2008-09-08),https://lens.org/097-399-589-805-967,Design Right,yes,33,22,1,1,0,,,D 9528,0,0,,,,EXPIRED
